⊠ No □

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	FORM 10-Q	
(Mark One)		
QUARTERLY REPORT PURSUANT TO SECT	TION 13 OR 15(d) OF THE SECUI	RITIES EXCHANGE ACT OF 1934
Fo	r the quarterly period ended Septe	mber 30, 2024
	OR	
☐ TRANSITION REPORT PURSUANT TO SECT	TION 13 OR 15(d) OF THE SECU	RITIES EXCHANGE ACT OF 1934
	For the transition period from	n to
	Commission file number 000-563	342
VER	RANO HOLDINGS	CORP.
(Exact 1	name of registrant as specified in	n its charter)
British Columbia, Canada		98-1583243
(State or other jurisdiction of incorporation or o	rganization)	(I.R.S. Employer Identification No.)
224 W Hill Street, Suite 400, Chicago, Illinois		60610
(Address of Principal Executive Office	es)	(Zip Code)
	(312) 265-0730	
(Regist	rant's telephone number, includin	g area code)
	N/A	
(Former name, former	r address and former fiscal year, is	f changed since last report)
Securities registered pursuant to Section 12(b) of the	Act:	
TT: 1 0 1 1	Trading Symbol	Name of each exchange on which registered
Title of each class		

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes

<u>Table of Contents</u>

emerging growt	Č	,	an accelerated filer, a non-accelerated filer, a accelerated filer," "smaller reporting company,"	1 0 1 3	
	Large accelerated filer	\boxtimes	Accelerated filer		
	Non-accelerated filer		Smaller reporting company		
			Emerging growth company		
revised financia Indicate by chec	l accounting standards provided pursuar k mark whether the registrant is a shell	nt to Section 13(a) of t	in Rule 12b-2 of the Exchange Act). Yes □ No	X	
As of November	r 5, 2024, the registrant had 356,925,414	4 Class A subordinate	voting shares and no Class B proportionate voti	ng shares outstanding.	_

TABLE OF CONTENTS

		Pages
Part I - Financial In	nformation	1
Item 1.	Unaudited Interim Condensed Consolidated Financial Statements	<u> </u>
	Condensed Consolidated Balance Sheets	<u>2</u>
	<u>Unaudited Interim Condensed Consolidated Statements of Operations</u>	<u>3</u>
	Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity	<u>4</u>
	<u>Unaudited Interim Condensed Consolidated Statements of Cash Flows</u>	<u>6</u>
	Notes to Unaudited Interim Condensed Consolidated Financial Statements	<u>7</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>30</u>
<u>Item 3.</u>	Quantitative and Qualitative Disclosures About Market Risk	<u>40</u>
Item 4.	Controls and Procedures	<u>40</u>
Part II - Other Infor	<u>rmation</u>	<u>41</u>
Item 1.	<u>Legal Proceedings</u>	<u>41</u>
Item 1A.	Risk Factors	<u>41</u>
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>41</u>
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	<u>41</u>
<u>Item 4.</u>	Mine Safety Disclosures	<u>41</u>
<u>Item 5.</u>	Other Information	<u>41</u>
<u>Item 6.</u>	<u>Exhibits</u>	<u>42</u>
<u>Signatures</u>		<u>44</u>

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this "Form 10-Q") contains "forward-looking information" and "forward-looking statements" within the meaning of United States securities laws (together, "forward-looking statements"). All statements, other than statements of historical fact, made by the Company or its affiliates that address activities, events or developments that the Company or its affiliates expect or anticipate will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as "may," "will," "would," "could," "should," "believes," "assumes," "estimates," "projects," "potential," "expects," "plans," "intends," "anticipates," "targeted," "continues," "forecasts," "designed," "goal," "progress," or the negative of those words or other similar or comparable words.

The forward-looking statements contained herein are based on certain key expectations and assumptions, including, but not limited to, expectations and assumptions concerning:

- our ability to obtain, maintain and renew licenses and other regulatory approvals in all states and localities of our operations and planned operations on a timely basis;
- government regulations, including future U.S. state and federal legislative and regulatory developments involving medical and adult-use cannabis and the timing thereof;
- our outlook on our expansion and growth of business and operations;
- our ability to achieve our goals, business plans and strategy;
- our ability to access capital and obtain necessary financing to pursue our growth and business plans;
- our operational results and other financial and business conditions and prospects;
- the timing and completion of acquisitions and other commercial transactions;
- the integration and operation of acquired businesses;
- the timing and amount of capital expenditures;
- the availability of facilities, equipment, skilled labor and services needed for cannabis operations;
- demand, developments and trends in the medical and adult-use cannabis industry;
- competition in the cannabis industry in the markets in which we operate or plan to operate;
- the medical benefits, viability, safety, efficacy, and dosing of cannabis;
- the size of the medical cannabis market and the adult-use cannabis market in each state; and
- conditions in general economic and financial markets.

Forward-looking statements may relate to future financial conditions, results of operations, plans, strategies, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then-current expectations of the party making the statement and assumptions concerning future events, which are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from that which was expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to:

- the illegality of cannabis under federal law, the U.S. federal regulatory landscape and enforcement related to medical or adult-use cannabis, including political risks, civil asset forfeiture and regulation by additional regulatory authorities;
- regulatory and political changes to U.S. federal, state and local laws related to medical or adult-use cannabis, including political risks and regulation by additional regulatory authorities;
- our limited operating history;
- the impacts of economic uncertainty stemming from disruptions in U.S. and global markets, inflation, rising interest rates, and changes in consumer and business confidence:
- our outstanding indebtedness and potential future indebtedness;
- any potential changes in our liquidity due to potential for instability in market and economic conditions and adverse developments to financial institutions;
- reliance on key management;
- market acceptance of existing and new products and potential returns or recalls of our products;
- · customer acceptance of our brand portfolio;
- the accuracy of our forecasted demand for our products;
- the potential for fraudulent activity by employees, contractors and consultants;
- our exposure to growth-related operational and execution risks;
- potential negative findings in our clinical research with respect to our products;
- our ongoing litigation matter with Goodness Growth Holdings, Inc;

- potential product liability claims;
- our exposure to natural phenomena and resulting potential uninsured or under insured losses;
- our structure and our resulting reliance on the performance of our subsidiaries and affiliates;
- our expansion-by-acquisition strategy;
- · our ability to acquire businesses and cannabis licenses in desired markets and the integration and operation of acquired businesses;
- the typically limited operations of businesses we acquire;
- the unconventional due diligence process in the cannabis industry;
- our ability to acquire and lease properties suitable for the cultivation, production and sale of cannabis;
- potential limited representations and warranties of businesses we may acquire;
- our acquisition of businesses in developing cannabis markets;
- our lack of portfolio diversification;
- our use of joint ventures, strategic partnerships and alliances;
- our contractual relationships with our consolidated variable interest entities;
- existing competition and new market entrants;
- the introduction of synthetic alternatives to cannabis products by pharmaceutical and other companies;
- the immaturity of the cannabis industry and limited comparable, competitive and established industry best practices;
- the availability of and our reliance on third-party suppliers, service providers, contractors and manufacturers;
- · wholesale and retail price fluctuations;
- public opinion and perception of the cannabis industry;
- the availability of raw or other materials;
- rising or volatile energy costs;
- agricultural and environmental risks and the impacts of environmental regulations on the cannabis industry and environmental protections;
- physical security risks, such as theft;
- potential scrutiny from Canadian authorities;
- disparate state-by-state regulatory landscapes and licensing regimes for medical and adult-use cannabis;
- the difficulties cannabis businesses face accessing and maintaining banking or financial services due to federal regulations;
- the cost and difficulty of complying with various regulatory schemes;
- the impact of state social equity legislation as it relates to the cannabis industry;
- the risk of high bonding and insurance costs;
- environmental regulations;
- effects of changes in laws and policies governing employees and by union organizing activity;
- potential divestment of licenses if required by regulatory authorities;
- our dependency on the banking industry;
- · required public disclosure and governmental filings containing personal information of our officers, investors and other stakeholders;
- potential findings by regulatory authorities that one of shareholders is unsuitable;
- the risk that our directors, officers, employees or investors are barred from entering the U.S.;
- the ability to, and constraints on, promoting and marketing cannabis products;
- potential U.S. Food and Drug Administration governance of the cannabis industry;
- the potential limitations on our ability to enforce our contracts or any liens granted to us;
- the potential lack of access to federal bankruptcy protections in the U.S.;
- reliance on information technology systems, the potential disclosure of personal information of patients and customers and cybersecurity risks;
- · our reliance on third-party software providers;
- cost related to preserving our brand identity;
- our ability to protect our intellectual property due to limited intellectual property protection available for cannabis products and the potential infringement by third parties;
- potential infringement or misappropriation claims;
- the risk of receiving no return on our securities;
- our elimination of monetary liability and indemnification rights against our directors, officers and employees under British Columbia law;
- · our dual class capital structure with Class A subordinate voting shares and Class B proportionate voting shares;
- the time and resources necessary to comply with corporate governance practices and securities rules and regulations in the U.S. and Canada;
- our management's ability to maintain effective internal controls;

Table of Contents

- · our remediation plan and ability to remediate the material weaknesses in our internal controls over financial reporting;
- potential dilution if we issue additional Subordinate Voting Shares or Proportionate Voting Shares;
- market perception of sales of a substantial amount of Subordinate Voting Shares;
- transfer restrictions on our Subordinate Voting Shares;
- price volatility of our Subordinate Voting Shares;
- our shareholders' limited participation in our affairs;
- our expectation to not declare or pay out dividends;
- the concentration of our voting control;
- the taxation of cannabis companies in the U.S., including the impact of Section 280E of the Internal Revenue Code of 1986, as amended; and
- other risks described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission on March 15, 2024, as more particularly described under the heading "Item 1A. Risk Factors" therein.

Although we believe that the expectations and assumptions on which forward-looking statements are based are reasonable at the time made, undue reliance should not be placed on the forward-looking statements, because no assurance can be given that they will prove to be correct. Forward-looking statements address future events and conditions, and thus involve inherent risks and uncertainties. Readers are cautioned that the above list of cautionary statements is not exhaustive.

The cannabis industry involves risks and uncertainties that are subject to change based on various factors. Certain forward-looking statements contained herein concerning the cannabis industry and our general expectations concerning the cannabis industry are based on estimates prepared by us using data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the cannabis industry. Such data is inherently imprecise.

Consequently, all forward-looking statements made in this Form 10-Q and our other documents are qualified by such cautionary statements and there can be no assurance that the anticipated results or developments will actually be realized or, even if realized, that they will have the expected consequences to or effects on us. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required under applicable securities legislation.

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

VERANO HOLDINGS CORP. Condensed Consolidated Balance Sheets

(\$ in Thousands)

	September 30, 2024		D	ecember 31, 2023
		(Unaudited)		
ASSETS				
Current Assets:				
Cash and Cash Equivalents	\$	64,981	\$	174,760
Accounts Receivable, net		46,937		38,981
Held for Sale Assets		220		1,955
Inventory		194,045		155,768
Prepaid Expenses and Other Current Assets		15,538		22,732
Total Current Assets		321,721		394,196
Property, Plant and Equipment, net		584,598		501,304
Right of Use Assets, net		95,593		93,459
Intangible Assets, net		1,047,519		1,086,146
Goodwill		252,182		231,291
Deposits and Other Assets		13,066		12,349
TOTAL ASSETS	\$	2,314,679	\$	2,318,745
LIABILITIES AND SHAREHOLDERS' EQUITY				
LIABILITIES				
Current Liabilities:				
Accounts Payable	\$	42,489	\$	31,281
Accrued Liabilities		69,921		66,766
Income Tax Payable		285,274		248,471
Current Portion of Lease Liabilities		11,008		9,750
Current Portion of Debt		22,532		52,005
Acquisition Consideration Payable		4,151		3,915
Total Current Liabilities		435,375		412,188
Long-Term Liabilities:				
Debt, net of Current Portion		397,617		393,637
Lease Liabilities, net of Current Portion		90,800		87,397
Deferred Income Taxes		168,164		182,21
Other Long-Term Liabilities		5,005		3,228
Total Long-Term Liabilities		661,586		666,47
TOTAL LIABILITIES		1,096,961		1,078,665
SHAREHOLDERS' EQUITY		1,217,944		1,240,080
NON-CONTROLLING INTEREST		(226)		_
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$	2,314,679	\$	2,318,745

Unaudited Interim Condensed Consolidated Statements of Operations

(\$ in Thousands except shares and per share amounts)

	For the Three Months Ended September 30,					For the Nine Months Ended September 30,				
		2024		2023		2024		2023		
Revenues, net of Discounts	\$	216,683	\$	240,088	\$	660,379	\$	701,263		
Cost of Goods Sold, net		107,586		106,868		323,982		343,668		
Gross Profit		109,097	_	133,220		336,397		357,595		
Operating Expenses										
Selling, General, and Administrative Expenses		92,327		86,316		269,690		246,224		
Loss on Impairment - Investment in Associates				6,571				6,571		
Total Operating Expenses		92,327		92,887		269,690		252,795		
Loss from Investments in Associates				(45)				(306)		
Income from Operations		16,770	_	40,288	_	66,707		104,494		
Other Income (Expense):										
Loss on Disposal of Property, Plant and Equipment		(604)		(234)		(747)		(555)		
Loss on Debt Extinguishment		_		_		(3,068)		(663)		
Interest Expense, net		(12,771)		(15,166)		(42,122)		(45,084)		
Other Income (Expense), net		(484)	_	2,145	_	(2,438)	_	2,542		
Total Other Income (Expense), net		(13,859)		(13,255)		(48,375)		(43,760)		
Income Before Provision for Income Taxes		2,911	_	27,033	_	18,332		60,734		
Provision For Income Taxes		(45,478)		(44,797)		(87,485)		(100,796)		
Net Loss Before Non-Controlling Interest		(42,567)		(17,764)		(69,153)		(40,062)		
Net Income Attributable to Non-Controlling Interest		_		78		<u>—</u>		78		
Net Loss Attributable to Verano Holdings Corp. & Subsidiaries	\$	(42,567)	\$	(17,842)	\$	(69,153)	\$	(40,140)		
Net Loss per share – basic & diluted	\$	(0.12)	\$	(0.05)	\$	(0.20)	\$	(0.12)		
Basic & Diluted – weighted average shares outstanding		351,168,596		343,432,601		346,727,978		342,484,942		

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity

(\$ in Thousands)

	Subordinate Voting Shares (as converted)	Share Capital	Accumulated Other Comprehensive Income (Loss) E		Accumulated Earnings (Deficit)		Non-Controlling Interest		Total
Balance as of July 1, 2023	343,367,514	\$ 1,673,049	\$	(8)	\$ (346,697)	\$	_	\$	1,326,344
Share-based compensation	161,942	4,909		_	_		_		4,909
Foreign Currency Translation Adjustment	_	_		(4)	_		_		(4)
Net Income (Loss)	_	_		_	(17,842)	_	78	_	(17,764)
Balance as of September 30, 2023	343,529,456	\$ 1,677,958	\$	(12)	\$ (364,539)	\$	78	\$	1,313,485
	Subordinate Voting Shares (as converted)	Share Capital		ccumulated Other Comprehensive Income (Loss)	Accumulated Earnings (Deficit)		Non-Controlling Interest		Total
Balance as of July 1, 2024	346,417,144	\$ 1,689,723	\$	2	\$ (468,333)	\$	_	\$	1,221,392
Share-based compensation	92,229	4,667		_	_		_		4,667
Issuance of shares in conjunction with acquisitions	10,416,041	34,453		_	_		_		34,453
Foreign Currency Translation Adjustment	_	_		(1)	_		_		(1)
Distributions paid to non-controlling interest holders	_	_		_	_		(226)		(226)
Net Loss	356,925,414	\$ 1,728.843	\$	_	(42,567) \$ (510,900)	_	(226)	_	(42,567) 1,217,718

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (Continued) (\$ in Thousands)

	Subordinate Voting Shares (as converted)	Share Capital		A	Comprehensive Income (Loss)	Accumulated Earnings (Deficit)	Non-Controlling Interest	Total
Balance as of January 1, 2023	339,983,374	\$	1,665,957	\$	(8)	\$ (324,399)	s —	\$ 1,341,550
Share-based compensation	1,104,515		9,391		_	_	_	9,391
Issuance of shares to relieve liability obligations, net	816,021		2,610		_	_	_	2,610
Foreign Currency Translation Adjustment	_		_		(4)	_	_	(4)
Contingent consideration & other adjustments to purchase accounting	1,625,546		_		_	_	_	_
Net Income (Loss)			_		<u> </u>	(40,140)	78	 (40,062)
Balance as of September 30, 2023	343,529,456	\$	1,677,958	\$	(12)	\$ (364,539)	\$ 78	\$ 1,313,485
	Subordinate Voting Shares (as converted)		Share Capital	A	Accumulated Other Comprehensive Income (Loss)	Accumulated Earnings (Deficit)	Non-Controlling Interest	Total
Balance as of January 1, 2024	Shares	\$			Comprehensive	Earnings (Deficit)	Interest	\$ Total 1,240,080
Balance as of January 1, 2024 Share-based compensation	Shares (as converted)	\$	Capital		Comprehensive Income (Loss)	Earnings (Deficit)	Interest	\$
• •	Shares (as converted) 344,074,096	\$	Capital 1,681,840		Comprehensive Income (Loss)	Earnings (Deficit)	Interest	\$ 1,240,080
Share-based compensation	Shares (as converted) 344,074,096 2,404,096	\$	Capital 1,681,840 12,550		Comprehensive Income (Loss)	Earnings (Deficit)	Interest	\$ 1,240,080 12,550
Share-based compensation Issuance of shares in conjunction with acquisitions	Shares (as converted) 344,074,096 2,404,096	\$	Capital 1,681,840 12,550		Comprehensive Income (Loss) (13) —	Earnings (Deficit)	Interest	\$ 1,240,080 12,550 34,453
Share-based compensation Issuance of shares in conjunction with acquisitions Foreign Currency Translation Adjustment Contingent consideration & other adjustments to	Shares (as converted) 344,074,096 2,404,096 10,416,041	\$	Capital 1,681,840 12,550		Comprehensive Income (Loss) (13) —	Earnings (Deficit)	Interest	\$ 1,240,080 12,550 34,453
Share-based compensation Issuance of shares in conjunction with acquisitions Foreign Currency Translation Adjustment Contingent consideration & other adjustments to purchase accounting	Shares (as converted) 344,074,096 2,404,096 10,416,041	\$	Capital 1,681,840 12,550		Comprehensive Income (Loss) (13) —	Earnings (Deficit)	\$ — — — — — — — — — — — — — — — — — — —	\$ 1,240,080 12,550 34,453 14

Unaudited Interim Condensed Consolidated Statements of Cash Flows

(\$ in Thousands)

	Nine Months En	ded September 30,
	2024	2023
CASH FLOW FROM OPERATING ACTIVITIES		-
Net loss attributable to Verano Holdings Corp. and Subsidiaries	\$ (69,153)	\$ (40,140)
Net income attributable to non-controlling interest	_	78
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	108,150	105,559
Right of use assets amortization	9,466	7,831
Loss on disposal of property, plant and equipment	747	555
Loss on debt extinguishment	3,068	663
Loss on impairment of investment in associates	_	6,571
Decrease in fair value of contingent consideration	_	(3,466)
Stock based compensation	13,034	8,979
Other, net	8,368	3,862
Changes in operating assets and liabilities:		
Accounts receivable, net	(8,277)	(17,098)
Inventory	(18,310)	
Accounts payable	(1,167)	
Income tax payable	36,523	(1,900)
Other assets, net	7,894	7,073
Other liabilities, net	(21,649)	
NET CASH PROVIDED BY OPERATING ACTIVITIES	68,694	77,361
NET CASH TROVIDED BY OFERAING ACTIVITIES	00,074	77,301
CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of business, net of cash acquired	(35,875)	_
Purchases of property, plant and equipment	(84,803)	
Proceeds from disposal of assets	52	2,180
Other investing activities	(226)	
NET CASH USED IN INVESTING ACTIVITIES	(120,852)	
NET CASH USED IN INVESTING ACTIVITIES	(120,002)	(24,323)
CASH FLOW FROM FINANCING ACTIVITIES		
Payment of deferred acquisition price payable	(32)	(13,250)
Proceeds from issuance of debt		50,949
Principal repayments of debt	(56,466)	
Debt issuance costs paid		(1,081)
Payment of debt extinguishment	(1,000)	
Other financing activities	(137)	
NET CASH USED IN FINANCING ACTIVITIES	(57,635)	
NET CASH USED IN FINANCING ACTIVITIES	(37,033)	(7,904)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(109,793)	45,074
	(103,132)	
Effects of exchange rate fluctuations on cash and cash equivalents	14	(4)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	174,760	84,851
CASH AND CASH EQUIVALENTS, DEGINARYO OF FEMOLO	171,700	
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 64,981	\$ 129,921
CUBBLEMENTAL DICCLOSUBE OF CACH FLOW INFORMATION		-
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	¢ 20.929	6 44 402
Interest paid, net	\$ 39,838	
Issuance of shares to relieve liability obligations, net	<u> </u>	\$ 2,610
NONCASH INVESTING AND FINANCING ACTIVITIES		
Issuance of debt for acquisition of business	\$ 26,700	\$
Issuance of shares under business combinations	\$ 34,453	\$

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

1. OVERVIEW AND BASIS OF PRESENTATION

(a) Description of Business

Unless otherwise stated or the context requires otherwise, references herein to the "Company," "Verano," "we," "us," and "our" mean Verano Holdings Corp. and its direct and indirect subsidiaries, and controlled and managed entities.

The Company is a vertically integrated cannabis operator that focuses on limited-licensed markets in the United States ("U.S."). As a vertically integrated operator, the Company owns, operates, manages, controls, and/or has licensing, consulting or other commercial agreements with cultivation, processing, and retail licenses across 14 state markets (Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia).

The Company also conducts pre-licensing activities in other markets. In these markets, the Company has either applied for licenses, or plans on applying for licenses, but does not currently own or manage any cultivation, processing, or retail licenses.

The Company's Class A subordinate voting shares, no par value (the "Subordinate Voting Shares") are listed on Cboe Canada ("Cboe") under the ticker symbol "VRNO" and are quoted in the United States on the OTCQX marketplace operated by the OTC Market Group, under the ticker symbol "VRNOF".

The Company's corporate headquarters is located at 224 W Hill Street, Suite 400, Chicago, Illinois 60610.

(b) Basis of Presentation

The accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Unless otherwise indicated, all references to "\$" or "US\$" in this Form 10-Q refer to United States dollars, and all references to "C\$" refer to Canadian dollars. These Unaudited Interim Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2023 (the "2023 Annual Audited Financials"), included in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2024 (the "Form 10-K"). Certain prior year amounts have been reclassified to conform to the current year's presentation, which the Company does not consider to be material. The accompanying Unaudited Interim Condensed Consolidated Financial Statements include the accounts of Verano Holdings Corp. and its direct and indirect subsidiaries as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with Accounting Standards Codification ("ASC") 810 Consolidation. The preparation of the Company's Unaudited Interim Condensed Consolidated Financial Statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of assets and liabilities in such financial statements and in the accompanying notes. Actual results may differ materially from these estimates. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the 2024 full year or any future periods. The accompanying consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated balance sheet as of December 31, 2023 contained in the 2023 Annual Audited Financials included in the Form 10-K.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

1. OVERVIEW AND BASIS OF PRESENTATION (Continued)

(c) Basis of Consolidation

The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with ASC 810 *Consolidation*. All transactions and balances between these entities have been eliminated upon consolidation.

(d) Significant Accounting Policies

There have been no changes to the Company's significant accounting policies as described in *Note 2 - Significant Accounting Policies* to the 2023 Annual Audited Financials included in the Form 10-K.

(e) Earnings (Loss) per Share

Basic earnings (loss) per share is calculated using the treasury stock method, by dividing the net earnings (losses) attributable to shareholders by the weighted average number of shares (including the Company's Class B proportionate voting shares, no par value (the "Proportionate Voting Shares") on an as converted to Subordinate Voting Shares basis of 100 Subordinate Voting Shares to one Proportionate Voting Share) outstanding during each of the periods presented. Contingently issuable shares (including shares held in escrow) are not considered outstanding shares and consequently are not included in the earnings (loss) per share calculations. Diluted income per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares.

To determine diluted income (loss) per share, the Company assumes that any proceeds from the exercise of dilutive share options would be used to repurchase shares at the average market price during the period. The diluted income (loss) per share calculation excludes any potential conversion of share options and convertible debt, if any, that would increase earnings per share or decrease loss per share. No potentially dilutive share equivalents were included in the computation of diluted loss per share for the three and nine months ended September 30, 2024 and 2023 because their impact would have been anti-dilutive.

(f) Recently Issued Accounting Standards

In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update 2023-07 - ASC 280 Segment Reporting - Improvements to Reportable Segment Disclosures ("ASU 280"), which extends the existing requirements for annual disclosures to quarterly periods, and requires that both annual and quarterly disclosures present segment expenses using line items consistent with information regularly provided to the chief operating decision maker. ASU 280 is effective for annual periods beginning after December 15, 2023 and quarterly periods beginning after December 15, 2024. The Company does not expect implementation of the new disclosure guidance to have a material impact to its consolidated financial statements.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

2. INVENTORY

The Company's inventory consists of the following as of September 30, 2024 and December 31, 2023:

	S	eptember 30, 2024	December 31, 2023
Raw Materials	\$	3,075	\$ 5,336
Work in Process		139,409	114,620
Packaging and Miscellaneous		10,093	7,899
Finished Goods		41,468	27,913
	<u> </u>		
Total Inventory	\$	194,045	\$ 155,768

During the year ended December 31, 2023, the Company classified Packaging and Miscellaneous as a component of Prepaid Expenses and Other Current Assets on the Consolidated Balance Sheets as of December 31, 2023. Packaging and Miscellaneous has been reclassified to Inventory in the Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2024, to better reflect the character of the underlying assets. Prior periods have been reclassified to conform to the current period presentation.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

3. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment and related accumulated depreciation consists of the following as of September 30, 2024 and December 31, 2023:

	 September 30, 2024	_	December 31, 2023
Land	\$ 32,029	\$	30,934
Buildings and Improvements	195,928		194,274
Furniture and Fixtures	21,657		19,884
Computer Equipment and Software	28,513		25,861
Leasehold Improvements	264,160		230,877
Tools and Equipment	99,695		90,386
Vehicles	4,341		4,373
Assets Under Construction (1)	 111,702		39,844
Total Property, Plant and Equipment, Gross	758,025		636,433
Less: Accumulated Depreciation	(173,427)		(135,129)
Total Property, Plant and Equipment, Net	\$ 584,598	\$	501,304

⁽¹⁾ Assets under construction represent construction in progress related to facilities not yet completed or otherwise not placed in service.

For the three months ended September 30, 2024 and September 30, 2023, depreciation expense included in costs of goods sold totaled \$9,511 and \$8,354, respectively. For the three months ended September 30, 2024 and September 30, 2023, depreciation expense included in selling, general, and administrative expense totaled \$4,401 and \$4,014, respectively.

For the nine months ended September 30, 2024 and September 30, 2023, depreciation expense included in costs of goods sold totaled \$27,065 and \$25,410, respectively. For the nine months ended September 30, 2024 and September 30, 2023, depreciation expense included in selling, general, and administrative expense totaled \$12,558 and \$11,521, respectively.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

4. INTANGIBLE ASSETS AND GOODWILL

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value as of the acquisition date. Amortization of definite life intangible assets is provided on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods for intangible assets are reviewed by the Company at each year end, and any changes in estimates are accounted for prospectively.

As of September 30, 2024, intangible assets consisted of the following:

	Licenses		Tradenames		Technology	Total
<u>Cost</u>						
Balance as of January 1, 2024	\$	1,269,326	\$	54,166	\$ 6,431	\$ 1,329,923
Additions from business combination	\$	29,900	\$	_	\$ _	\$ 29,900
Balance as of September 30, 2024	\$	1,299,226	\$	54,166	\$ 6,431	\$ 1,359,823
Accumulated Amortization						
Balance as of January 1, 2024		225,751		15,001	3,025	243,777
Amortization		63,683		4,066	778	68,527
Balance as of September 30, 2024	\$	289,434	\$	19,067	\$ 3,803	\$ 312,304
Net Book Value						
Balance as of January 1, 2024		1,043,575		39,165	3,406	1,086,146
Balance as of September 30, 2024	\$	1,009,792	\$	35,099	\$ 2,628	\$ 1,047,519

The following table outlines the estimated annual amortization expense related to intangible assets as of September 30, 2024:

Year Ending December 31:	Estimated Amortization
2024 (Remaining)	\$ 23,285
2025	93,142
2026	92,427
2027	92,354
2028	92,336
Thereafter	653,975
Total	\$ 1,047,519

The changes in the carrying amount of goodwill, by reportable segment, for the nine months ended September 30, 2024 were as follows:

	Janua	ry 1, 2024	Impairment	djustments to ourchase price allocation	Acquisitions	Se	eptember 30, 2024
Cultivation	\$	49,318	\$ _	\$ 	\$ 4,810	\$	54,128
Retail		181,973	_	_	16,081		198,054
Total	\$	231,291	\$ _	\$ _	\$ 20,891	\$	252,182

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

5. EARNINGS (LOSSES) PER SHARE

The Company presents basic earnings (losses) per share. Basic earnings (losses) per share is calculated by dividing the earnings (loss) attributable to shareholders by the weighted average number of Subordinate Voting Shares (with outstanding Proportionate Voting Shares, if any, accounted for on an as converted to Subordinate Voting Shares basis) outstanding during the periods presented. Diluted earnings (losses) per share is computed based on the weighted average number of Subordinate Voting Shares (with outstanding Proportionate Voting Shares, if any, accounted for on an as converted to Subordinate Voting Shares basis) outstanding, to the extent dilutive.

The computations of net earnings (loss) per share on a basic and diluted basis, including reconciliations of the numerators and denominators, for the three and nine months ended September 30, 2024 and September 30, 2023 were as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,			
		2024		2023		2024		2023	
Numerator									
Net Loss attributable to Verano Holdings Corp.	\$	(42,567)	\$	(17,842)	\$	(69,153)	\$	(40,140)	
Denominator									
Basic									
Weighted-average shares outstanding – basic		351,168,596		343,432,601		346,727,978		342,484,942	
<u>Diluted</u>									
Weighted-average shares outstanding - diluted		351,168,596		343,432,601		346,727,978		342,484,942	
Net Loss per share - basic & diluted	\$	(0.12)	\$	(0.05)	\$	(0.20)	\$	(0.12)	

Potentially dilutive securities of approximately 2,223,321 and 3,672,228 for the three and nine months ended September 30, 2024, respectively, were not included in the computation of diluted earnings per share because their effect would have been anti-dilutive.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

6. TRANSACTIONS

Business Combinations

The Company has determined that the acquisitions described below are business combinations under ASC Topic 805, *Business Combinations*. Acquisitions that are determined to be the acquisition of a business are accounted for by applying the acquisition method, whereby the assets acquired, and the liabilities assumed are recorded at their fair values at the date of acquisition with any excess of the aggregate consideration over the fair values of the identifiable net assets allocated to goodwill. Operating results for the companies acquired have been included in these Unaudited Interim Condensed Consolidated Financial Statements from the date of the acquisition. Any goodwill recognized is attributed based on reporting units.

The purchase price allocations for the acquisitions reflect various fair value estimates and analyses which are subject to change within the measurement period, which is the one-year period subsequent to the acquisition date. The primary areas of the purchase price allocation that are subject to change relate to the fair value of certain tangible assets, the value of intangible assets acquired, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair value of the net assets acquired at the acquisition date during the measurement period.

Measurement period adjustments that the Company determined to be material will be applied prospectively in the Company's future consolidated financial statements, and depending on the nature of the adjustments, other periods subsequent to the period of acquisition could be affected.

2024 Business Combinations

203 Organix L.L.C. & Salubrious Wellness Clinic, Inc.

On July 29, 2024, the Company entered into two equity purchase agreements, (a) one with The Cannabist Company Holdings Inc. ("Cannabist"), CC VA Holdco LLC, Columbia Care – Arizona, Tempe, L.L.C., Thomas Allison and Salubrious Wellness Clinic, Inc. ("SWC"), pursuant to which the Company acquired all of the issued and outstanding equity interests of SWC, and (b) one with Cannabist, CC VA Holdco LLC, Columbia Care-Arizona, Prescott, L.L.C. and 203 Organix, LLC ("203" and together with SWC, "Cannabist AZ"), pursuant to which the Company acquired all of the issued and outstanding equity interests of 203. The Company added an active cultivation and production facility and increased the Company's retail footprint in Arizona. The transactions closed on August 16, 2024. Pursuant to the equity purchase agreement, the Company paid total cash consideration of \$13,251, which is subject to a post-closing adjustment period of 120 days.

The Company's Consolidated Statements of Operations includes net revenue of \$2,140 and net loss of \$1,324 related to the acquired operations of Cannabist AZ for the three months ended September 30, 2024. Cannabist AZ is reported in both the Retail and Cultivation segments.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

6. TRANSACTIONS (Continued)

Columbia Care Eastern Virginia LLC

On July 29, 2024, the Company entered into an equity purchase agreement with Cannabist, Columbia Care Eastern Virginia LLC ("CC East Virginia"), and the members of CC East Virginia party thereto (the "Virginia EPA"), pursuant to which the Company acquired all of the issued and outstanding equity interests of CC East Virginia. CC East Virginia is the sole vertical cannabis operator in HSA 5 in Eastern Virginia. The transaction closed on August 21, 2024. Pursuant to the Virginia EPA, the Company paid \$24,122 in cash consideration and equity consideration of 10,416,041 Subordinate Voting Shares with an estimated fair value of \$34,453, all of which was distributed on the closing date of the transaction. In addition, on the closing date of the transaction, the Company issued a \$26,700 promissory note (the "CC East Virginia Promissory Note") with an estimated fair value of \$25,150 and which bears interest at a rate of 7% per annum and matures on the two-year anniversary of the transaction closing date. The CC East Virginia Promissory Note is subject to a post-closing adjustment period of 120 days.

The Company's Unaudited Interim Condensed Consolidated Statements of Operations includes net revenue of \$5,105 and net loss of \$226 related to the acquired operations of CC East Virginia for the three months ended September 30, 2024. CC East Virginia is reported in both the Retail and Cultivation segments.

For the acquisitions of CC East Virginia and Cannabist AZ, the purchase price allocation as of the date of acquisition was based on a preliminary valuation and is subject to revision as more detailed analyses are completed and additional information about the fair value of assets acquired and liabilities assumed becomes available. The primary areas that remain preliminary for the acquisitions of CC East Virginia and Cannabist AZ relate to the fair values of goodwill, intangible assets, and income taxes.

For the acquisitions of CC East Virginia and Cannabist AZ, the major classes of assets and liabilities to which we have preliminarily allocated the purchase price were as follows:

	C	C East Virginia	Cannabist AZ
Cash and Cash Equivalents	\$	1,150	\$ 348
Accounts Receivable, net		535	252
Inventory		16,237	7,145
Prepaid Expenses and Other Current Assets		310	33
Property, Plant and Equipment, net		20,798	5,796
Right of Use Assets, net		3,323	2,212
Deposits and Other Assets		791	230
Intangible Assets, net		26,700	3,200
Goodwill		19,810	1,081
Accounts Payable and Accrued Liabilities		(2,461)	(3,790)
Income Tax Payable		_	(280)
Current Portion of Lease Liabilities		(470)	(208)
Lease Liabilities, net of Current Portion		(2,894)	(1,761)
Deferred Income Taxes		_	(952)
Other Long-Term Liabilities		(104)	(55)
Purchase Price	\$	83,725	\$ 13,251

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

6. TRANSACTIONS (Continued)

Goodwill was assigned to both the Retail and Cultivation segments. The goodwill was primarily attributed to increased synergies that are expected to be achieved from the integration of CC East Virginia and Cannabist AZ. Substantially all of the goodwill is expected to be non-deductible for income tax purposes.

The following tables represent the supplemental consolidated financial results on an unaudited pro forma basis, as if the Cannabist AZ acquisition had been consummated on January 1, 2023:

	Three Months En	ptember 30,		September 30,			
	2024		2023		2024		2023
Revenues	\$ 218,851	\$	244,800	\$	672,224	\$	716,046
Net Income (Loss)	\$ (42,397)	\$	(18,845)	\$	(68,826)	\$	(42,180)

The following tables represent the supplemental consolidated financial results on an unaudited pro forma basis, as if the CC East Virginia acquisition had been consummated on January 1, 2023:

	Three Months En	ded S	eptember 30,	Nine Months Ended September 30,						
	2024		2023		2024		2023			
Revenues	\$ 222,939	\$	250,099	\$	687,922	\$	728,112			
Net Income (Loss)	\$ (40,920)	\$	(20,197)	\$	(63,264)	\$	(44,027)			

These pro forma results were based on estimates and assumptions, which we believe are reasonable. They are not the results that would have been realized had we been a combined company during the periods presented and are not necessarily indicative of our consolidated results of operations in future periods. The pro forma results include adjustments related to purchase accounting, primarily amortization of intangible assets. Acquisition costs and other nonrecurring charges were immaterial and are included in the earliest period presented.

2022 Business Combinations

WSCC, Inc.

On July 6, 2021, Verano entered into a merger agreement to acquire 100% of the equity interests of WSCC, Inc ("Sierra Well"). Sierra Well held cannabis licenses that allow it to cultivate, produce and sell medical and recreational cannabis products in the state of Nevada, including sales through its retail dispensaries located in Carson City and Reno. The transaction closed on September 7, 2022.

During the quarter ended March 31, 2024, the Company paid cash consideration of \$32 and issued 31,181 Subordinate Voting Shares to the former shareholders of Sierra Well, which had been held back to secure indemnification obligations of such shareholders. As of September 30, 2024, all consideration related to the acquisition has been paid.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

7. DEBT

As of September 30, 2024, and December 31, 2023 debt consisted of the following:

	September 30, 2024			
Credit Facility	\$	295,800	\$	348,950
Promissory Notes		28,237		1,582
Mortgage Loans		108,312		111,221
Vehicle and Equipment Loans		719		1,081
Unamortized Debt Issuance Costs		(12,919)		(17,192)
Total Debt	\$	420,149	\$	445,642
Less: Current Portion of Debt		22,532		52,005
Total Long-Term Debt, net	\$	397,617	\$	393,637

Credit Facility

On October 27, 2022, Verano and certain of its subsidiaries and affiliates from time-to-time party thereto (collectively, the "Borrowers"), entered into a Credit Agreement (the "2022 Credit Agreement") with Chicago Atlantic Admin, LLC ("Chicago Atlantic"), as administrative agent for the lenders, and the lenders from time-to-time party thereto (the "Lenders"), pursuant to which the Lenders advanced the Borrowers a \$350,000 senior secured term loan, all of which was used to repay the principal indebtedness outstanding under the Company's previous senior secured term loan credit facility. In connection with such repayment, such previous credit facility was terminated and is no longer in force or effect.

The 2022 Credit Agreement provides the Borrowers with the right, subject to conditions, to request an additional incremental term loan in the aggregate principal amount of up to \$100,000; provided that the Lenders elect to fund such incremental term loan. Beginning in October 2023, the loan requires scheduled amortization payments of \$350 per month and the remaining principal balance is due in full on October 30, 2026.

The 2022 Credit Agreement also provides the Borrowers with the right to (a) incur up to \$120,000 of additional indebtedness from third-party lenders secured by real estate excluded as collateral under the 2022 Credit Agreement, (b) incur additional mortgage financing from third-party lenders secured by real estate acquired after the closing date, and (c) upon the SAFE Banking Act or similar legislation making banking services available to U.S. cannabis companies being passed by the United States Congress, incur up to \$50,000 pursuant to a revolving credit facility from third-party lenders that is pari passu or subordinated to the 2022 Credit Agreement obligations, each of which are subject to customary conditions.

The obligations under the 2022 Credit Agreement are secured by substantially all of the assets of the Borrowers, excluding vehicles, specified parcels of real estate and other customary exclusions.

The 2022 Credit Agreement provides for a floating annual interest rate equal to the prime rate then in effect plus 6.50%, which rate may be increased by 3.00% upon an event of default that is not a material event of default or 6.00% upon a material event of default.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

7. **DEBT** (Continued)

At any time, the Company may voluntarily prepay up to \$100,000 of the principal balance, subject to a one-time \$1,000 prepayment premium upon the first prepayment, and may prepay the remaining outstanding principal balance for a prepayment premium at varying rates based on the timing of any subsequent prepayments. The Borrowers may not voluntarily prepay more than \$100,000 of the principal balance without prepaying the entire outstanding principal balance of the loan.

The 2022 Credit Agreement includes customary representations and warranties and customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to material indebtedness, and events of bankruptcy and insolvency.

The 2022 Credit Agreement also includes customary negative covenants limiting the Borrowers' ability to incur additional indebtedness and grant liens that are not otherwise permitted, and the ability to enter into or consummate acquisitions or dispositions that are not otherwise permitted, among others. Additionally, the 2022 Credit Agreement requires the Borrowers to meet certain financial tests regarding minimum cash balances, minimum levels of Adjusted EBITDA (as defined in the 2022 Credit Agreement) and a minimum fixed charge coverage ratio.

As of September 30, 2024, the Company was in compliance with such covenants.

Permitted Partial Optional Prepayment and Lien Release

On April 30, 2024, the Company, made a Permitted Partial Optional Prepayment (as defined in the 2022 Credit Agreement) in the amount of \$50,000 pursuant to the 2022 Credit Agreement and paid \$1,000 prepayment premium in connection therewith.

In connection with such Permitted Partial Optional Prepayment, Chicago Atlantic and certain Lenders agreed to (a) release certain Borrowers from their obligations under, and as parties to, the 2022 Credit Agreement and related agreements (the "Released Borrowers") and (b) release all liens over the Released Borrowers' property, including real estate, held by Chicago Atlantic for the benefit of the Lenders, in each case, pursuant to a limited consent and waiver, dated as of April 29, 2024, by and among the Borrowers, certain of the Lenders party thereto and Chicago Atlantic.

Columbia Care Eastern Virginia LLC

On July 29, 2024, the Company entered into the Virginia EPA to purchase all of the issued and outstanding equity interests of CC East Virginia. The transaction closed on August 21, 2024. Pursuant to the Virginia EPA, the Company issued the CC East Virginia Promissory Note in the amount of \$26,700, which is subject to further adjustment, and which bears interest at a rate of 7% per annum beginning on the closing date, through maturity on the two-year anniversary of the closing date.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

8. SHARE CAPITAL

Subordinate Voting Shares and Proportionate Voting Shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from equity. The proceeds from the exercise of stock options or warrants together with amounts previously recorded in reserves over the vesting periods are recorded as share capital. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with ASC 740, *Income Taxes*.

(a) Issued and Outstanding

As of September 30, 2024, the Company had 356,925,414 Subordinate Voting Shares issued and outstanding and no Proportionate Voting Shares outstanding. The Company has the following two classes of share capital, with each class having no par value:

(i) Subordinate Voting Shares

The holders of the Subordinate Voting Shares are entitled to receive dividends issued by the Company and one vote per share at shareholder meetings of the Company. All Subordinate Voting Shares are ranked equally regarding the Company's residual assets. The Company is authorized to issue an unlimited number of Subordinate Voting Shares.

(ii) Proportionate Voting Shares

Each Proportionate Voting Share is convertible into 100 Subordinate Voting Shares. The holders of the Proportionate Voting Share are entitled to receive dividends issued by the Company on an as converted to Subordinate Voting Share basis and 100 votes per share at shareholder meetings of the Company. The Proportionate Voting Shares are ranked equally on an as converted to Subordinate Voting Share basis regarding the Company's residual assets. The Company is authorized to issue an unlimited number of Proportionate Voting Shares.

(b) Stock-Based Compensation

In February 2021, the Company established the Verano Holdings Corp. Stock and Incentive Plan (the "Plan"), which provides for stock-based remuneration for its eligible directors, officers, employees, consultants, and advisors. The maximum number of restricted stock units ("RSUs"), options and other stock based awards that may be issued under the Plan cannot exceed 10% of the Company's then issued and outstanding share capital, determined on an as converted to Subordinate Voting Shares basis. All goods and services received in exchange for the grant of any stock-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company cannot reliably estimate the fair value of the goods and services received, the Company measures their value indirectly by reference to the fair value of the equity instruments granted. Equity-settled stock-based payments under stock-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to equity.

The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. Estimates are subsequently revised if there is any indication that the number of shares expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period with no adjustment to prior periods for expense previously recognized.

Option and RSU grants generally vest in installments over 12 to 30 months and options typically have a life of ten years.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

8. SHARE CAPITAL (Continued)

Options

The Company had 33,262 fully vested and exercisable options, entitling the holder thereof to one Subordinate Voting Share per each option upon exercise, with a weighted average exercise price of C\$32.05 and a weighted average remaining contractual life of 6.41 years as of September 30, 2024.

5,694 fully vested options, entitling the holder thereof to one Subordinate Voting Share per each option upon exercise, were cancelled during the nine months ended September 30, 2024 due to termination of employment. No options were granted or forfeited during the nine months ended September 30, 2024. As of September 30, 2024 and December 31, 2023, there were no in-the-money options.

RSUs

The following table summarizes the number of unvested RSU awards as of September 30, 2024 and December 31, 2023 and the changes during the nine months ended September 30, 2024:

		Weighted Avg. Grant Date Fair
	Number of Shares	Value C\$
Univested RSUs at December 31, 2023	8,812,537	4.72
Granted	2,682,741	5.61
Forfeited	356,269	4.69
Vested	2,528,817	5.64
Unvested RSUs at September 30, 2024	8,610,192	4.82

The stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 were as follows:

	Three Months Ended September 30,					Nine Months Ended September 3			
		2024		2023		2024		2023	
Stock Options	\$		\$	63	\$		\$	226	
Restricted Stock Units		4,790		4,624		13,034		8,753	
Total Stock Based Compensation Expense	\$	4,790	\$	4,687	\$	13,034	\$	8,979	

(c) Share Repurchase Program

On June 17, 2024, the Company's Board of Directors authorized the repurchase of up to 5%, or 17,320,857 of its Subordinate Voting Shares over a 12-month period, and in no event repurchasing greater than an aggregate cost of \$50,000. During the nine months ended September 30, 2024, the Company repurchased zero Subordinate Voting Shares. The total remaining repurchase authorization remains at \$50,000.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

9. INCOME TAXES

The following table summarizes the Company's income tax expense and effective tax rates for the three and nine months ended September 30, 2024 and 2023:

	Th	ree Months E	nded S	eptember 30,	Nine Months Ended September 3				
	-	2024		2023		2024	2023		
Income before Income Taxes	\$	2,911	\$	27,033	\$	18,332	\$	60,734	
Income Tax Expense		(45,478)		(44,797)		(87,485)		(100,796)	
Effective Tax Rate		1562 %	, D	166 %)	477 %)	166 %	

The effective tax rates for the three and nine months ended September 30, 2024 and 2023 were based on the Company's forecasted annualized effective tax rates and were adjusted for discrete items that occurred within the periods presented. Net discrete tax items of \$9,927 and \$8,517 were recorded during the three months ended September 30, 2024 and 2023, respectively. Net discrete tax items of \$18,623 and \$20,704 were recorded during the nine months ended September 30, 2024 and 2023, respectively. Discrete items recorded during the three and nine months ended September 30, 2024 and 2023 primarily relate to penalties and interest on unpaid tax liabilities, impacts of prior period return to provision adjustments, remeasurement of deferred taxes for state tax rate changes, and book remeasurement adjustments not recognized for tax purposes.

Due to its cannabis operations, the Company is subject to the limitations of the U.S. Internal Revenue Code of 1986, as amended (the "Code") Section 280E, under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under Section 280E of the Code. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income and the Company's effective tax rates are well in excess of statutory tax rates.

Taxes paid during the nine months ended September 30, 2024 and 2023 were \$74,026 and \$114,659, respectively.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

10. LEASES

The Company has operating leases for some of its retail dispensaries and processing and production facilities located throughout the U.S., as well as for its corporate offices located in Chicago, Illinois. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date.

Leases with an initial term of 12 months or less are not recorded on the Company's balance sheet. Certain leases require payments for taxes, insurance, and maintenance, and are considered non-lease components. The Company accounts for non-lease components separately.

The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset.

The Company leases certain business facilities from third parties under non-cancellable operating lease agreements that contain minimum rental provisions that expire through 2037. Some leases also contain renewal provisions and provide for rent abatement and escalating payments.

During the three months ended September 30, 2024 and 2023, the Company recorded approximately \$5,210 and \$4,691 in operating lease expense, respectively, of which \$198 and \$167 was included in cost of goods sold for the same periods, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded approximately \$15,122 and \$13,451 in operating lease expense, respectively, of which \$426 and \$538 was included in cost of goods sold for the same periods, respectively.

Other information related to operating leases as of and for the periods ended September 30, 2024 and December 31, 2023, were as follows:

	September 30, 2024	December 31, 2023
Weighted average remaining lease term - years	7.88	8.19
Weighted average discount rate	9.99 %	9.52 %

Maturities of lease liabilities for operating leases as of September 30, 2024 were as follows:

	Year Ending December 31,	Maturities of Lease Liability
	2024 (Remaining) \$	5,144
	2025	20,226
	2026	19,297
	2027	18,619
	2028	17,792
	Thereafter	70,533
	Total Lease Payments	151,611
	Less: Imputed Interest	(49,803)
Pre	sent Value of Lease Liability <u>\$</u>	101,808

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

11. CONTINGENCIES AND OTHER

(a) Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 30, 2024, other than as set forth below, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's consolidated operations. There are no proceedings in which the Company is a party and any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

On January 31, 2022, the Company entered into an Arrangement Agreement (the "GGH Arrangement Agreement") with Vireo Growth, Inc., formerly known as Goodness Growth Holdings, Inc. ("GGH"), pursuant to which it agreed to acquire all of the issued and outstanding equity interests of GGH in exchange for equity interests in the Company, subject to the conditions set forth in the GGH Arrangement Agreement. On October 13, 2022, the Company provided written notice to GGH of GGH's breach of the GGH Arrangement Agreement and exercised the Company's termination rights under the GGH Arrangement Agreement. On October 21, 2022, GGH filed suit against the Company in the Supreme Court of British Columbia alleging that the Company breached (i) the GGH Arrangement Agreement through, among other things, the purported wrongful repudiation of the GGH Arrangement Agreement, (ii) the duty of good faith, and (iii) the duty of honest performance in contract. In addition, on November 14, 2022, the Company filed a counterclaim asserting that GGH owes it a termination fee in the amount of \$14,875, or alternatively, the reimbursement of out-of-pocket fees and expenses of up to \$3,000 as a result of our termination of the GGH Arrangement Agreement, which was based upon our belief that GGH breached covenants and representations in the GGH Arrangement Agreement and the occurrence of other termination events. GGH filed a response to such counterclaim on December 7, 2022, in which GGH denied it was obligated to pay any termination fee or transaction expenses. As of September 30, 2024, both the Company and GGH are engaged in ongoing discovery efforts.

On May 2, 2024, GGH filed an application with the Supreme Court of British Columbia seeking an order granting summary trial in the ongoing litigation between the Company and GGH regarding the GGH Arrangement Agreement. In the application, GGH stated it is seeking \$860,900 in damages, plus costs and interest (the "GGH Application for Summary Trial"). On June 19, 2024, the Company filed an application in response seeking: (i) dismissal of the GGH Application for Summary Trial on the grounds that the issues raised by it are not suitable for disposition by summary trial and will not assist the efficient resolution of the proceeding; and (ii) an order that the report on damages filed by GGH in support of the GGH Application for Summary Trial is inadmissible and shall be excluded from evidence in the trial, or any summary trial, of this matter. On September 17, 2024, the Company filed an amended response and counterclaim with the Supreme Court of British Columbia, primarily in response to communications recently disclosed by GGH. The Company can provide no guarantees or assurances that it will prevail or settle this lawsuit or its counterclaim on favorable terms, if at all, and an adverse outcome could have a material adverse effect on its business, results of operations and financial condition.

(b) Contingencies

During the first quarter of 2023, the Company discovered a potential liability related to a previous acquisition that was deemed to be both probable and estimable. Per ASC 450 *Contingencies*, when both of these criteria are present, a contingent liability should be recorded. Based on this, the Company recorded a corresponding charge in Other Income, net of \$1,893 for the nine months ended September 30, 2023.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

11. CONTINGENCIES AND OTHER (Continued)

(c) Illegality of Cannabis at the U.S. Federal Level

Verano operates within states where cannabis use, medical or adult-use or both, has been approved by state and local regulatory bodies. Notwithstanding the permissive regulatory environment of medical, and in some cases also adult-use cannabis at the state level, under U.S. federal law cannabis (other than hemp) is a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 811) (the "Controlled Substances Act") which means it is viewed by the U.S. federal government as a drug that has a high potential for abuse and no therapeutic value. Therefore, even in states or territories that have legalized cannabis to some extent, the cultivation, processing, distribution, possession and sale of cannabis violates the Controlled Substances Act. Moreover, individuals and entities may violate U.S. federal law if they aid and abet another in violating the Controlled Substances Act or conspire with another to violate the law. Violating the Controlled Substances Act is also a predicate for other crimes, including money laundering laws and the Racketeer Influenced and Corrupt Organizations Act. Violations of any U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities, civil forfeiture or divestiture.

Strict compliance with state and local laws with respect to cannabis may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against the Company. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its cannabis licenses in the U.S., the listing and trading of its securities on stock exchanges and platforms, its financial position, operating results, profitability, liquidity and the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time and resources could be substantial.

There can be no assurance that the comprehensive U.S. federal legislation that would de-schedule and de-criminalize cannabis will be passed in the near future or at all. If such legislation is passed, there is no guarantee that it will include provisions that preserve the current state-based cannabis programs under which the Company operates or that such legislation will otherwise be favorable to the Company and its business.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

12. SEGMENTS

The Company conducts and manages its business through two reportable segments, representing the major lines of its cannabis business: cultivation (wholesale) and retail. The cultivation (wholesale) segment consists of the cultivation, production and sale of cannabis products to retail stores. The retail segment consists of the retailing of cannabis to patients and consumers. Summarized financial information for these segments is as follows:

	Thre	ee Months End	ded S	September 30,	Nir	Nine Months En		ded September 30,	
		2024		2023		2024		2023	
Revenues, net of Discounts									
Cultivation (Wholesale)	\$	90,450	\$	92,389	\$	268,829	\$	259,266	
Retail		164,404		185,707		497,675		556,307	
Intersegment Eliminations		(38,171)		(38,008)		(106,125)		(114,310)	
Total Revenues, net of Discounts		216,683		240,088		660,379		701,263	
Gross Profit									
Cultivation (Wholesale)		28,262		33,499		80,478		57,068	
Retail		80,835		99,721		255,919		300,527	
Total Gross Profit		109,097		133,220		336,397		357,595	
Depreciation and Amortization									
Cultivation (Wholesale)		19,877		18,384		58,159		55,434	
Retail		16,988		16,882		49,991		50,125	
Total Depreciation and Amortization		36,865		35,266		108,150		105,559	
Income taxes									
Cultivation (Wholesale)		3,662		20,840		18,161		39,851	
Retail		41,816		23,957		69,324		60,945	
Total Income Taxes		45,478		44,797		87,485		100,796	

The following table reconciles gross profit to consolidated income before provision for income taxes.

	Three Months Ended September 30,				Nine Months Ended September 30,			
		2024		2023		2024		2023
Gross Profit	\$	109,097	\$	133,220	\$	336,397	\$	357,595
Total Operating Expenses		(92,327)		(92,887)		(269,690)		(252,795)
Loss from Investments in Associates		_		(45)		-		(306)
Total Other Income (Expense), net		(13,859)		(13,255)		(48,375)		(43,760)
Income Before Provision for Income Taxes		2,911		27,033		18,332		60,734

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

13. LOYALTY OBLIGATIONS

The Company has customer loyalty programs where retail customers accumulate points for each dollar of spending, net of tax. These points are recorded as a contractual liability until customers redeem their points for discounts on eligible products as part of an in-store sales transaction. In addition, the Company records a performance obligation as a reduction of revenue based on the estimated probability of point obligation incurred.

The Company has a calculated standalone selling price that ranges between \$0.03\cdot and \$0.06\cdot per loyalty point. Upon redemption, the loyalty program obligation is relieved, and the offset is recorded as revenue. The Company estimates that 20% of points will not be redeemed (breakage) prior to their six-month expiration dates. The Company continues to evaluate breakage and redemption values to determine the standalone selling price.

As of December 31, 2023, there were approximately 110,000,000¹ points outstanding with an approximate value of \$5,781. As of September 30, 2024, there were approximately 126,000,000¹ points outstanding with an approximate value of \$6,144. During the second quarter of 2024, the Florida market transitioned to a new loyalty rewards program. The points associated with the prior rewards program were transitioned to store credits which approximated the value attributable to the respective outstanding loyalty points. Such balances are included in accrued liabilities on the Company's Condensed Consolidated Balance Sheets.

¹ Such amount not in Thousands

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

14. CONSOLIDATION

In accordance with ASC 810, the Company consolidates through the variable interest entity ("VIE") model. The following table presents the summarized financial information about the Company's consolidated VIEs, which are included in the Company's Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023.

	Sept	tember 30, 2024	December 31, 2023		
Current Assets	\$	4,439 \$	14,671		
Non-Current Assets		25,125	28,568		
Current Liabilities		26,498	30,437		
Non-Current Liabilities		6,051	7,614		
Equity attributable to Verano Holdings Corp.		(2,985)	5,188		

Consolidated Variable Interest Entities

Consolidated VIEs occur when (a) the Company closes an acquisition while the state has not finalized the transfer of the cannabis license or (b) the Company owns an equity interest in a joint venture, which it exercises control over.

Consolidation occurs on the effective date of the purchase agreement, or in the case of joint venture VIEs, on the effective date of a limited liability company agreement governing the applicable joint venture, and an MSA. The MSA grants the management company, Verano, the ability to make business operating decisions, manage and staff employees, determine product mix, and the authority to direct allocation of cash. The MSA or the limited liability company agreement also allows Verano to limit distributions of the entity at Verano's discretion. Certain states may limit the distribution or transfer of cash until license transfer.

The Company has entered into financing arrangements with certain VIEs to provide funding for potential capital expenditures including, but not limited to, the construction of dispensaries and other facilities.

The Company applies ASC 810-10-15 to determine control of the legal entity. With respect to VIEs acquired via acquisition, the purchase agreements limit the sellers involvement in future operations, and their risks of loss. With respect to joint venture VIEs, the limited liability company agreements limit the partners' involvement in future operations and control over financial decisions, including distributions. In addition, Verano enters into an MSA with the legal entity that grants the Company strategic decision-making ability of the business operations.

The Company is involved in all qualitative and quantitative aspects of each consolidated VIE, such as but not limited to, software choices, procurement, staffing and payroll, advertising, and use of cash flow. With respect to VIEs acquired via acquisition, the Company absorbs all risk of loss and receives expected future returns based on the purchase agreement and MSA, resulting in Verano being the primary beneficiary.

Verano does not fully own all entities consolidated under ASC 810 and records a non-controlling interest for such non-owned portion in the Unaudited Interim Condensed Consolidated Financial Statements. The income of less-than-wholly owned entities is attributed to non-controlling interest and Verano based on the contractual arrangements between the other interest holders and Verano, or, in the absence of contractual arrangements, on a pro rata basis based on relative ownership percentage. As an exception to the aforementioned attribution method, during periods in which a less-than-wholly owned entity records an accumulated deficit, the net losses of the less-than-wholly owned subsidiary are, generally, attributed entirely to Verano.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

15. FAIR VALUE MEASUREMENTS

The Company applies fair value accounting for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers all related factors of the asset by market participants in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and credit-risk.

The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels, and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and
- Level 3 Inputs for the asset or liability that are not based on observable market data.

Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and acquisition consideration payable.

For the Company's long-term debt (which primarily consists of a credit facility and mortgage loans), for which there were no quoted market prices of active trading markets, it was not practicable to estimate the fair value of these financial instruments. The carrying amount of debt as of September 30, 2024 and December 31, 2023 was \$420,149 and \$445,642, which included \$22,532 and \$52,005, respectively, of short-term debt due within one year.

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The fair value of the Company's financial instruments associated with each of the three levels of the hierarchy are:

	As of September 30, 2024							
	 Level 1		Level 2		Level 3		Total	
Cash and Cash Equivalents	\$ 64,981	\$	_	\$		\$	64,981	
Investments	2,137		_		_		2,137	
Acquisition Consideration Payable	 _		_		(4,151)		(4,151)	
Total	\$ 67,118	\$	_	\$	(4,151)	\$	62,967	
			As of Decem	ber	31, 2023			
	 Level 1		As of Decem	ber	31, 2023 Level 3		Total	
Cash and Cash Equivalents	\$ Level 1 174,760	\$		s s		\$	Total 174,760	
Cash and Cash Equivalents Investments	\$ 	\$				\$		
*	\$ 174,760	\$				\$	174,760	

As of September 30, 2024, the Company held publicly traded shares of \$2,137, which is included in other current assets in the accompanying Condensed Consolidated Balance Sheet, and is a Level 1 financial instrument.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

16. RELATED PARTY TRANSACTIONS

2022 Credit Agreement

George Archos, the Chairman, Chief Executive Officer and Founder of the Company, participated in the 2022 Credit Agreement as a Lender funding \$1,000 of the \$350,000 principal amount. Mr. Archos is excluded from certain approval rights of the lenders and any penalties and fees due to Mr. Archos under the 2022 Credit Agreement are immaterial to the Company.

Two Pointo

In October 2022, the Company entered into a conditional management and services agreements with each of Americana Dream, LLC and Green Therapy, LLC, operators of dispensaries in Illinois pursuant to social equity licenses issued by Illinois regulatory authorities (together, the "LLCs"), and in 2023 the Company received an aggregate of \$10 for services rendered under the agreements. The Company sold products to the LLCs and two associated entities on a wholesale basis in the aggregate amounts of \$681 and \$1,061, net of discounts, for the three months ended September 30, 2024 and 2023, respectively. The Company sold products to the LLCs and two associated entities on a wholesale basis in the aggregate amounts of \$2,856 and \$2,117, net of discounts, for the nine months ended September 30, 2024 and 2023, respectively. Two Pointo, LLC ("Two Point") has contractual rights to purchase ownership interests in the LLCs and associated entities, subject to submitting a request for and receiving applicable Illinois regulatory approvals and other conditions. The existing owners of the LLCs and associated entities will maintain ownership interests together with Two Point. In 2023, Darren Weiss, the Company's President, received in connection with application support services rendered to an LLC in 2019, (i) a 2.73% profit interest in Two Point subject to Two Point's purchase of ownership interests in the LLCs, and (ii) a profit interest in Two Point of 0.30%, and David Spreckman, the Company's Chief Marketing Officer, received a profit interest in Two Point of 0.30% for services. All profit interests issued to Messrs. Weiss and Spreckman were voluntarily forfeited in 2024 as if they were never granted. Maria Fragias, an immediate family member of George Archos, the Company's Chairman and Chief Executive Officer, is the beneficiary of a trust that holds a 7.92% ownership interest and a 3.95% profit interest in Two Point. To the Company's knowledge, none of the trust or such persons has received any distributions, payments, or proceeds from Two Point. As of September 30, 2024, and December 31, 2023, the amounts due from the LLCs and two associated entities were \$454 and \$443, respectively.

Leases

The Company leases real property for a retail dispensary in Aurora, Illinois from 740 Rte. 59, LLC ("740"). Pursuant to the lease agreement, the Company made payments totaling \$46 and \$46 during each of the three months ended September 30, 2024 and 2023, respectively, and \$138 and \$138 during each of the nine months ended September 30, 2024 and 2023, respectively. Payments consist of base rent, real estate taxes and customary tenant charges. George Archos, the Company's Chief Executive Officer, holds an indirect 50% ownership interest in 740. Pursuant to the lease agreement, the initial term expires on June 30, 2030.

The Company leases real property for a retail dispensary in Lombard, Illinois from 783 Butterfield LLC ("783"). Pursuant to the lease agreement, the Company made payments to 783 totaling \$92 and \$90 during the three months ended September 30, 2024 and 2023, respectively, and \$274 and \$270 during the nine months ended September 30, 2024 and 2023, respectively. Payments consist of base rent, real estate taxes and customary tenant charges. George Archos, the Company's Chief Executive Officer, holds a 50% indirect ownership interest in 783. Pursuant to the lease agreement, the initial term expires on January 11, 2031.

Sweed

High Tech Holdings, Inc. ("Sweed") provides point of sale software systems to retail cannabis businesses under the names "Sweed" and "Leaftrade." Sweed provides these software systems to the Company. For these services the Company paid Sweed \$674 during the year ended December 31, 2023 and \$1,117 during the nine months ended September 30, 2024. GP Management Group, LLC, an entity beneficially owned and controlled by George Archos, holds a 0.476% ownership interest in Sweed.

VERANO HOLDINGS CORP.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

17. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date of issuance of this Form 10-Q and has determined there have been no subsequent events that have occurred during such period that would require adjustments to its disclosures in the Unaudited Interim Condensed Consolidated Financial Statements.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management discussion and analysis (this "MD&A") of the financial condition and results of operations of the Company is for the three and nine months ended September 30, 2024 and September 30, 2023. It is supplemental to, and should be read in conjunction with, the Company's Unaudited Interim Condensed Consolidated Financial Statements and the accompanying notes for the three and nine months ended September 30, 2024 and with the Company's 2023 Annual Audited Financials for the years ended December 31, 2023, 2022 and 2021 included in the Form 10-K. The financial statements referenced in this MD&A are prepared in accordance with GAAP. Financial information presented in this MD&A is presented in United States dollars ("\$" or "US\$") and expressed in thousands, unless otherwise indicated. This MD&A contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected, forecasted, or expected in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the Form 10-K. See "Cautionary Statement Regarding Forward-Looking Statements" above and "Risk Factors" in Part I, Item 1A. "Risk Factors" in the Form 10-K. The Company's management believes the assumptions underlying the Company's financial statements and accompanying notes are reasonable. However, the Company's financial statements and accompanying notes may not be an indication of the Company's financial condition and results of operations in the future.

OVERVIEW OF THE COMPANY

Verano, one of the U.S. cannabis industry's leading companies based on historical revenue, geographical scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying *Yes* to plant progress and the bold exploration of cannabis. An operator of licensed cannabis cultivation, processing, wholesale distribution and retail facilities, our goal is the ongoing development of communal wellness by providing responsible access to regulated medical and adult-use cannabis products to discerning customers. As of November 5, 2024, Verano's active operations span 14 states, including 152 retail dispensaries and 15 cultivation and processing facilities with over 1.1 million square feet of cultivation capacity. We produce a wide variety of high quality cannabis products sold under our portfolio of consumer brands, including EncoreTM, AvexiaTM, MÜVTM, SavvyTM, BITSTM and VeranoTM. We also design, build and operate branded retail environments including Zen LeafTM and MÜVTM dispensaries that deliver a cannabis shopping experience in both medical and adult-use markets, including through Cabbage Club, an annual membership program offering exclusive benefits for cannabis consumers.

Notwithstanding the permissive regulatory environment of medical, and in some cases, also adult-use (i.e., recreational) cannabis, at the state level, it remains illegal under U.S. federal law to cultivate, manufacture, distribute, sell or possess cannabis in the U.S. Because federal law prohibits transporting any federally restricted substance across state lines, cannabis cannot be transported across state lines. As a result of current federal law prohibitions, the U.S. cannabis industry is conducted on a state-by-state basis. To date, in the U.S. 38 states plus the District of Columbia and the U.S. territories of Puerto Rico, Guam, the Commonwealth of Northern Marina Islands, and the U.S. Virgin Islands have authorized comprehensive medical cannabis programs, 24 states plus the District of Columbia and the U.S. territories of Guam, the Commonwealth of Northern Mariana Islands, and the U.S. Virgin Islands have authorized comprehensive programs for medical and adult-use (i.e. recreational) cannabis, and 7 states allow the use of low tetrahydrocannabinol and high cannabidiol products for specified medical uses. Verano operates within states where cannabis use, medical or both medical and adult-use, has been approved by state and local regulatory bodies. Strict compliance with state and local laws with respect to cannabis may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against the Company or any of its subsidiaries.

Our strategy is to vertically integrate as a single cohesive company in multiple states through the consolidation of seed-to-sale cultivating, manufacturing, distributing, and dispensing cannabis brands and products at scale. Our cultivation, processing and wholesale distribution of cannabis consumer packaged goods are designed to support our national retail dispensary chains, and to develop and foster long-term wholesale supply relationships with third-party retail dispensary operators. Our strategy includes geographic diversity by establishing a footprint to enable us to adapt to changes in both industry and market conditions.

SELECTED RESULTS OF OPERATIONS

The following presents selected financial data derived from the (i) Unaudited Interim Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2024 and 2023 and (ii) the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023, and should be read in conjunction with the Unaudited Interim Condensed Consolidated Financial Statements and accompanying notes presented in Item 1 of this Form 10-Q. The selected Unaudited Interim Condensed Consolidated financial information below may not be indicative of the Company's future performance.

Three Months Ended September 30, 2024, as Compared to Three Months Ended September 30, 2023

	For the Three Months Ended September 30,							
(\$ in thousands)		2024		2023	1	\$ Change		
Revenues, net of discounts	\$	216,683		\$ 240,088		216,683 \$ 240,088		(23,405)
Gross Profit		109,097		133,220		(24,123)		
Net Loss attributable to Verano Holdings Corp. & Subsidiaries		(42,567)		(17,842)		(24,725)		
Net Loss per share – basic & diluted		(0.12)		(0.05)		(0.07)		

Revenues, net of discounts

Revenues, net of discounts, for the three months ended September 30, 2024 was \$216,683, a decrease of \$(23,405) or (9.7)%, compared to revenue of \$240,088 for the three months ended September 30, 2023. The decrease in revenue was driven primarily by expected declines in New Jersey and Illinois retail as third-party dispensaries continue to open across these states and a decline in product availability in our Florida market due to cultivation expansion projects. This is partially offset by new Zen LeafTM store openings in the Connecticut market during the third and fourth quarters of 2023 and acquisition activity during the three months ended September 30, 2024. Additionally, consistent with other multi-state cannabis operators, the Company has continued to see increased competition and promotional activity in select retail markets, specifically in New Jersey and Illinois. During the three months ended September 30, 2024, the Company opened two new stores in Florida and acquired eight additional stores, two in Arizona and six in Virginia, as part of acquisition activity. Retail revenue for the three months ended September 30, 2024 was approximately 64.5% of total revenue compared to 66.8% of total revenue for the three months ended September 30, 2023, in each case, excluding intersegment eliminations. Cultivation (wholesale) revenue decreased due to competition related to third-party wholesale sales, mainly in the New Jersey market, when compared to the three months ended September 30, 2023. Cultivation (wholesale) revenue for the three months ended September 30, 2024 was 35.5% of total revenue compared to 33.2% of total revenue for the three months ended September 30, 2024 was 35.5% of total revenue compared to 33.2% of total revenue for the three months ended September 30, 2024, in each case, excluding intersegment eliminations.

Gross Profit

Gross profit for the three months ended September 30, 2024 was \$109,097, representing a gross profit margin on the sale of cannabis, cannabis extractions, edibles and related accessories of 50.3%. This is compared to gross profit for the three months ended September 30, 2023 of \$133,220, which represented a 55.5% gross profit margin on the sale of cannabis, cannabis extractions, edibles and related accessories. The decrease in gross profit and gross profit margin on the sale of cannabis extractions, edibles and related accessories during the three months ended September 30, 2024 compared to the three months ended September 30, 2023, was due to reduced top-line revenue coupled with a \$3,280 non-cash impact related to the inventory step-up from acquisitions, partially offset by Ohio adult-use launch during August 2024. Also, the Company continued to experience price compression in Arizona, Florida, Illinois and New Jersey due to increased competition.

Table of Contents

Net Loss

Net Loss attributable to the Company for the three months ended September 30, 2024 was \$(42,567), an increase of \$24,725, compared to a net loss of \$(17,842) for the three months ended September 30, 2023. The increase in net loss was primarily driven by an overall decrease in gross profit coupled with an increase in selling, general and administrative expenses ("SG&A") for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.

	For the Three Months Ended September 30,						
(\$ in thousands)		2024	2023	\$	Change		
Cost of Goods Sold, net	\$	107,586 \$	106,868	\$	718		
Selling, General, and Administrative Expenses		92,327	86,316		6,011		
Other Income (Expense), net		(13,859)	(13,255)		(604)		
Provision for Income Taxes		(45,478)	(44,797)		(681)		

Cost of Goods Sold, net

Cost of goods sold, net includes the costs directly attributable to cultivating and processing cannabis and for retail purchases of finished goods, such as flower, edibles, and concentrates. Cost of goods sold, net for the three months ended September 30, 2024 was \$107,586, an increase of \$718 or 0.7%, as compared to the three months ended September 30, 2023. The increase was attributable to price compression, primarily in New Jersey and also in Arizona and Illinois, coupled with a non-cash impact related to the inventory step-up from acquisitions during the third quarter of 2024.

Selling, General, and Administrative Expenses

Selling, general and administrative expenses for the three months ended September 30, 2024 were \$92,327, an increase of \$6,011 or 7.0%, compared to SG&A expenses of \$86,316 for the three months ended September 30, 2023. SG&A expenses as a percentage of revenue was 42.6% and 36.0% for the three months ended September 30, 2024 and September 30, 2023, respectively. The increase was primarily due to a \$2,590 increase in salaries and benefits, due to increased headcounts related to new store openings during the three months ended September 30, 2024 compared to the three months ended September 30, 2023.

Other Income (Expense), net

Other income (expense), net for the three months ended September 30, 2024, was \$(13,859), an increase of \$604 as compared to the three months ended September 30, 2023. The other income (expense), net increase was mainly due to the Company's contributions to Florida's Smart & Safe adult-use legalization campaign partially offset by lower interest expense related to the 2022 Credit Agreement.

Provision for Income Taxes

Income tax expense is recognized based on the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year-end. Income tax expense for the three months ended September 30, 2024, was \$45,478, an increase of \$681 or 1.5% when compared to the three months ended September 30, 2023.

Nine Months Ended September 30, 2024, as Compared to Nine Months Ended September 30, 2023

	For the Nine Months Ended September 30,						
(\$ in thousands)		2024		2023		\$ Change	
Revenues, net of discounts	\$	660,379	\$	701,263	\$	(40,884)	
Gross Profit		336,397		357,595		(21,198)	
Net Loss attributable to Verano Holdings Corp. & Subsidiaries		(69,153)		(40,140)		(29,013)	
Net Loss per share – basic & diluted		(0.20)		(0.12)		(0.08)	

Revenues, net of discounts

Revenues, net of discounts, for the nine months ended September 30, 2024 was \$660,379, a decrease of \$(40,884) or (5.8)%, compared to revenue of \$701,263 for the nine months ended September 30, 2023. The decrease in revenue was driven primarily by expected declines in New Jersey and Illinois retail markets as third-party dispensaries continue to open across the states. This is partially offset by increases in Maryland retail and wholesale in relation to the adult-use program launch in July 2023, new Zen LeafTM store openings in the Connecticut market during the third and fourth quarters of 2023, and acquisition activity during the three months ended September 30, 2024. During the nine months ended September 30, 2024, the Company opened eight new stores, one in Connecticut, six in Florida and one in Pennsylvania. Additionally, the Company acquired eight additional stores, two in Arizona and six in Virginia, as part of acquisition activity during the third quarter of 2024. Consistent with other multi-state cannabis operators, the Company has continued to see increased competition and promotional activity in select retail markets, specifically in New Jersey and Illinois. Retail revenue for the nine months ended September 30, 2024 was approximately 64.9% of total revenue compared to 68.2% of total revenue for the nine months ended September 30, 2023, in each case, excluding intersegment eliminations. Increased cultivation (wholesale) revenues were driven by third-party wholesale sales in the New Jersey market and increased adult-use third-party wholesale sales in the Maryland market, both, of which attributed to increased production output and sales of cannabis flower and cannabis related products when compared to the nine months ended September 30, 2023. Cultivation (wholesale) revenue for the nine months ended September 30, 2024 was 35.1% of total revenue compared to 31.8% of total revenue for the nine months ended September 30, 2024, in each case, excluding intersegment eliminations.

Gross Profit

Gross profit for the nine months ended September 30, 2024 was \$336,397, representing a gross profit margin on the sale of cannabis, cannabis extractions, edibles and related accessories of 50.9%. This is compared to gross profit for the nine months ended September 30, 2023 of \$357,595, which represented a 51.0% gross profit margin on the sale of cannabis, cannabis extractions, edibles and related accessories. The decrease in gross profit and gross profit margin on the sale of cannabis, cannabis extractions, edibles and related accessories during the nine months ended September 30, 2024 was attributable to overall top-line revenue decline, specifically in the third quarter of 2024.

Net Loss

Net loss attributable to the Company for the nine months ended September 30, 2024 was \$(69,153), an increase of \$29,013, compared to a net loss of \$(40,140) for the nine months ended September 30, 2023. The increase in net loss was driven by overall top-line revenue decline, an increase in SG&A expenses and a loss on debt extinguishment attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.

	For the Nine Months Ended September 30,						
(\$ in thousands)	2024		2023		\$ Change		
Cost of Goods Sold, net	\$ 323,982	\$	343,668	\$	(19,686)		
Selling, General, and Administrative Expenses	269,690		246,224		23,466		
Other Income (Expense), net	(48,375)		(43,760)		(4,615)		
Provision for Income Taxes	(87,485)		(100,796)		13,311		

Cost of Goods Sold, net

Cost of goods sold, net, includes the costs directly attributable to cultivating and processing cannabis and for retail purchases of finished goods, such as flower, edibles, and concentrates. Cost of goods sold, net, for the nine months ended September 30, 2024 was \$323,982, a decrease of \$(19,686) or (5.7)%, as compared to the nine months ended September 30, 2023. The decrease was primarily driven by decreased top-line revenue within the retail markets due to expected declines in New Jersey and Illinois retail markets as third-party dispensaries continue to open across the states, driving increased competition.

Selling, General, and Administrative Expenses

Selling, general and administrative expenses for the nine months ended September 30, 2024 were \$269,690, an increase of \$23,466 or 9.5%, compared to SG&A expenses of \$246,224 for the nine months ended September 30, 2023. SG&A expenses as a percentage of revenue was 40.8% and 35.1% for the nine months ended September 30, 2024, and September 30, 2023, respectively. The increase was primarily due to a \$11,853 increase in salaries and benefits due to increased headcounts related to new store openings, and a \$8,130 increase in general and administrative expenses primarily driven by enhancements in processes and technology, during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. Additionally, SG&A expenses for the nine months ended September 30, 2024 included higher stock based compensation expense compared to the nine months ended September 30, 2023, caused by a prior period expense acceleration benefit during the nine months ended September 30, 2023 and lower award grants during the nine months ended September 30, 2023.

Other Income (Expense), net

Other income (expense), net for the nine months ended September 30, 2024, was \$(48,375), a change of \$(4,615) as compared to the nine months ended September 30, 2023. The other income (expense), net change was mainly due to a loss on debt extinguishment attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement and the Company's contributions to Florida's Smart & Safe adult-use legalization campaign.

Provision for Income Taxes

Income tax expense is recognized based on the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year-end. Income tax expense for the nine months ended September 30, 2024, was \$(87,485), a decrease of \$13,311 or 13.2% primarily due to impacts of prior period return to provision adjustments and a decrease in pre-tax earnings when compared to the nine months ended September 30, 2023.

Results of Operations by Segment

The Company has two reportable segments: (i) cultivation (wholesale) and (ii) retail. Due to the vertically integrated nature of its business, the Company reviews its revenue at the cultivation (wholesale) and retail levels while reviewing its operating results on a consolidated basis.

The following tables summarize revenues, net of discounts, by segment for the three and nine months ended September 30, 2024 and 2023:

For the Three	Months	Ended	September	30.

	* *			*			
(\$ in thousands)	2024 20		2023	2023 \$ Change		% Change	
Revenues, net of discounts							
Cultivation (Wholesale)	\$	90,450	\$	92,389	\$	(1,939)	(2.1)%
Retail		164,404		185,707		(21,303)	(11.5)%
Intersegment Eliminations		(38,171)		(38,008)		(163)	0.4 %
Total Revenues, net of discounts	\$	216,683	\$	240,088	\$	(23,405)	(9.7)%

Revenues, net of discounts, for the cultivation (wholesale) segment were \$90,450 for the three months ended September 30, 2024, a decrease of \$(1,939) or (2.1)%, compared to the three months ended September 30, 2023, in each case, excluding intersegment eliminations. The decrease in cultivation (wholesale) revenues, net of discounts, was primarily driven by competition related to third-party wholesale sales, mainly in the New Jersey market.

Revenues, net of discounts, for the retail segment were \$164,404 for the three months ended September 30, 2024, a decrease of \$(21,303) or (11.5)%, compared to the three months ended September 30, 2023, in each case, excluding intersegment eliminations. Top contributors to retail sales were new Zen LeafTM store openings in the Connecticut market during the third and fourth quarters of 2023 and acquisition activity during the three months ended September 30, 2024. The decrease in retail revenues, net of discounts was primarily driven by increased competition in both the New Jersey and Illinois markets which contributed to the year over year revenue decrease.

For the Nine Months Ended September 30,

				,
(\$ in thousands)	 2024	2023	\$ Change	% Change
Revenues, net of discounts				
Cultivation (Wholesale)	\$ 268,829	\$ 259,266	\$ 9,563	3.7 %
Retail	497,675	556,307	(58,632)	(10.5)%
Intersegment Eliminations	(106,125)	(114,310)	8,185	(7.2)%
Total Revenues, net of discounts	\$ 660,379	\$ 701,263	\$ (40,884)	(5.8)%

Revenues, net of discounts, for the cultivation (wholesale) segment were \$268,829 for the nine months ended September 30, 2024, an increase of \$9,563 or 3.7%, compared to the nine months ended September 30, 2023, in each case, excluding intersegment eliminations. The increase in cultivation (wholesale) revenues, net of discounts, was primarily driven by increased third-party wholesale sales in the Illinois and New Jersey markets coupled with a burgeoning adult-use third-party wholesale sales in the Maryland market, partially offset by increased competition in the New Jersey third-party wholesale market during the third quarter of 2024.

Revenues, net of discounts, for the retail segment were \$497,675 for the nine months ended September 30, 2024, a decrease of \$(58,632) or (10.5)%, compared to the nine months ended September 30, 2023, in each case, excluding intersegment eliminations. Top contributors to retail sales were mainly due to increases in Maryland retail and wholesale in relation to the adult-use program launch in July 2023, new Zen LeafTM store openings in the Connecticut market during the third and fourth quarters of 2023, and acquisition activity during the three months ended September 30, 2024. The overall decrease in retail revenues, net of discounts, was primarily driven by continued increased competition and promotional activity, as expected, in select retail markets, specifically in New Jersey and Illinois. Additionally, modest pricing pressure contributed to the decrease in revenues, net of discounts, when comparing the nine months ended September 30, 2024 to the nine months ended September 30, 2023.

Drivers of Operational Performance

Revenue

The Company derives its revenue from both its cultivation (wholesale) business in which it cultivates, produces and sells cannabis products to third-party retail customers, and its retail business, in which it directly sells cannabis products to retail patients and consumers. For the three months ended September 30, 2024, approximately 35.5% of the Company's revenue was generated from the cultivation (wholesale) business, excluding intersegment eliminations, and approximately 64.5% from the retail business, excluding intersegment eliminations. For the nine months ended September 30, 2024, approximately 35.1% of revenue was generated from the cultivation (wholesale) business and approximately 64.9% from the retail business, excluding intersegment eliminations.

Gross Profit

Gross profit is revenue less cost of goods sold, net. Cost of goods sold, net includes the costs directly attributable to product sales and includes amounts paid for finished goods, such as flower, edibles, and concentrates, as well as packaging and other supplies, fees for services and processing, rent, utilities, and related costs. Cannabis costs are affected by various state regulations that limits the sourcing and procurement of cannabis products, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes. Gross margin measures the Company's gross profit as a percentage of revenue.

The Company's expansion strategy and revenue growth have taken priority and will continue to do so for the foreseeable future as it expands its footprint, by exploring new markets and opening or acquiring new dispensary locations, and scales production within current markets. In the core markets in which the Company is already operational and, as the state markets mature, the Company anticipates that there will be pressure on margins in the cultivation (wholesale) and retail channels. The Company's current production capacity has not been fully realized and it is expected that price compression at the cultivation (wholesale) level, will be offset by operational optimization.

Total Expenses

Total expenses, other than the cost of goods sold, consist of selling costs to support customer relationships and to deliver product to the Company's retail stores. It also includes a significant investment in the corporate infrastructure required to support ongoing business.

Selling costs generally correlate to revenue. As a percentage of sales, selling costs are expected to increase slightly in currently operational markets (Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia) as facility and market expansion occurs. The increase is expected to be driven primarily by the growth of the Company's retail and cultivation (wholesale) channels and the ramp up from new retail openings.

SG&A expenses also include costs incurred at the Company's corporate offices, primarily related to back-office personnel costs, including salaries, incentive compensation, benefits, stock-based compensation and professional service costs. Going forward, SG&A expenses are expected to continue in line with the Company's expansion plans. Furthermore, the Company expects to continue to incur acquisition and transaction costs related to these expansion plans and anticipates stock compensation expenses related to recruiting and hiring talent, along with legal and professional fees associated with being a public-reporting company and publicly traded in Canada and a public-reporting company in the U.S.

Provision for Income Taxes

The Company is subject to income taxes in the jurisdictions in which it operates and, consequently, income tax expense is a function of the allocation of taxable income by jurisdiction and the various activities that impact the timing of taxable events. As the Company operates in the cannabis industry, it is subject to the limits of Section 280E of the Code under which the Company is only allowed to deduct expenses directly related to the sale of products. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under Section 280E of the Code and a higher effective tax rate than most industries.

During the second quarter of 2023, Connecticut, Illinois, and New Jersey enacted tax legislation to exempt, or decouple, from Section 280E of the Code, all of which became retroactively effective as of January 1, 2023. The Company has significant operations in these states and is now permitted to deduct ordinary and necessary cannabis business expenses in these states.

LIQUIDITY, FINANCING ACTIVITIES AND CAPITAL RESOURCES

As of September 30, 2024 and December 31, 2023, the Company had total current liabilities of \$435,375 and \$412,188, respectively. As of September 30, 2024 and December 31, 2023, the Company had cash and cash equivalents of \$64,981 and \$174,760, respectively, to meet its current obligations. The Company had working capital deficit of \$(113,654) as of September 30, 2024, a decrease of working capital of \$(95,662) as compared to December 31, 2023. This decrease in working capital was largely driven by acquisition activity and capital expenditures during the nine months ended September 30, 2024.

The Company is an early-stage growth company, generating cash from revenues and deploying its capital to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and long term. Capital is primarily being utilized for capital expenditures, facility improvements, strategic investment opportunities, product development and marketing, as well as customer, supplier, and investor and industry relations. The Company takes a cautious approach in allocating its capital to maximize its returns while ensuring appropriate liquidity. Given inflation and the uncertainty of the future economic environment, the Company has taken additional measures in monitoring and deploying its capital to minimize the negative impact on its operations and expansion plans.

Liquidity Requirements

Our short-term liquidity requirements consist primarily of funds necessary to pay for our acquisitions, to repay borrowings, maintain our operations and other general business needs. We believe that internally generated funds and other sources of liquidity discussed below will be sufficient to meet working capital needs, capital expenditures, payments of income tax payables and other business requirements for at least the next 12 months. We believe we will meet known or reasonably likely future cash requirements through the combination of cash generated from operating activities, available cash balances and available borrowings. If these sources of liquidity need to be augmented, additional cash requirements would likely be financed through the issuance of equity securities or additional borrowings; however, there can be no assurances that we will be able to obtain additional equity financing or debt financing on acceptable terms in the future.

Our long-term liquidity requirements consist primarily of completing additional acquisitions, capital expenditures, scheduled debt payments, future payments of income tax payables, maintaining and expanding our operations and other general business needs. We expect to meet our long-term liquidity requirements through various sources of capital, which may include future debt or equity issuances, net cash provided by operations and other secured and unsecured borrowings. We believe that the foregoing sources of capital will provide sufficient funds for our operations, anticipated expansion and scheduled debt payments for the long-term. Our ability to fund our operating needs will depend on our future ability to continue to generate positive cash flow from operations and our ability to obtain debt or equity financing on acceptable terms.

Credit Facility

On October 27, 2022, Verano and certain of its subsidiaries and affiliates from time-to-time party thereto (collectively, the "Borrowers"), entered into a Credit Agreement (the "2022 Credit Agreement") with Chicago Atlantic Admin, LLC ("Chicago Atlantic"), as administrative agent for the lenders, and the lenders from time-to-time party thereto (the "Lenders"), pursuant to which the Lenders advanced the Borrowers a \$350,000 senior secured term loan, all of which was used to repay the principal indebtedness outstanding under the Company's previous senior secured term loan credit facility. In connection with such repayment, such previous credit facility was terminated and is no longer in force or effect.

The 2022 Credit Agreement provides the Borrowers with the right, subject to conditions, to request an additional incremental term loan in the aggregate principal amount of up to \$100,000; provided that the Lenders elect to fund such incremental term loan. Beginning in October 2023, the loan requires scheduled amortization payments of \$350 per month and the remaining principal balance is due in full on October 30, 2026.

The 2022 Credit Agreement also provides the Borrowers with the right to (a) incur up to \$120,000 of additional indebtedness from third-party lenders secured by real estate excluded as collateral under the 2022 Credit Agreement, (b) incur additional mortgage financing from third-party lenders secured by real estate acquired after the closing date, and (c) upon the SAFE Banking Act or similar legislation making banking services available to U.S. cannabis companies being passed by the United States Congress, incur up to \$50,000 pursuant to a revolving credit facility from third-party lenders that is pari passu or subordinated to the 2022 Credit Agreement obligations, each of which are subject to customary conditions.

The obligations under the 2022 Credit Agreement are secured by substantially all of the assets of the Borrowers, excluding vehicles, specified parcels of real estate and other customary exclusions.

Table of Contents

The 2022 Credit Agreement provides for a floating annual interest rate equal to the prime rate then in effect plus 6.50%, which rate may be increased by 3.00% upon an event of default that is not a material event of default or 6.00% upon a material event of default.

At any time, the Company may voluntarily prepay up to \$100,000 of the principal balance, subject to a one-time \$1,000 prepayment premium upon the first prepayment, and may prepay the remaining outstanding principal balance for a prepayment premium at varying rates based on the timing of any subsequent prepayments. The Borrowers may not voluntarily prepay more than \$100,000 of the principal balance without prepaying the entire outstanding principal balance of the loan.

The 2022 Credit Agreement includes customary representations and warranties and covenants and customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to material indebtedness, and events of bankruptcy and insolvency.

The 2022 Credit Agreement also includes customary negative covenants limiting the Borrowers' ability to incur additional indebtedness and grant liens that are not otherwise permitted, and the ability to enter into or consummate acquisitions or dispositions that are not otherwise permitted, among others. Additionally, the 2022 Credit Agreement requires the Borrowers to meet certain financial tests regarding minimum cash balances, minimum levels of Adjusted EBITDA (as defined in the 2022 Credit Agreement) and a minimum fixed charge coverage ratio.

As of September 30, 2024, the Company was in compliance with such covenants.

Permitted Partial Optional Prepayment and Lien Release

On April 30, 2024, the Company, made a Permitted Partial Optional Prepayment (as defined in the 2022 Credit Agreement) in the amount of \$50,000 pursuant to the 2022 Credit Agreement and paid \$1,000 prepayment premium in connection therewith.

In connection with such Permitted Partial Optional Prepayment, Chicago Atlantic and certain Lenders agreed to (a) release certain Borrowers from their obligations under, and as parties to, the 2022 Credit Agreement and related agreements (the "Released Borrowers") and (b) release all liens over the Released Borrowers' property, including real estate, held by Chicago Atlantic for the benefit of the Lenders, in each case, pursuant to a limited consent and waiver, dated as of April 29, 2024, by and among the Borrowers, certain of the Lenders party thereto and Chicago Atlantic.

Columbia Care Eastern Virginia LLC

On July 29, 2024, the Company entered into the Virginia EPA to purchase all of the issued and outstanding equity interests in CC East Virginia. The transaction closed on August 21, 2024. Pursuant to the Virginia EPA, the Company issued the CC East Virginia Promissory Note in the amount of \$26,700, which is subject to further adjustment, and which bears interest at a rate of 7% per annum beginning on the closing date, through maturity on the two-year anniversary of the closing date.

Tax Liabilities

The Company has U.S. income tax payable liabilities. These income tax payable liabilities will require payment from our liquidity sources, and we believe we have sufficient liquidity for both short-term and long-term payments of our income tax payable liabilities and in addition to our other obligations.

Table of Contents

Sources and Uses of Cash

Cash Provided by (Used in) Operating Activities, Investing and Financing Activities

Net cash provided by (used in) operating, investing, and financing activities for the nine months ended September 30, 2024 and 2023 were as follows:

	Nine Months Ended September 30,						
	 2024	2023		\$ Change			
Net Cash Provided by Operating Activities	\$ 68,694 \$	77,361	\$	(8,667)			
Net Cash Used in Investing Activities	(120,852)	(24,323)		(96,529)			
Net Cash Used in Financing Activities	(57,635)	(7,964)		(49,671)			

Cash flows from Operating Activities. During the nine months ended September 30, 2024 and 2023, the Company had net cash inflows of \$68,694 and \$77,361, respectively. The \$(8,667) decrease was mainly driven by an increase in inventory from acquisition activity during the third quarter of 2024, when comparing the nine months ended September 30, 2024 to the nine months ended September 30, 2023.

Cash Flows from Investing Activities. During the nine months ended September 30, 2024 and 2023, the Company had net cash outflows of \$(120,852) and \$(24,323), respectively. The \$(96,529) increase in net cash outflows during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 is primarily driven by cash outflows related to the purchases of property, plant and equipment of \$(84,803) during the nine months ended September 30, 2024, compared to purchases of property, plant and equipment of \$(26,503) during the nine months ended September 30, 2023, as well as acquisition activity during the third quarter of 2024.

Cash Flows from Financing Activities. During the nine months ended September 30, 2024 and 2023, the Company had net cash outflows of \$(57,635) and \$(7,964), respectively. The \$(49,671) increase in net cash outflows during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 was largely attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement during the nine months ended September 30, 2024.

Changes in or Adoption of Accounting Practices

Refer to the discussion of recently adopted/issued accounting pronouncements under Part I, Item 1, Notes to Unaudited Interim Condensed Consolidated Financial Statements, Note 1 - Overview and Basis of Presentation.

Critical Accounting Policies and Significant Judgements and Estimates

There were no material changes to our critical accounting policies and estimates from the information provided in "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in the Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our market risk disclosures as set forth in Part II, Item 7A of the Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (who is our principal executive officer) and Chief Financial Officer (who is our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as of September 30, 2024, the end of the period covered by this Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-Q, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Exchange Act and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures due to the material weaknesses in internal control over financial reporting identified as of December 31, 2023 and as described in Item 9A. Controls and Procedures in the Form 10-K. We believe, that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

We previously identified and disclosed material weaknesses in internal control over financial reporting as described in Item 9A. Controls and Procedures in the Form 10-K. These material weaknesses are currently in the process of being remediated, as of September 30, 2024. Other than the previously identified and disclosed plans to remediate the material weaknesses in internal control over financial reporting as described in Item 9A. Controls and Procedures in the Form 10-K, there have not been any changes in our internal control over financial reporting during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company may be subject to legal proceedings, claims, investigations and government inquiries in the ordinary course of business. The Company has received, and may in the future continue to receive, claims from third parties.

Please see the Notes to Unaudited Interim Condensed Consolidated Financial Statements, Note 11 - Contingencies and Other - Claims and Litigation, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS.

Part I, Item 1A. "Risk Factors" in our Form 10-K includes a discussion of our risk factors. There have been no material changes from the risk factors described in the Form 10-K. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future SEC filings.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None which have not been reported on a Current Report on Form 8-K.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

Laura Marie Kalesnik, the Company's Chief Legal Officer, General Counsel and Secretary, adopted a prearranged share trading plan with a brokerage firm on September 9, 2024, provided that such prearranged share trading plan will not become effective until the completion of the applicable cooling-off period following the termination of Ms. Kalesnik's currently effective prearranged share trading plan (the "Cooling-Off Period"). Ms. Kalesnik's currently effective prearranged trading plan will remain in place until all contemplated sales are completed. Ms. Kalesnik's plan provides for the sale of 72,888 Subordinate Voting Shares between (i) the later of (x) June 1, 2025 and (y) the first trading date following the completion of the Cooling-Off Period, and (ii) December 1, 2025; provided, that such number of Subordinate Voting Shares reflects estimated tax withholdings and actual sale amounts may vary. Ms. Kalesnik's trading plan was entered into during an open trading window and is intended to satisfy the affirmative defenses of Rule 10b5-1(c) under the Exchange Act and the Company's policies regarding insider transactions.

ITEM 6. EXHIBITS

Exhibit Number	Description of Exhibit
3.1*	Articles of Verano Holdings Corp., dated February 11, 2021 (filed as Exhibit 3.1 to our Registration Statement on Form 10 filed on April 26, 2022 (File No. 000-56342) and incorporated herein by reference).
3.2*	Notice of Articles of Verano Holdings Corp., dated February 11, 2021 (filed as Exhibit 3.2 to our Registration Statement on Form 10 filed on April 26, 2022 (File No. 000-56342) and incorporated herein by reference).
10.1*+	Equity Purchase Agreement, dated July 29, 2024, among Verano Holdings, LLC, Verano Holdings Corp., Columbia Care Eastern Virginia LLC and the members of Columbia Care Eastern Virginia LLC and The Cannabist Company Holdings Inc. (filed as Exhibit 10.1 to the Current Report on Form 8-K filed on July 31, 2024 (File No. 000-56342) and incorporated herein by reference).
10.2*	Form of Verano Holdings, LLC Promissory Note (filed as Exhibit 10.2 to the Current Report on Form 8-K filed on July 31, 2024 (File No. 000-56342) and incorporated herein by reference).
10.3**+	Equity Purchase Agreement, dated July 29, 2024, as amended on October 28, 2024, among Verano Arizona, LLC, 203 Organix L.L.C., CC VA HoldCo LLC, Columbia Care-Arizona, Prescott, L.L.C. and The Cannabist Company Holdings Inc.
10.4*+	Equity Purchase Agreement, dated July 29, 2024, among Verano Arizona, LLC, Salubrious Wellness Clinic, Inc., CC VA HoldCo LLC, Thomas Allison, Columbia Care-Arizona, Prescott, L.L.C. and The Cannabist Company Holdings Inc. (filed as Exhibit 10.4 to the Current Report on Form 8-K filed on July 31, 2024 (File No. 000-56342) and incorporated herein by reference).
31.1**	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2**	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1***	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2***	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL Document)

Table of Contents

- * Previously filed.
- ** Filed herewith
- *** Furnished herewith
- + Certain portions of the exhibit have been omitted pursuant to Regulation S-K Item 601(a)(5)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 7, 2024

VERANO HOLDINGS CORP.

By: /s/ George Archos

Name: George Archos

Title: Chief Executive Officer

By: /s/ Brett Summerer

Name: Brett Summerer

Title: Chief Financial Officer

EQUITY PURCHASE AGREEMENT

BY AND AMONG

VERANO ARIZONA, LLC,

203 ORGANIX L.L.C.,

CC VA HOLDCO LLC,

COLUMBIA CARE-ARIZONA, PRESCOTT, L.L.C.,

AND

THE CANNABIST COMPANY HOLDINGS INC.

Dated as of July 29, 2024

FH12251261.5

TABLE OF CONTENTS

<u>Page</u>

Section 1.1	Certain Definitions 1
Section 1.2	Other Defined Terms 10
A DELCT E II DUD CU	ACE AND GALE TRANSACTIONS 1
	ASE AND SALE TRANSACTIONS 1 Purchase and Sale 1
	Purchase Price 1
	Estimated Closing Statement 1 Post-Closing Adjustment 1
	Closing Transactions 3
Section 2.5	
Section 2.0	Tax withholding 5
ARTICLE III REPRE	SENTATIONS AND WARRANTIES CONCERNING THE COMPANY 6
Section 3.1	Organization; Authorization 6
Section 3.2	Non-contravention 6
Section 3.3	Capitalization 7
Section 3.4	Financial Statements and Related Matters 7
Section 3.5	Absence of Developments 9
Section 3.6	Real Property 9
Section 3.7	Assets 11
Section 3.8	Tax Matters 11
Section 3.9	Material Contracts 15
Section 3.10	Intellectual Property; Data Privacy and Security 16
Section 3.11	Litigation 17
Section 3.12	Brokerage 18
Section 3.13	Employees 18
Section 3.14	Employee Benefit Plans 20
Section 3.15	Insurance 22
Section 3.16	Compliance with Laws; Permits 22
Section 3.17	Environmental Matters 23
Section 3.18	Affiliated Transactions 24
Section 3.19	Indebtedness 24
Section 3.20	Product Liability 24
Section 3.21	Bank Accounts; Identification Numbers. 24
Section 3.22	Organization; Authorization 24
ADTICLE IV DEDDE	SENTATIONS AND WARRANTIES OF BUYER 25
Section 4.1	Organization; Authorization 25
	Non-contravention 25
Section 4.2	Sufficiency of Funds. 25
	No Other Representations or Warranties 25
50011011 7.4	100 other representations of warranties 23
ARTICLE V PRE-CL	OSING COVENANTS 25

FH12251261.5

Section 5.1	Conduct of Business Prior to the Closing. 25
Section 5.3	Access to Information; Confidentiality. 27
Section 5.4	Notice of Certain Events. 28
Section 5.5	Governmental Approvals. 28
Section 5.6	No Solicitation by the Company 29
Section 5.7	Security Interest. 29
Section 5.8	Closing Conditions. 30
ARTICLE VI ADDIT	IONAL AGREEMENTS 33
Section 6.1	Survival of Representations and Warranties 33
Section 6.2	General Indemnification 33
Section 6.3	Certain Tax Matters 35
Section 6.4	Indemnification Procedures 38
Section 6.5	Expenses 40
Section 6.6	Further Assurance and Post-Closing Actions 40
Section 6.7	Restrictive Covenants 40
Section 6.8	Release 43
ARTICLE VII COND	OITIONS TO CLOSING 44
Section 7.1	Conditions to Obligations of All Parties. 44
Section 7.2	Conditions to Obligations of Buyer. 44
Section 7.3	Conditions to Obligations of the Company, Cannabist and the Member. 45
ARTICLE VIII TERM	MINATION 45
Section 8.1	Termination. 45
Section 8.2	Effect of Termination. 46
ARTICLE IX MISCE	LLANEOUS 46
Section 9.1	Amendment and Waiver 46
Section 9.2	Notices 47
Section 9.3	Assignment 47
Section 9.4	•
Section 9.5	Interpretation 48
Section 9.6	Entire Agreement 48

Section 9.7 Counterparts; Electronic Delivery 48

Section 9.10 No Third-Party Beneficiaries 49 Schedules 49

Section 9.9 Specific Performance 49

Section 9.12 Excluded Claims. 50

Section 9.11

Section 9.8 Governing law; Waiver of Jury Trial; Arbitration 48

EQUITY PURCHASE AGREEMENT

This Equity Purchase Agreement (this "<u>Agreement"</u>) is entered into as of July 29, 2024, by and among (i) Verano Arizona, LLC, an Arizona limited liability company ("<u>Buyer</u>"), (ii) 203 Organix L.L.C., an Arizona limited liability company (the "<u>Company</u>"), (iii) Columbia Care-Arizona, Prescott, L.L.C., an Arizona limited liability company (the "<u>Member</u>"), (iv) The Cannabist Company Holdings Inc., a British Columbia corporation ("<u>Cannabist</u>") and (v) solely for purposes of <u>Sections 2.4(d)</u> and <u>6.2(e)</u>, CC VA Holdco LLC, a Delaware limited liability company ("<u>CC VA</u>"). Buyer, the Company, the Member, CC VA and Cannabist are collectively referred to herein as the "<u>Parties</u>", and individually as a "<u>Party</u>".

RECITALS

WHEREAS, the Company is engaged in the business of cultivating, producing, manufacturing, distributing and selling cannabis in the State of Arizona;

WHEREAS, the Member owns beneficially and of record all of the issued and outstanding equity interests of the Company as of the date hereof (the "Equity");

WHEREAS, Buyer desires to purchase from the Member, and the Member desire to sell to Buyer, all of the Equity;

WHEREAS, substantially simultaneously with the date hereof, Buyer and Cannabist (along with the others party thereto) have entered into (a) an equity purchase agreement, pursuant to which Buyer will acquire 100% of the issued and outstanding equity interests of Columbia Care Eastern Virginia LLC (the "<u>Virginia Purchase Agreement</u>") and (b) an equity purchase agreement, pursuant to which Buyer will acquire 100% of the issued and outstanding equity interests of Salubrious Wellness Clinic, Inc. (the "<u>SWC Arizona Purchase Agreement</u>"); and

WHEREAS, Cannabist will derive substantial economic and other direct and indirect benefits from the transactions contemplated hereby.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants contained herein and intending to be legally bound, the Parties hereby agree as follows:

Article I CERTAIN DEFINITIONS

Section I.1 <u>Certain Definitions</u>. Capitalized terms used but not otherwise defined herein have the meanings set forth below.

"<u>Acquisition Proposal</u>" means any proposal or offer from any Person or "group" (as defined in Section 13(d) of the Exchange Act), other than Buyer or its Affiliates, relating to any (a) direct or indirect acquisition (whether in a single transaction or a series of related transactions) of a material portion of the assets of the Company, (b) direct or indirect acquisition

1

(whether in a single transaction or a series of related transactions) of a material portion of the equity interests of the Company or (c) merger, consolidation, reorganization, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving the Company, in each case, other than the transactions contemplated hereby.

"Affiliate" of any particular Person means any other Person controlling, controlled by or under common control with such Person, where "control" means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise.

"Affiliated Group" means a group of Persons that elects, is required to, or otherwise files a Tax Return or pays a Tax as an affiliated group, consolidated group, combined group, unitary group, or other group recognized by applicable Tax Law.

"Applicable Accounting Guidelines" means the methodologies and guidelines set forth on Schedule 1.1(a) attached hereto.

"Arizona Cannabis Laws" means the marijuana establishment Laws of any jurisdictions within the State of Arizona to which the Company is, or may at any time become, subject, and the rules and regulations adopted by the Arizona Department of Health Services or any other state or local Governmental Entity with authority to regulate any marijuana operation (or proposed marijuana operation).

"Business Day" means any day other than a Saturday or Sunday or a day on which banks in Chicago, Illinois, Toronto, Ontario or Vancouver, British Columbia are required or authorized by Law to close or Cboe is not open for trading.

"Buyer Group" means Buyer and its subsidiaries and Affiliates (including, following the Closing, the Company).

"Buyer Indemnified Parties" means the Buyer Group, their respective Affiliates and the direct and indirect equityholders, managers, members, partners, officers, directors, employees, agents, representatives, successors, beneficiaries and assigns thereof.

"<u>Buyer Tax Losses</u>" means (a) all Indemnified Taxes, (b) all costs and expenses of preparing Tax Returns for a Pre-Closing Tax Period and (c) all costs and expenses of contesting any audit or other legal Proceeding related to Taxes that could result in the imposition of an Indemnified Tax.

"Canadian Securities Authorities" means, collectively, the British Columbia Securities Commission, the Ontario Securities Commission, the Alberta Securities Commission and the other applicable securities regulatory authorities in the provinces and territories of Canada.

"Cash" means cash of the Company (other than Restricted Cash) determined in accordance with GAAP as of 12:01 a.m. Central Time on the Closing Date; provided, however, that the calculation of "Cash" shall be reduced by (a) the use or transfer of any cash outside the

Ordinary Course of Business or any cash used to pay any distributions to the Member, repurchase any Equity, pay any Transaction Expenses or Transaction Payments or pay off any Indebtedness, in each case, between 12:01 a.m. Central Time on the Closing Date and the Closing and (b) the amount of the Restricted Cash.

"Cboe" means Cboe Canada or, if the Class A subordinate voting shares in the capital of Verano Holdings Corp., a British Columbia corporation, are no longer listed on Cboe Canada, then Cboe shall mean the established stock exchange on which such shares are then listed.

"Code" means the Internal Revenue Code of 1986, as amended.

"Contract" means any written or oral contract, lease, license, commitment, sales order, purchase order, agreement, indenture, mortgage, note, bond, instrument, plan or other comparable document.

"Current Assets" means the aggregate amount of the current assets of the Company to the extent such assets arise in the Ordinary Course of Business. Notwithstanding anything contained herein to the contrary, Current Assets shall exclude all Cash and Tax assets of the Company. Current Assets shall be determined in accordance with the Applicable Accounting Guidelines.

"<u>Current Liabilities</u>" means the aggregate amount of the current liabilities of the Company. Notwithstanding anything contained herein to the contrary, Current Liabilities shall exclude (a) all Tax liabilities and (b) all Indebtedness, Transaction Expenses and Transaction Payments to the extent included in the calculation of the Final Purchase Price. Current Liabilities shall be determined in accordance with the Applicable Accounting Guidelines.

"Data Room" means the Company's due diligence data site hosted on Box.

"Environmental Laws" means, whenever in effect, all Laws and similar provisions having the force or effect of Law, all Permits and all contractual obligations concerning public health and safety, worker health and safety, or pollution or protection of the environment or natural resources, including with respect to emissions, discharges, releases or threatened releases of Hazardous Materials or otherwise relating to the manufacture, processing, marketing, labeling, registration, notification, packaging, import, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.

"ERISA" means the Employee Retirement Income Security Act of 1974, as amended.

"ERISA Affiliate" means any Person that, together with the Company, is or was (at any relevant time) treated as a single employer under Section 414 of the Code.

"Exchange Act" means the Securities Exchange Act of 1934.

"Federal Cannabis Laws" means any U.S. federal Laws, civil, criminal or otherwise, as such relate, either directly or indirectly, to the cultivation, harvesting, production, distribution, sale and possession of cannabis, marijuana or related substances or products containing or relating to the same, including, without limitation, the prohibition on drug trafficking under 21

U.S.C. § 841(a), et seq., the conspiracy statute under 18 U.S.C. § 846, the bar against aiding and abetting the conduct of an offense under 18 U.S.C. § 2, the bar against misprision of a felony (concealing another's felonious conduct) under 18 U.S.C. § 4, the bar against being an accessory after the fact to criminal conduct under 18 U.S.C. § 3, and federal money laundering statutes under 18 U.S.C. §§ 1956, 1957, and 1960 and the regulations and rules promulgated under any of the foregoing.

"Flow-Thru Entity" means any entity, plan or arrangement that is treated for income Tax purposes as a partnership.

"Fundamental Representations" means the representations and warranties set forth in Section 3.1 (Organization; Authorization), Section 3.2 (Non-contravention), Section 3.3 (Capitalization), Section 3.7 (Assets), Section 3.8 (Tax Matters), Section 3.12 (Brokerage), Section 3.14 (Employee Benefit Plans), Section 3.16 (Compliance with Laws; Permits), Section 3.18 (Affiliated Transactions) and Section 3.22 (Organization; Authorization).

"GAAP" means United States generally accepted accounting principles, consistently applied.

"GDPR" means EU General Data Protection Regulation (GDPR): Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, together with any guidance or implementing regulations promulgated by qualified data protection authorities or individual EU member states.

"Governmental Entity" means any federal, state, county, municipal, local or foreign government authority, or any entity exercising executive, legislative, judicial, regulatory, Tax or administrative functions of or pertaining to government of the United States, or any other country, including any political subdivision or regulatory authority thereof, and any department, court arbitrator, agency or official of any of the foregoing.

"Hazardous Materials" means any substance, waste, or material which is regulated by or may give rise to standards of conduct or liability pursuant to Environmental Laws, including petroleum and any byproduct or derivative thereof, asbestos, polychlorinated biphenyls, urea formaldehyde, per- and polyfluoroalkyl substances, and any substance that is defined or regulated as hazardous or toxic or is corrosive, flammable, explosive, infectious, radioactive, or carcinogenic.

"Indebtedness" means, without duplication, the aggregate dollar amount of: (a) all indebtedness of the Company for borrowed money, including all fees and interest accrued thereon; (b) all liabilities of the Company evidenced by a note, bond, debenture or other debt security, including all interest accrued thereon; (c) all lease obligations of the Company that under GAAP are required to be capitalized (provided, that obligations arising under the Master Lease Agreement following the Closing shall not be counted as "Indebtedness"); (d) all guarantees, pledges or similar assurances by the Company to pay another Person's indebtedness or to perform another Person's obligation in the case of default; (e) all liabilities under letters of credit, bankers' acceptances or similar instruments; (f) all liabilities of the Company secured by a

Lien on any assets of the Company; (g) all liabilities (contingent or otherwise) of the Company in respect of the deferred purchase price or "earn-out" payment for any asset, business, property or services; (h) all liabilities owed by the Company to the Member or any Affiliate, equityholder or beneficiary of the Member or to any former equityholder or any Affiliate of such former equityholder; (i) all liabilities owed by the Company to current and former employees and their dependents under any pension or deferred compensation plan or Contract; (j) all severance and retention obligations of the Company (including the employer portion of any employment or payroll Taxes related thereto); (k) solely to the extent not included in the calculation of Final Working Capital, all obligations of the Company in respect of accrued and unused vacation and unpaid annual, quarterly and/or period bonuses, incentives and commissions (whether or not accrued) payable to any current or former employee, director or independent contractor of the Company related to pre-Closing time periods, including the year in which the Closing occurs (including the employer portion of any employment or payroll Taxes related thereto); (1) all unpaid Taxes of the Company for any Pre-Closing Tax Period or portion of a Straddle Period ending on the Closing Date (calculated on a jurisdiction by jurisdiction basis, with zero dollars (\$0) being the lowest amount for a jurisdiction); (m) any prepayment, breakage, make-whole or similar penalties or charges payable in connection with the discharge of any Indebtedness at Closing; (n) any hedging arrangements, currency swap agreements or similar financial agreements; (o) all bank overdrafts; (p) all customer credits, credits against accounts receivable or any similar credits; (q) all deferred revenue, customer deposits and similar credit balances; (r) all obligations to repay deposits or such other amounts advanced by a third party; (s) any amounts owed pursuant to any settlement agreement; and (t) obligations with respect to deferred capital expenditures.

"Indemnified Taxes" means, without duplication, any of the following Taxes (in each case, whether imposed, assessed, due or otherwise payable directly, as a successor or transferee, jointly and/or severally, pursuant to a Tax allocation, sharing, indemnity or similar agreement entered (or assumed) by the Company on or prior to the Closing Date, in connection with the filing of a Tax Return, as a result of an assessment or adjustment by any Governmental Entity, by means of withholding, or for any other reason and whether disputed or not): (a) all Taxes of any Member, (b) all Taxes of the Company (other than Transfer Taxes) for any Pre-Closing Tax Period, or portion of any Straddle Period ending on the Closing Date, (c) all Taxes of any Person imposed on the Company as a transferee or successor, by Contract or pursuant to any Law, which Taxes relate to an event or transaction occurring before the Closing, (d) all Taxes resulting from (i) a breach of a representation or warranty in Section 3.8 (Tax Matters) or a representation or warranty with respect to Taxes in Section 3.14 (Employee Benefit Plans) (in each case construed as if they were not qualified by "knowledge," "material," "material adverse effect" or similar language), or a breach of a covenant or other agreement of any Member contained in this Agreement, (e) all Transfer Taxes, (f) all Taxes imposed as a result of any loss, reduction, disallowance, or unavailability (in whole or in part) of any refund (whether as cash or a credit or offset against Taxes otherwise payable) that (i) was received by the Company on or before the Closing Date, or (ii) was included in the computation of Working Capital, as finally determined, and (g) all Taxes imposed on the Company under Treasury Regulation 1.1502-6 (or any comparable provision of foreign, state, or local law) as a result of the Company's (or any predecessor's) inclusion as a member of an affiliated, consolidated, combined or unitary group

on or prior to the Closing Date, including an affiliated group under Section 1504 of the Code. Indemnified Taxes shall exclude Taxes to the extent included in (A) the computation of Working Capital, as finally determined, (B) the computation of Indebtedness, as finally determined, (C) the Transaction Expenses paid or deposited as of the Closing Date under Section 2.5(c)(i)(B), or (D) the Transactions Payments paid or deposited as of the Closing Date under Section 2.5(c)(i)(C).

"Insider" means an officer, director, manager, equityholder, employee or Affiliate of the Company or any natural person related by marriage or adoption to any such natural person or any entity in which any such Person owns any beneficial interest.

"Intellectual Property" means all worldwide: (a) patents, industrial designs, and utility models, and applications for any of the foregoing, and patentable subject matter, whether or not the subject of any application, and all reissues, reexaminations, divisions, divisionals, renewals, extensions, provisionals, continuations and continuations-in-part thereof, and all patents, applications, documents and filings claiming priority to or serving as a basis for priority thereof; (b) trademarks, service marks, certification marks, trade names, trade dress, logos, slogans, tag lines, and other source or business identifiers or designators of origin (all whether registered or not), all applications and registrations for any of the foregoing, all renewals and extensions thereof, and all common law rights in and goodwill associated with any of the foregoing (collectively, "Trademarks"); (c) uniform resource locators, Internet domain names and numbers, social media accounts, websites and any registrations and applications for any of the foregoing; (d) works of authorship, copyrights, mask work rights, database rights, and design rights, all whether registered or unregistered, applications and registrations for any of the foregoing, renewals and extensions thereof, all moral rights associated with any of the foregoing, and all economic rights of authors and inventors, however denominated, associated with any of the foregoing; (e) computer software and databases, including source code and object code, development tools, comments, user interfaces, menus, buttons and icons, and all files, data, scripts, application programming interfaces, manuals, design notes, programmers' notes, architecture, algorithms and other items and documentation related thereto or associated therewith, and any derivative works, foreign language versions, fixes, upgrades, updates, enhancements, new versions, previous versions, new releases and previous releases thereof; and all media and other tangible property necessary for the delivery or transfer thereof (collectively, "Software"); (f) trade secrets and other proprietary and confidential information, including inventions (whether or not patentable), invention disclosures, ideas, developments, improvements, know-how, designs, drawings, algorithms, source code, methods, processes, techniques, formulae, research and development, compilations, compositions, manufacturing and production processes, devices, technical data, specifications, reports, analyses, data analytics, customer lists, supplier lists, pricing and cost information and business and marketing plans and proposals; and (g) any rights recognized under applicable Law that are equivalent or similar to any of the foregoing.

"IT Assets" means Software, systems, servers, computers, hardware, firmware, middleware, networks, data communications lines, routers, hubs, switches and all other

information technology equipment, and all associated documentation, in each case, used or held for use in the operation of the business of the Company.

"<u>Law</u>" means any law, statute, regulation, ordinance, rule, common law, Order, decree, judgment, consent decree, settlement agreement or governmental requirement enacted, promulgated, entered into, agreed or imposed by any Governmental Entity, including state, federal and foreign criminal and civil laws and/or related regulations and the Arizona Cannabis Laws.

"<u>Leased Real Property</u>" means all leasehold, subleasehold, licensed estates and other rights to use or occupy any land, buildings, structures, improvements, fixtures or other interest in real property held by the Company.

"<u>Leasehold Improvements</u>" means all buildings, structures, improvements and fixtures, building systems and equipment, and all components thereof, located on any Leased Real Property which are owned or leased by Company, regardless of whether title to such buildings, structures, improvements or fixtures are subject to reversion to the landlord or other third party upon the expiration or termination of the Lease for such Leased Real Property.

"Lien" means any mortgage, deed of trust, pledge, hypothecation, lien (statutory or otherwise), security interest, encumbrance, charge, easement, right-of-way, encroachment, covenant, condition, restriction, or any other title defect, option, right of first refusal, right of first offer or restriction on transfer, use, voting, receipt of income or distribution or any other attribute of ownership; provided, however, that the Liens on the Equity held by the Member and the Liens on the Company's assets created pursuant to Section 5.7 shall be excluded as Liens hereunder.

"Loss" means any loss, liability, damage, contingency, judgment, fine, penalty, deficiency, Tax, claim, demand (whether or not arising out of a Third Party Claim), including any loss of benefit and the reasonable fees, costs and expenses of attorneys, accountants, consultants, investigators, experts and other professionals and any other amounts paid in respect of the investigation, defense, assertion or settlement of any claim or the enforcement of any rights under this Agreement, including the fees, costs and expenses incurred in respect of any audit, examination or controversy; provided, however, that Loss shall exclude punitive damages, except to the extent that any such damages or losses are required to be paid to a third party pursuant to a Third Party Claim.

"Malicious Code" means any (a) back door, time bomb, drop dead device, or other Software routine designed to disable a computer program automatically with the passage of time or under the positive control of a Person other than the user of the program; (b) virus, Trojan horse, worm, or other Software routines or hardware components designed to permit unauthorized access, to disable, erase, or otherwise harm Software, hardware, or data; or (c) similar program.

"Material Adverse Effect" means any event, circumstance, state of facts, change or development that, individually or in the aggregate, has, or would reasonably be expected to have, a material and adverse effect, change or development upon the business, operations, assets,

liabilities, condition (financial or otherwise), prospects, employees or business relations of the Company. For the avoidance of doubt, a loss of, or any material adverse change or development with respect to the use of, a Marijuana Permit held by the Company shall be deemed a Material Adverse Effect.

"Order" means any judgment, decision, decree, order, settlement, injunction, writ, stipulation, determination, charge, ruling or award (whether judicial, administrative, arbitral or regulatory) of any Governmental Entity or arbitrator.

"Ordinary Course of Business" means the ordinary course of business, consistent with past practice, including with regard to nature, frequency and magnitude; provided, that no default or breach of a Contract or the commencement of any Proceeding shall be deemed Ordinary Course of Business.

"Owned Intellectual Property" means all Intellectual Property owned or purported to be owned by the Company.

"Permits" means all licenses, permits, certificates, exemptions, consents, waivers, concessions, variances, authorizations, approvals, registrations and similar privileges or rights to operate or conduct any business granted by any Governmental Entity, including the Marijuana Permits.

"Person" means any natural person, sole proprietorship, partnership, joint venture, trust, unincorporated association, corporation, limited liability company, entity, arbitrator or Governmental Entity.

"<u>Personal Information</u>" means information that, alone or in combination with other information, is capable of identifying an individual or household or can be used to contact an individual, or serve advertisements to an individual, including name; Social Security number; government-issued identification numbers; health or medical information, including health insurance information; financial account information; passport numbers; user names/email addresses in combination with a password or security code that would allow access to an online account; unique biometric identifiers (e.g., fingerprints, retinal scans, face scans, or DNA profile); employee ID numbers; date of birth; digital signature; and Internet Protocol (IP) addresses; or any other data that constitutes personal information or personal data under applicable Law.

"Pre-Closing Tax Period" means any taxable period of the Company that ends on or before the Closing Date.

"Privacy and Security Requirements" means, to the extent applicable to the Company, (a) any Laws regulating the Processing of Protected Data, including Section 5 of the Federal Trade Commission Act, GDPR, all state Laws related to unfair or deceptive trade practices, the California Consumer Privacy Act and any implementing regulations therein, the Fair Credit Reporting Act, the Controlling the Assault of Non-Solicited Pornography And Marketing Act of 2003, all Laws related to online privacy policies, the Telephone Consumer Protection Act, the

Illinois Biometric Information Privacy Act, all Laws related to faxes, telemarketing, and text messaging, and all Laws related to breach notification; (b) the Payment Card Industry Data Security Standard issued by the PCI Security Standards Council, as it may be amended from time to time ("PCI DSS"); (c) all Contracts between the Company and any Person that is applicable to the PCI DSS and/or the Processing of Protected Data; and (d) all policies and procedures applicable to the Company relating to the PCI DSS and/or the Processing Protected Data, including without limitation all website and mobile application privacy policies and internal information security procedures.

"Proceeding" means any complaint, demand, action, claim, counterclaim, suit, charge, grievance, mediation, inquiry, arbitration, audit, hearing, investigation, litigation or other proceeding of any nature (whether civil, criminal, administrative, judicial or investigative, whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Entity or arbitrator.

"Process" means the creation, collection, use (including for the purposes of sending telephone calls, text messages and emails), storage, maintenance, processing, recording, distribution, transfer, transmission, receipt, import, export, protection, safeguarding, access, disposal or disclosure or other activity regarding data (whether electronically or in any other form or medium).

"Promissory Note" has the meaning set forth in the Virginia Purchase Agreement.

"Protected Data" means (a) Personal Information and (b) any other data the Company is required by Law, Contract or privacy policy to safeguard and/or keep confidential or private, including all such data transmitted to the Company by customers of the Company or Persons that interact with the Company.

"Real Estate Leases" shall mean the leases set forth on Schedule 3.9(a)(vii).

"Restricted Cash" means cash deposits, cash collateralizing any obligation or liability, cash in reserve or escrow accounts, custodial cash and cash subject to a lockbox, dominion, control or similar agreement or otherwise subject to any legal or contractual restriction on the ability to freely transfer or use such cash for any lawful purpose.

"SEC" means the U.S. Securities and Exchange Commission.

"Securities Laws" means the securities legislation, securities regulation and securities rules, and the policies, notices, instruments and blanket orders having the force of Law (including those of the SEC, the Canadian Securities Authorities and Cboe), in force from time to time in the United States, including any states of the United States and the provinces or territories of Canada.

"Security Breach" means any (a) security breach or breach of Personal Information under applicable Privacy and Security Requirements; (b) unauthorized access, acquisition, use, disclosure, modification, deletion, or destruction of information (including Protected Data); or

- (c) unauthorized interference with system operations of IT Assets, including any phishing incident or ransomware attack.
 - "Software" has the meaning set forth in the definition of "Intellectual Property".
 - "Straddle Period" means any taxable period that includes (but does not end on) the Closing Date.
 - "Target Working Capital" means an amount equal to \$(36,017).
- "Tax" (and, with correlative meaning, "Taxes," "Taxable" and "Taxing") means any net or gross income, net or gross receipts, net or gross proceeds, capital gains, capital stock, sales, use, user, leasing, lease, transfer, natural resources, premium, ad valorem, value added, franchise, profits, gaming, license, capital, withholding, payroll or other employment, estimated, goods and services, severance, excise, stamp, fuel, interest equalization, registration, recording, occupation, premium, turnover, personal property (tangible and intangible), real property, unclaimed or abandoned property, alternative or add-on, windfall or excess profits, environmental, social security, disability, unemployment or other tax or customs duties or amount imposed by (or otherwise payable to) any Governmental Entity, or any interest, any penalties, additions to tax or additional amounts assessed, imposed, or otherwise due or payable under applicable Laws with respect to taxes, in each case, whether disputed or not.
- "<u>Tax Return</u>" means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and any amendments, submitted to (or required under applicable Laws to be submitted to) a Governmental Entity.
- "<u>Tax Sharing Agreement</u>" means any agreement including any provision pursuant to which the Company is obligated to indemnify any Person for, or otherwise pay, any Tax of another Person, or share any Tax benefit with another Person.
 - "Trademarks" has the meaning set forth in the definition of "Intellectual Property".
- "Transaction Expenses" means the fees, costs and expenses (including the fees, costs and expenses of legal counsel, investment bankers, brokers and other advisors) incurred or otherwise payable by or on behalf of the Member or the Company in connection with or related to the sales process, the preparation, negotiation, documentation and execution of this Agreement and the other agreements contemplated hereby, the performance of each such Party's obligations hereunder and the consummation of the transactions contemplated hereby and thereby, in each case whenever due and payable.
- "<u>Transaction Payments</u>" means the aggregate amount of any change in control, success, transaction, retention, severance or other similar bonuses or amounts payable by, or liabilities of, the Company arising from or that otherwise may be triggered by the transactions contemplated by this Agreement (including the employer portion of any employment or payroll Taxes related thereto).

"<u>Treasury Regulations</u>" means the United States Treasury Regulations promulgated under the Code, and any reference to any particular Treasury Regulation Section shall be interpreted to include any final or temporary revision of or successor to that Section regardless of how numbered or classified.

"Working Capital" means an amount equal to Current Assets <u>less</u> Current Liabilities, in each case measured as of 12:01 a.m. Central Time on the Closing Date; <u>provided</u>, <u>however</u>, Working Capital shall not include any Current Assets or Current Liabilities that relate to or arise from any intercompany or other related party transactions or any transactions with any Affiliate of a Member, including intercompany receivables and payables. Working Capital shall be determined in accordance with the Applicable Accounting Guidelines and may be a negative amount.

Section I.2 Other Defined Terms. The following terms are defined in the sections indicated.

Agreement preamble

Arizona Transaction Approval 7.2(f)

Assessments 3.16(c)

Asset Purchase Price Allocation 6.3(f)

Basket Amount 6.2(b)

Business Relation 6.7(a)(ii)

Buyer preamble

Buyer Prepared Returns 6.3(a)(iii)

Cannabist preamble

Cap 6.2(b)

CC VA preamble

Claim Notice 6.4(d)

Closing 2.5(a)

Closing Date 2.5(a)

Closing Item 2.4(a)

Closing Statement 2.4(a)

COBRA 3.14(b)

Collateral 5.7(a)(ii)

Company Recitals

Company Collateral 5.7(a)(i)

Company Employee Benefit Plan 3.14(a)

Company Governing Documents 2.5(b)(iv)

Confidential Information 5.8(a)(ii)

CSA 9.13

Deposit 2.5(c)(i)(a)

Employment and Services Agreement 3.14(f)

Environmental Claims 3.17(b)

Equity Recitals

Estimated Cash 2.3

Estimated Closing Statement 2.3

Estimated Indebtedness 2.3

Estimated Transaction Expenses 2.3

Estimated Transaction Payments 2.3

Estimated Working Capital 2.3

Excess Amount 2.4(c)

Excluded Federal Claims 9.13

Final Cash 2.4(a)

Final Indebtedness 2.4(a)

Final Transaction Expenses 2.4(a)

Final Transaction Payments 2.4(a)

Final Working Capital 2.4(a)

Financial Statements 3.4(a)

Funds Flow 2.5

IRS 3.14(a)

Latest Balance Sheet 3.4(a)

Latest Balance Sheet Date 3.4(a)

Lien Releases 2.5(b)(iii)

Marijuana Permits 3.16(b)

Material Contract 3.9(b)

Member Prepared Returns 6.3(a)(ii)

Member preamble

Notes 2.5(b)(ii)

Objection Notice 6.2(d)

Party preamble

Pledged Collateral 5.7(a)(ii)

Purchase Price 2.2

Restricted Period 6.7(b)

Schedules 9.11

Service Contracts 3.6(j)

Shortfall Amount 2.4(d)

Survival Period 6.1

SWC Arizona Purchase Agreement preamble

Tax Contest 6.3(d)

Third Party Claim 6.4(a)

Transfer Taxes 6.3(f)

UCC 5.7(a)(iii)

Utility Systems 3.6(h)

Valuation Firm 2.4(b)

Virginia Purchase Agreement preamble

WARN Act 3.13(e)

Article II PURCHASE AND SALE TRANSACTIONS

- Section II.1 <u>Purchase and Sale</u>. Subject to the terms and conditions set forth herein, at the Closing, the Member shall sell, transfer, convey, assign and deliver to Buyer, and Buyer shall purchase from the Member, all of the Equity, free and clear of all Liens, which Equity shall comprise all of the issued and outstanding equity interests of the Company such that immediately after the consummation of such purchase and sale the Company shall be a wholly-owned subsidiary of Buyer.
- Section II.2 <u>Purchase Price</u>. The aggregate consideration (to be delivered in the manner described in <u>Section 2.5(c)</u> and subject to adjustment pursuant to <u>Section 2.4</u>) for the Equity to be purchased by Buyer hereunder shall be an aggregate amount equal to (a) \$9,900,000, (b) <u>plus</u> Final Cash, (c) (i) <u>plus</u>, subject to <u>Section 2.4(a)(ii)</u>, the amount, if any, that Final Working Capital is greater than Target Working Capital or (ii) <u>minus</u> the amount, if any, that Final Working Capital is less than Target Working Capital, (d) <u>minus</u> Final Indebtedness, (e) <u>minus</u> Final Transaction Expenses, and (f) <u>minus</u> Final Transaction Payments (collectively, the "<u>Purchase Price</u>").
- Section II.3 <u>Estimated Closing Statement</u>. Prior to the date hereof, Cannabist shall prepare and deliver to Buyer a statement ("<u>Estimated Closing Statement</u>") setting forth its reasonable estimate of: (a) Cash ("<u>Estimated Cash</u>"), (b) Working Capital ("<u>Estimated Working Capital</u>") (provided, that in no event will the Estimated Working Capital be deemed to be greater than \$500,000 more than the Target Working Capital but for the proviso contained herein, the Estimated Working Capital shall be deemed to equal \$500,000 more than the Target Working Capital but for the proviso contained herein, the Estimated Working Capital shall be deemed to equal \$500,000 more than the Target Working Capital), (c) the aggregate amount of Indebtedness of the Company as of immediately prior to the Closing ("<u>Estimated Indebtedness</u>"), (d) the aggregate amount of Transaction Expenses ("<u>Estimated Transaction Payments</u>") and (f) the resulting Purchase Price (the "<u>Estimated Purchase Price</u>"). Cannabist and its representatives shall review and consult with Buyer regarding the Estimated Closing Statement, and Cannabist shall consider all comments reasonably made by Buyer and its representatives with respect to the Estimated Closing Statement.

Section II.4 Post-Closing Adjustment.

(a) Within 120 calendar days after the Closing Date, Buyer will deliver to Cannabist a statement (the "Closing Statement") setting forth Buyer's calculation of the following items (each a "Closing Item"): (i) Cash (as finally determined pursuant to this Section 2.4, "Final Cash"), (ii) Working Capital (as finally determined pursuant to this Section 2.4, "Final Working Capital") (provided, that in no event will the Final Working Capital be deemed to be greater than \$500,000 more than the Target Working Capital; provided, further, that in the event the Final Working Capital would be more than \$500,000 more than the Target Working Capital but for the proviso contained herein, the

FH12251261.5

1

Final Working Capital shall be deemed to equal \$500,000 more than the Target Working Capital); (iii) the aggregate amount of Indebtedness of the Company as of immediately prior to the Closing (as finally determined pursuant to this Section 2.4, "Final Indebtedness"); (iv) the aggregate amount of Transaction Expenses (as finally determined pursuant to this Section 2.4, "Final Transaction Expenses"), (v) the aggregate amount of Transaction Payments (as finally determined pursuant to this Section 2.4, "Final Transaction Payments") and (vi) the resulting Purchase Price (as finally determined pursuant to this Section 2.4, the "Final Purchase Price").

Cannabist shall have 30 calendar days to dispute in writing any Closing Item, after which time any undisputed (b) Closing Items shall be final, conclusive and binding on the Parties. If Cannabist timely disputes any Closing Item, Buyer and Cannabist shall, for a period of 20 calendar days thereafter, use commercially reasonable and good faith efforts to attempt to resolve their differences in respect thereof; provided, that at any time after such 20 day period, either Buyer or Cannabist may elect to have Marcum LLP (the "Valuation Firm") resolve any Closing Items that remain in dispute, in which event Buyer and Cannabist will instruct the Valuation Firm to deliver within 45 calendar days after appointment (or such other time period mutually agreed upon by Buyer and Cannabist) a written statement setting forth its determination, which statement shall be final, conclusive and binding on the Parties, absent manifest error, and shall be enforceable as an arbitration award in any court of competent jurisdiction under the Federal Arbitration Act or its state law equivalents. All fees and expenses relating to the work, if any, to be performed by the Valuation Firm will be borne by Buyer and the Member, respectively, in the proportion that the aggregate dollar amount of the disputed Closing Items submitted to the Valuation Firm by Buyer or Cannabist that are unsuccessfully disputed by it (as finally determined by the Valuation Firm) bears to the aggregate dollar amount of disputed Closing Items submitted by Buyer and Cannabist. Except as provided in the preceding sentence, all other costs and expenses incurred by Buyer and Cannabist in connection with resolving any dispute hereunder before the Valuation Firm will be borne by the Party incurring such cost and expense. The Valuation Firm shall determine only those Closing Items submitted to the Valuation Firm and its determination will be based upon and consistent with the terms and conditions of this Agreement. The determination by the Valuation Firm will be based solely on presentations with respect to such disputed Closing Items by Buyer and Cannabist to the Valuation Firm and not on the Valuation Firm's independent review. Buyer and Cannabist shall use their commercially reasonable efforts to make their respective presentations as promptly as practicable following submission to the Valuation Firm of the disputed Closing Items (but in no event later than 15 days after engagement of the Valuation Firm), and each of Buyer and Cannabist will be entitled, as part of its presentation, to respond to the presentation of the other and any questions and requests of the Valuation Firm. In deciding any matter, the Valuation Firm (i) will be bound by the provisions of this Section 2.4 and (ii) absent manifest error, may not assign a value to any disputed Closing Item greater than the greatest value for such Closing Item claimed by either Buyer or Cannabist or less than the smallest value for such Closing Item claimed by Buyer or Cannabist. Notwithstanding anything to the contrary contained herein, at

any time Buyer and Cannabist may agree to settle any Closing Item dispute, including any dispute submitted to the Valuation Firm, which agreement shall be in writing and final, conclusive and binding upon all of the Parties with respect to the subject matter of any such dispute so resolved; provided, that Buyer and Cannabist shall provide a copy of such agreement to the Valuation Firm and shall instruct the Valuation Firm not to resolve such dispute, it being agreed that if the Valuation Firm nonetheless resolves such dispute for any reason, the agreement of Buyer and Cannabist shall control.

- (c) If the Final Purchase Price exceeds the Estimated Purchase Price (such excess amount, if any, the "Excess Amount"), then within ten days following the determination of the Final Purchase Price, the Buyer shall pay to the Member such Excess Amount by wire transfer of immediately available funds to the account designated in writing by the Member.
- (d) If the Final Purchase Price is less than the Estimated Purchase Price (such shortfall amount, if any, the "Shortfall Amount"), then within ten days following the determination of the Final Purchase Price, Cannabist and the Member shall, jointly and severally, pay to the Buyer such Shortfall Amount by wire transfer of immediately available funds to the account designated in writing by the Buyer. Buyer may deduct any unpaid Shortfall Amount from the amount due to CC VA under the Promissory Note in the order of interest due and owing and then in the order of maturities.

Section II.5 <u>Closing Transactions</u>.

- (a) <u>Closing</u>. Subject to the terms and conditions of this Agreement, the closing of the transactions contemplated by this Agreement (the "<u>Closing</u>") shall take place no later than three Business Days after the last of the conditions to Closing set forth in <u>Article VII</u> have been satisfied or waived (other than conditions which, by their nature, are to be satisfied on the Closing Date), or at such other time or on such other date as the Company and Buyer may mutually agree upon in writing. The day on which the Closing takes place shall be referred to as the "<u>Closing Date</u>".
- (b) <u>Company Closing Deliveries</u>. At or prior to the Closing, the Company, Member or Cannabist, as applicable, shall deliver to Buyer, each in form and substance satisfactory to Buyer:
 - (i) membership interest powers with respect to the Equity, in each case, duly executed by the Member;
 - (ii) evidence that all required consents, waivers and deliverables necessary, as determined by Buyer, under Cannabist's (A) 6.0% secured convertible notes due 2025, (B) 9.50% senior-secured first-lien notes due 2026, and (C) 9.0% senior-secured first-lien notes due 2027 (collectively, the "Notes"), have been delivered or received, as applicable;

- (iii) duly-executed customary Lien and guarantor release documentation from the holders of the Notes evidencing release and termination of all Liens on the Equity or any assets of the Company and release of any guarantees by the Company in respect thereof ("Lien Releases");
- (iv) (A) certified copies of the articles of organization (certified from the Secretary of State of the State of Arizona) and the limited liability company operating agreement of the Company (collectively, the "Company Governing Documents") and (B) a certified copy of the written resolutions duly adopted by the Member and the managers of the Company approving this Agreement, the transactions contemplated hereby and the performance of the Company in respect thereof;
- (v) a certificate of good standing (or the equivalent thereof) for the Company issued by the Secretary of State of the State of Arizona;
- (vi) resignations of all managers and officers of the Company and evidence of the termination of all Contracts with Insiders set forth on <u>Schedule 3.19</u>;
 - (vii) evidence that the consents, notices and authorizations set forth on <u>Schedule 3.2</u> have been obtained;
- (viii) a certificate, dated as of the Closing Date and signed by a duly authorized officer of the Company, that each of the conditions set forth in Section 7.2(a), Section 7.2(b), and Section 7.2(c) have been satisfied;
- (ix) properly completed and executed IRS Forms W-9 certifying that each of the Member and the Company is a "United States person" within the meaning of Code Section 7701(a)(30) and Code Section 1445(f)(3) and is exempt from U.S. backup withholding;
 - (x) evidence that the Arizona Transaction Approval has been obtained;
 - (xi) three USB copies of the Data Room;
- (xii) a landlord estoppel certificate in the form attached hereto as <u>Exhibit A</u> from the applicable landlord with respect to each Leased Real Property;
 - (xiii) evidence of the termination of the Contracts set forth on Schedule 2.5(b)(xiii);
 - (xiv) the updated Funds Flow pursuant to Section 2.5(c);
- (xv) if required by Cboe in their sole discretion, an opinion of counsel to the Company, in form and substance reasonably satisfactory to Cboe, with respect to the Company and their compliance with applicable Law;

- (xvi) a list of all logins, passwords and authorized Persons for all tax accounts, bank accounts, social media, customer loyalty programs, portals and similar accounts and software used by the Company;
- (xvii) duly executed payoff and release letters from the applicable payees of Transaction Expenses as set forth on the Estimated Closing Statement;
- (xviii) a transition services agreement in the form attached hereto as <u>Exhibit B</u>, which shall include a royalty-free license to produce cannabis products using the "Hedy", "Triple 7", and "Seed & Strain" brands, duly executed by Cannabist;
- (xix) evidence that (A) the Company has been released as a co-lessee from its obligations under the Master Lease Agreement No. 201217401, dated as of November 9, 2020, by and between Xtraction Services, Inc. and Columbia Care LLC (as amended, and together with all schedules and exhibits, the "Master Lease Agreement"), and (B) the lease obligations related to the equipment used or held by the Company under the Master Lease Agreement along with the purchase option in connection therewith has been assigned to the Company; and
- (xx) such other documents or instruments as Buyer reasonably requests at least two Business Days prior to the Closing Date and that are reasonably necessary to consummate the transactions contemplated by this Agreement.

(c) <u>Buyer Deliveries</u>.

- (i) No later than the later of (A) 24 hours following delivery of the initial Funds Flow and the Estimated Closing Statement to Buyer and (B) July 31, 2024, Buyer (or an Affiliate of Buyer) shall pay (or cause to be paid), as applicable:
 - (A) to the Member, an amount of cash equal to the Estimated Purchase Price (the "Deposit");
 - (B) to the applicable payees as set forth on the Estimated Closing Statement, the Estimated Transaction Expenses; and
 - (C) to the applicable payees as set forth on the Estimated Closing Statement, the Estimated Transaction Payments.
 - (ii) At or prior to the Closing, Buyer (or an Affiliate of Buyer) shall deliver to the Company:
 - (A) a certificate, dated as of the Closing Date and signed by a duly authorized officer of Buyer, that each of the conditions set forth in Section 7.3(a) and Section 7.3(b) have been satisfied; and

(B) such other documents or instruments as Cannabist reasonably requests at least two Business Days prior to the Closing Date and that are reasonably necessary to consummate the transactions contemplated by this Agreement.

The payments and issuances to be made by Buyer pursuant to Section 2.5(c)(i) shall be made to the accounts (including wire instructions) and in the amounts designated in writing by the applicable payees (including payees in connection with the Purchase Price, Transaction Expenses, Transaction Payments and Indebtedness), as memorialized in the funds flow mutually agreed to by Buyer and Cannabist prior to the date hereof (the "Funds Flow"), which Funds Flow shall include wire instructions, and all other information requested by Buyer; provided, that Cannabist shall deliver an updated Funds Flow two Business Days prior to the scheduled Closing Date. Notwithstanding the foregoing, all payments of the Transaction Payments shall be paid by depositing the amount in the applicable payroll account of the Company and such amounts shall be remitted by the Company (net of applicable withholding Taxes) to the applicable payee.

Section II.6 <u>Tax Withholding</u>. Notwithstanding anything herein to the contrary, Buyer and the Company, as applicable, shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement to any Person such amounts that Buyer or the Company (or any Affiliate thereof), as applicable, shall determine in good faith it is required to deduct and withhold from such Person under the Code and the rules and regulations promulgated thereunder, or any other provision of applicable Tax Law. To the extent that amounts are so withheld by Buyer or the Company, such withheld amounts, to the extent paid over to the applicable Governmental Entity in such manner as may be required by applicable Law, shall be treated for all purposes of this Agreement as having been paid to such Person in respect of which such deduction and withholding was made by Buyer or the Company, as applicable.

Article III REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY

As an inducement to Buyer to enter into this Agreement and consummate the transactions contemplated hereby, the Company, Cannabist and the Member hereby represent and warrant to Buyer that the following representations and warranties are true and correct as of the date hereof until and including the Closing Date (except as to any representations and warranties that specifically relate to an earlier date, in which case such representations and warranties were true and correct as of such earlier date):

Section III.1 <u>Organization; Authorization</u>. The Company is a limited liability company duly formed, validly existing and in good standing under the Laws of Arizona. Neither the character of the Company's properties or the nature of the Company's businesses requires the Company to qualify to do business as a foreign entity in any jurisdiction. The Company is not in default under and has not violated any provision of the Company Governing Documents. The Company has the full power and authority to execute and deliver each agreement contemplated hereby to which it is a party and to consummate the transactions contemplated hereby and thereby. The managers of the Company have duly approved this Agreement and all other agreements contemplated hereby to which the Company is a party and has duly authorized the execution and delivery of this Agreement and all other agreements

contemplated hereby to which the Company is a party and the consummation of the transactions contemplated hereby and thereby. No other proceedings on the part of the Company are necessary to approve and authorize the execution and delivery of the agreements contemplated hereby to which it is a party and the consummation of the transactions contemplated hereby and thereby. All agreements contemplated hereby to which the Company is a party have been duly executed and delivered by the Company and constitute the valid and binding agreements of the Company enforceable against the Company in accordance with their terms, except as such may be limited by bankruptcy, insolvency, reorganization or other Laws affecting creditors' rights generally and by general equitable principles.

Section III.2 Non-contravention.

- (a) Except as set forth on Schedule 3.2, the execution, delivery and performance of this Agreement and the other agreements contemplated hereby and the consummation of the transactions contemplated hereby and thereby by the Company and the Member do not and will not (i) trigger or otherwise result in the modification, termination or acceleration of any Contract or Permit, give any Person the right to modify or terminate any Contract or Permit or give any Person the right to modify, terminate or accelerate any benefit, right, liability or obligation, (ii) conflict with or result in a breach of any term or condition of any Contract or Permit (including a breach due to the failure to notify or obtain the prior consent or waiver of any Person), (iii) require the authorization, consent or approval of, an exemption or waiver from, notice or declaration to, or the filing of any document or with, or the payment of any amounts to, any Person, (iv) constitute a default under (whether with or without the giving of notice, the passage of time or both) the Company Governing Documents, any Contract or any Permit, (v) violate any Law or Order (other than Federal Cannabis Laws) or (vi) result in the creation of any Lien.
- (b) The Company is an "Unrestricted Subsidiary" under Cannabist's 6.0% secured convertible notes due 2025 and the Company is not a guarantor of any Notes.

Section III.3 Capitalization.

(a) Schedule 3.3(a) sets forth the issued and outstanding equity interests of the Company, the names of the record and beneficial owners thereof and the number of equity interests held by such owners. All Equity was validly issued in compliance with applicable Law and any requirements set forth in the Company Governing Documents and has been duly authorized and approved. All Equity is fully paid and non-assessable. No Equity is subject to any preemptive rights, rights of first refusal or restrictions on transfer. The Member owns of record and beneficially 100% of the Equity free and clear of all Liens (other than any restrictions under applicable securities Laws) and the Equity constitutes all of the issued and outstanding equity interests of the Company. There are no outstanding or authorized options, warrants, Contracts, calls, puts, rights to subscribe, conversion rights or other similar rights to which the Company is a party, or which are binding upon the Company providing for the issuance, disposition or acquisition of any equity interests of the Company (other than this Agreement). There are no outstanding or authorized equity appreciation, phantom interests, profits interests or similar rights with

respect to the Company. Other than the Company Governing Documents, there are no shareholder or equityholder agreements, voting trusts, proxies or other Contracts or understandings with respect to the voting of the Equity. The Company is not subject to any obligation (contingent or otherwise) to repurchase or otherwise acquire or retire any of the Equity. No former direct or indirect holder of any equity interests of the Company has any claim or rights against the Company that remains unresolved or to which the Company has or may have any liability, and no such claim is threatened. The Company has no obligation to make any investment (in the form of a loan, capital contribution or otherwise) in any Person.

(b) The Company has no, and has never had, any subsidiaries and does not own (and has not owned or held) any equity interests of any other Person or any other interest in any other Person or any rights to acquire any such equity interests or other interest.

Section III.4 Financial Statements and Related Matters.

- (a) Attached as <u>Schedule 3.4(a)</u> are the following financial statements (collectively, the "<u>Financial Statements</u>"): (i) the unaudited balance sheet of the Company as of June 30, 2024 (the "<u>Latest Balance Sheet</u>" and the date thereof, the "<u>Latest Balance Sheet Date</u>"), and the related statement of profit and loss and statement of cash flows for the six-month period then ended, and (ii) the unaudited balance sheet of the Company of the Company as of December 31, 2023 and December 31, 2022 and the related statement of profit and loss and statement of cash flows for each of the 12-month periods then ended. Each Financial Statement: (A) is true, accurate and complete in all material respects, does not omit to state any fact necessary to make the statements contained therein in light of the circumstances in which they were made, not misleading, and was prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated, (B) is consistent with the books and records of the Company (which, in turn, are accurate and complete in all material respects), (C) presents fairly in all material respects the financial condition of the Company as of the respective dates thereof and the operating results of the Company for the periods covered thereby and (D) does not reflect any transactions which are not bona fide transactions.
- (b) Except as set forth on Schedule 3.4(b), the Company has no liabilities (contingent or otherwise) and there is no existing condition, fact or set of circumstances that could reasonably be expected to result in any liabilities, except for: (i) performance obligations under Contracts described on Schedule 3.9(a) (or under Contracts entered into in the Ordinary Course of Business which, because of the dollar thresholds set forth in Section 3.9(a), are not required to be described on Schedule 3.9(a), none of which involves non-performance or a breach), (ii) liabilities reflected (and adequately reserved for) on the face of the Latest Balance Sheet and (iii) liabilities of the type set forth on the face of the Latest Balance Sheet which have arisen after the date of the Latest Balance Sheet in the Ordinary Course of Business (none of which is a liability for breach of

Contract or involves a tort, infringement, claim, lawsuit, warranty or environmental, health or safety matter).

- (c) The inventories and raw materials of the Company, including those reflected in the Financial Statements, are of a quantity and quality usable and saleable in the Ordinary Course of Business within a reasonable period of time and without discount outside of the Ordinary Course of Business, are merchantable and fit and sufficient for their particular purpose and are reasonable in kind and amount in light of the normal needs of the Company. None of the inventory of the Company is subject to any consignment, bailment, warehousing or similar Contract.
- (d) All of the notes and accounts receivable of the Company, including those reflected in the Financial Statements, arose from the bona fide sales of goods or services in the Ordinary Course of Business to Persons that are not Insiders, and are not subject to any defenses, counterclaims or offsets. The Company has not received any notice indicating that any account debtor does not intend to pay any notes or accounts receivable.
- (e) The Company has established and adhered to a system of internal accounting controls which are designed to provide assurance regarding the reliability of financial reporting. There has never been (i) any significant deficiency or weakness in the system of internal accounting controls used by the Company except as set forth on Schedule 3.4(e), (ii) any fraud by any of the Company's, managers, directors, officers, employees or independent contractors, (iii) any wrongdoing that involves any manager, director, officer, employee or independent contractor of the Company who has or had a role in the preparation of financial statements or the internal accounting controls used by the Company or (iv) any claim or allegation regarding any of the foregoing.

Section III.5 Absence of Developments.

- (a) Since December 31, 2023, there has been no Material Adverse Effect.
- (b) Except as set forth on <u>Schedule 3.5(b)</u>, since December 31, 2023, the Company has not taken any action described in <u>Section 5.1</u> that, if such action had been taken after the date hereof and prior to the Closing without the prior written consent of Buyer, would have violated <u>Section 5.1</u>.

Section III.6 Real Property.

- (a) The Company does not own, and has never owned, any real property. The Company is not a party to any option or other Contract to purchase any real property or interest therein.
- (b) The Company does not lease, sublease or license any real property, either as lessor or lessee, except for the Leased Real Property pursuant to the Real Estate Leases. The Company has delivered to Buyer true, correct and complete copies of the

Real Estate Leases. (i) The Company has not assigned, subleased, licensed, transferred, conveyed, mortgaged, deeded in trust or encumbered any interest in the interest or estate created thereby, or otherwise granted any right to use or occupy the Leased Real Property, or any portion thereof, nor has an agreement been entered into to do so; (ii) the Real Estate Leases are legal, valid, in full force and effect, binding and enforceable against the Company and the other party thereof in accordance with its terms and is the entire agreement to which the Company is a party with respect to such Leased Real Property; (iii) the possession and quiet enjoyment of the Leased Real Property under the Real Estate Leases has not been disturbed and there are no disputes with respect to such Real Estate Leases; (iv) no party to the Real Estate Leases is in breach or default under the Real Estate Leases and no event has occurred or circumstance or fact exists which, with the delivery of notice, the passage of time or both, would constitute such a breach or default, or permit the termination, modification or acceleration of rent under the Real Estate Leases; (v) no security deposit or portion thereof deposited with respect to the Real Estate Leases has been applied in respect of a breach or default under the Real Estate Leases which has not been redeposited in full; (vi) the Company does not owe, nor will owe in the future, any brokerage commissions or finder's fees with respect to the Real Estate Leases; (vii) the Company has not collaterally assigned or granted any other Lien in the Real Estate Leases or any interest therein; (viii) all public utilities currently serving the Leased Real Property and public and quasi-public improvements upon or adjacent to the Leased Real Property, as applicable (including, all applicable electric lines, water lines, gas lines and telephone lines): (A) are adequate to service the requirements of the Leased Real Property and the Company. and all payments for the same have been made, (B) enter the Leased Real Property directly through adjoining public streets and do not pass through adjoining private land and (C) are installed and operating, and all installation and connection charges have been paid for in full; (ix) each of the Leased Real Properties consists of a single zoning lot and no other property is within such zoning lot; (x) the Leased Real Property is not encumbered by a declaration or other agreement transferring any development rights or air rights appurtenant to the Leased Real Property to any other property; (xi) the Leased Real Property is in compliance with all applicable zoning ordinances; and (xii) the Company (A) has not transferred, and prior to the Closing will not transfer, any development rights applicable to the Leased Real Property and (B) has not made, and prior to the Closing will not make, any filings with any Governmental Entity for any construction on the Leased Real Property.

- (c) <u>Schedule 3.6(c)</u> sets forth a description of all material Leasehold Improvements for each Leased Real Property. The Company has good and marketable title to the Leasehold Improvements, free and clear of all Liens, and there are no outstanding options, rights of first offer or rights of first refusal to purchase any such Leasehold Improvements or any portion thereof or interest therein.
- (d) The Leased Real Property and the Leasehold Improvements comprise all of the real property used or intended to be used in, and that is necessary in the operation of, the business of the Company.

- (e) There are no structural deficiencies or latent defects affecting any of the Leasehold Improvements and there are no facts or conditions affecting any of the Leasehold Improvements which would, individually or in the aggregate, interfere in any material respect with the use or occupancy of the Leasehold Improvements or any portion thereof in the operation of the business of the Company. The Leasehold Improvements are in good condition and repair and the systems located therein are in good working order and adequate to operate such facilities as currently used and do not require material repair or replacement in order to serve their intended purposes, except for scheduled maintenance, repairs and replacements conducted or required in the Ordinary Course of Business with respect to the operation of the Leased Real Property that are not material in nature or cost.
- (f) There is no condemnation, expropriation or other Proceeding in eminent domain pending or threatened, affecting any Leased Real Property or any portion thereof or interest therein.
- (g) All buildings, fixtures, tangible personal property and Leasehold Improvements used in the business of the Company are located on the Leased Real Property and none of the Leasehold Improvements encroach on (i) any adjoining property owned by others or public rights of way, or (ii) any part of the Leased Real Property which is subject to or encumbered by a right-of-way, easement or similar Contract.
- (h) The Leased Real Property is supplied with all water, gas, electrical, telecommunications systems, sanitary sewer, storm sewer and other utility systems (the "<u>Utility Systems</u>") required for the current use thereof and all Utility Systems have been installed and are operational and sufficient for the operation of the business as conducted immediately prior to the Closing. The Company has not experienced any material interruption in the delivery of adequate quantities of any such utilities or services utilized or required in the operation of the business at the Leased Real Property.
- (i) Each parcel of Leased Real Property abuts on at least one side a public street or road in a manner so as to permit reasonable, customary, adequate and legal commercial and non-commercial vehicular and pedestrian ingress, egress and access to such parcel, or has adequate easements across intervening property to permit reasonable, customary, adequate and legal commercial and non-commercial vehicular and pedestrian ingress, egress and access to such parcel from a public street or road. There are no restrictions on entrance to or exit from the Leased Real Property to adjacent public streets and no conditions which will result in the termination of the present access from the Leased Real Property to existing highways or roads.
- (j) Except as disclosed on <u>Schedule 3.6(j)</u>, there are no service, maintenance, supply, leasing, brokerage, listing, or other Contracts to which the Company is a party (along with all amendments and modifications thereof, the "<u>Service Contracts</u>") affecting the Leased Real Property. Each of the Service Contracts can be terminated by the Company on or before the Closing Date. The Company has performed all of its obligations under each of the Service Contracts and no fact or circumstance has occurred

which, by itself or with the passage of time or the giving of notice or both, would constitute a default by any party under any of the Service Contracts. The Company has delivered to Buyer true, correct, and complete copies of all Service Contracts.

(k) There has not been in the past 12 months, and there is not now, any casualty affecting the Leased Real Property, and there is not now any disrepair or damage that remains unrepaired, due to any prior casualty, if any, affecting the Leased Real Property.

Section III.7 Assets.

(a) The Company owns good, marketable and valid title to, or holds a valid leasehold interest in, all of the properties and assets, tangible or intangible, used by the Company, located on the premises of the Company, or, if applicable, shown on the Latest Balance Sheet or acquired thereafter, free and clear of all Liens and not subject to any guarantees, including in connection with the Notes. The Company owns or has a valid leasehold interest in all properties and assets necessary for the conduct of its business as presently conducted. Except as disclosed on Schedule 3.7, neither the Member nor Cannabist owns, whether directly or indirectly (other than indirectly through the Member's equity ownership), any assets used by the Company. The Company's buildings, improvements, fixtures, machinery, equipment and other tangible assets (whether owned or leased) are, except for ordinary wear and tear, in good condition and repair and are usable in the Ordinary Course of Business.

Section III.8 Tax Matters.

- (a) The Company has timely filed (taking into account all available extensions of the applicable filing deadlines) all Tax Returns required to have been filed by it prior to the Closing Date pursuant to applicable Laws, and such Tax Returns are accurate, complete and correct in all material respects and have been prepared in compliance with all applicable Laws.
- (b) The Company has paid all Taxes due and payable by it prior to the Closing Date (whether or not shown or required to be shown on any Tax Return).
- (c) The Company has timely and properly withheld or collected (i) all required amounts from payments to its employees, agents, contractors, nonresidents, shareholders, lenders, and other Persons and (ii) all sales, use, ad valorem, and value added Taxes. The Company timely remitted all withheld Taxes to the proper Governmental Entity in accordance with all applicable Laws and all Forms W-2 and 1099 required with respect thereto have been properly completed and timely filed (taking into account all available extensions of the applicable filing deadlines).
- (d) The Company has not received any claim in writing by an authority in a jurisdiction where the Company does not file Tax Returns or pay Taxes that the Company is or may be subject to taxation by or required to file Tax Returns in that jurisdiction,

which claim has not been resolved. No audits or other legal Proceedings are in progress, pending, or threatened with regard to any Taxes or Tax Returns of or with respect to, the Company. The Company has not commenced a voluntary disclosure Proceeding in any state or local or non-U.S. jurisdiction that has not been fully resolved or settled. The Company has not executed or filed with any Governmental Entity any agreement or other document extending or having the effect of extending the statute of limitations for assessment, collection, or other imposition of any Tax (other than extensions as of right, for six (6) months or less from the original due date, to file a Return).

- (e) There are no Liens for Taxes (other than statutory Liens for Taxes not yet due and payable that have been properly accrued on the books of the Company) upon any of the assets of the Company.
- (f) The Company is, and at all times since its formation has been, properly classified as a partnership or a disregarded entity for U.S. federal and all applicable state Tax purposes. The Company has not at any time made an election to be treated as an S-corporation for U.S. federal, state, local or foreign Tax purposes.
- (g) The aggregate unpaid Taxes of the Company do not exceed the reserves for current Taxes (excluding any reserve established to reflect timing differences between book and Tax items) set forth on the Latest Balance Sheet (without regard any notes thereto). Since the Latest Balance Sheet, the Company has not (i) incurred any Taxes with respect to events or transactions outside the Ordinary Course of Business, (ii) changed a method of accounting for Tax purposes, (iii) entered into any agreement with any Governmental Entity (including a "closing agreement" under Code Section 7121) with respect to any Tax matter, (iv) surrendered any right to a Tax refund, (v) changed an accounting period with respect to Taxes, (vi) filed an amended Tax Return, (vii) changed or revoked any election with respect to Taxes, or (viii) made any Tax election inconsistent with past practices.
- (h) The Company has not engaged in any reportable transaction (or a substantially similar transaction) as defined in Code Section 6707A(c)(1) and Treasury Regulation Section 1.6011-4(b) (irrespective of the effective dates).
- (i) Except for the Equity for which a valid and timely election has been made under Code Section 83(b), as of the Closing Date, no Equity is subject to a "substantial risk of forfeiture" for purposes of Code Section 83.
- (j) Each of the Company's "nonqualified deferred compensation plans" within the meaning of Code Section 409A has been maintained in operational and documentary compliance with Code Section 409A and the Treasury Regulations promulgated thereunder and no such "nonqualified deferred compensation plan" has resulted or would reasonably be expected to result in any participant incurring income acceleration or Taxes under Code Section 409A. The Company has not agreed to pay, gross up, or otherwise indemnify any employee or contractor for any employment or income Taxes, including potential Taxes imposed under Code Section 409A or 4999.

- (k) The Company is not a party to any Contract covering any current or former employee or current or former contractor that, individually or collectively, could give rise to a (or already has resulted in a) payment or provision of any other benefit (including accelerated vesting) that could not be deductible by reason of Section 280G of the Code or could be subject to an excise Tax under Section 4999 of the Code (in each case, determined without regard to the exceptions provided for in Section 280G(b)(5) of the Code).
- (1) The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i) an installment sale transaction occurring on or before the Closing governed by Code Section 453 (or any similar provision of state, local or non-U.S. Laws); (ii) a transaction occurring on or before the Closing reported as an open transaction for U.S. federal income Tax purposes (or any similar doctrine under state, local, or non-U.S. Laws); (iii) any prepaid amounts or advance payments paid or received on or prior to the Closing Date or any deferred revenue realized on or prior to the Closing Date; (iv) a change in method of accounting with respect to a Pre-Closing Tax Period (or as a result of an impermissible method used in a Pre-Closing Tax Period); (v) an agreement entered into with any Governmental Entity (including a "closing agreement" under Code Section 7121) on or prior to the Closing Date; (vi) the application of Code Section 263A (or any similar provision of state, local, or non-U.S. Laws); or (vii) the use of the cash method of accounting in any Pre-Closing Tax Period or portion of any Straddle Period ending on the Closing Date. The Company does not have any "long-term Contracts" that are subject to a method of accounting provided for in Code Section 460 or any deferred income pursuant to IRS Revenue Procedure 2004-34, Treasury Regulation Section 1.451-5, Code Section 455 or Code Section 456 (or any corresponding provision of state or local Law). The Company does not own an interest in any Flow-Thru Entity and neither the Company nor any of its Affiliates is a party to any joint venture, partnership or other arrangement or contract that would be treated as a partnership for U.S. federal income Tax purposes.
 - (m) The Company is not party to or bound by any Tax Sharing Agreements.
- (n) The Company has maintained the books and records required to be maintained pursuant to Code Section 6001, and the rules and regulations thereunder, and any similar provision under state, foreign or local Law.
- (o) The Company is not, and has not been, a member of any Affiliated Group, other than the Affiliated Group of which it is presently a member. The Company has no liability for the Taxes of any Person under any provision of federal, state, local, or non-U.S. Law, as a transferee or successor, as a result of joint or several liability, by Contract or otherwise.
- (p) The Company has correctly classified those individuals performing services as common Law employees, leased employees, independent contractors, consultants or agents of the Company.

- (q) The Company has not used the cash receipts and disbursements method of accounting for federal or applicable state, local or foreign income Tax purposes in any period commencing after December 31, 2016.
- (r) The Company is not subject to any Tax holiday or Tax incentive or grant in any jurisdiction, other than pursuant to the applicable provisions of such jurisdiction's Tax Laws available to all similarly situated taxpayers and shown on the Company's Tax Returns.
- (s) Neither the Member nor the Company has a request for a private letter ruling, a request for administrative relief, a request for technical advice, a request for a change of any method of accounting, or other request pending with any Governmental Entity that relates to the Taxes or Tax Returns of the Company. No power of attorney granted by the Company with respect to any Taxes is currently in force.
- (t) No Member is a foreign person within the meaning of Code Section 1445. The Company is not (and has not been within the past five years) a "United States real property holding corporation" within the meaning of Code Section 897(c).
- (u) No asset of the Company is tax-exempt use property under Code Section 168(h). No portion of the cost of any asset of the Company has been financed directly or indirectly from the proceeds of any tax-exempt state or local government obligation described in Code Section 103(a). None of the assets of the Company is property that is required to be treated as being owned by any other person pursuant to the safe harbor lease provision of former Code Section 168(f)(8).
- (v) No debt of the Company is an "applicable high yield debt obligation" within the meaning of Code Section 163(e)(5). No interest accrued or paid by the Company (whether as stated interest, imputed interest, or original issue discount) on any debt obligation of the Company is not deductible for income Tax purposes).
- (w) Other than as a result of the transactions contemplated by this Agreement, the Company is not subject to any limitations on the use of net operating losses or unrealized losses under Code Section 269 or any other provision of the Code or Treasury Regulations.
- (x) Pursuant to Section 280E of the Code, the Company has not taken any deductions or credits for any expense amounts incurred (other than for an amount related to the cost of goods sold) and the Company has not filed any amended Tax returns excluding the impact of 280E of the Code.

Section III.9 <u>Material Contracts</u>.

(a) Except as set forth on <u>Schedule 3.9(a)</u>, the Company is not party to, or bound by, any: (i) collective bargaining agreement or other Contract with any labor organization; (ii) employment, staffing, independent contractor, retirement, equity based,

profit sharing, bonus (including transaction or retention bonus), consulting, incentive, separation, change in control, deferred compensation or severance Contract; (iii) Contract relating to Indebtedness or to mortgaging, pledging or otherwise placing a Lien on any of the Company's assets or to the guaranty of any obligation for borrowed money or otherwise; (iv) letter of credit arrangements; (v) Contract with respect to the lending or investing of funds; (vi) Contract relating to the development, ownership, use, registration, enforcement of or exercise of any rights under any Intellectual Property; (vii) Contract or lease under which the Company is a lessee of or holds or operates any property, real or personal, owned by any other Person; (viii) Contract under which the Company is a lessor of or permits any third party to hold or operate any property, real or personal, owned or controlled by the Company: (ix) customer, supplier, distributor, broker or maintenance Contracts; (x) Contract not terminable by the Company upon 90 days' or less notice without penalty; (xi) Contract prohibiting or in any way limiting or restricting the Company from freely engaging in business anywhere in the world or otherwise prohibiting competition or restricting the use or enforcement of any Intellectual Property, including any settlement, co-existence, consent-to-use or standstill agreement; (xii) Contract which contains any minimum volume requirement, right of first refusal or most favored nations provision; (xiii) Contract which contains any provision with respect to exclusivity in favor of any third Person; (xiv) Contract prohibiting, limiting or otherwise restricting in any way the Company from soliciting customers or suppliers, or soliciting or hiring employees, of any other Person; (xv) Contract involving the settlement of any Proceeding or threatened Proceeding; (xvi) Contract (including letters of intent) relating to any business acquisition or disposition of any Person or line of business (whether by merger, consolidation or other business combination, sale of securities, sale of assets or other similar transaction) entered into during the past five years; (xvii) Contract containing an obligation concerning or consisting of a ioint venture, alliance or similar arrangement; (xviii) Contract under which the Company is, or may become, obligated to pay an amount in respect of indemnification obligations, deferred purchase price, purchase price adjustment or otherwise in connection with any acquisition or disposition of assets or securities, merger, consolidation or other business combination; and (xix) Contract with an Insider.

(b) (i) No Material Contract has been breached (and there are no anticipated breaches) in any respect or cancelled by any party thereto, and there has been no event which, upon giving of notice or lapse of time or both, would constitute such a breach or default, (ii) the Company and each counterparty has performed all obligations under each Material Contract required to be performed and no facts exist which would render such performance unlikely, (iii) no Material Contract contains any termination right upon a change in control, (iv) each Material Contract is legal, valid, binding and enforceable against the Company and against each other party thereto, and is in full force and effect, and will continue to be in full force and effect and legally and validly binding and enforceable against, each other party thereto following the consummation of the transactions contemplated hereby (subject to bankruptcy, moratorium and similar Laws and subject to the application of specific performance and other equitable principles) and (v) no party to a Material Contract has made a claim of force majeure. For purposes of

this Agreement, "<u>Material Contract</u>" means each Contract listed or required to be listed on <u>Schedule 3.9(a)</u>. The Company has heretofore delivered to Buyer a true and correct copy of all Material Contracts (and a true and correct written description of all oral Material Contracts), together with all amendments, exhibits, attachments and waivers thereto.

Section III.10 Intellectual Property; Data Privacy and Security.

- (a) The Company is the sole and exclusive owner of all Owned Intellectual Property, free and clear of all Liens. All Owned Intellectual Property is valid and enforceable. Schedule 3.10(a) contains an accurate and complete list of all Owned Intellectual Property (including Trademarks, and Software). All registered Intellectual Property has been maintained effective by the filing of all necessary filings, maintenance and renewals and timely payment of requisite fees. No loss or expiration of any Owned Intellectual Property is threatened, pending or reasonably foreseeable, except for patents expiring at the end of their statutory terms (and not as a result of any act or omission by the Company, including failure by the Company to pay any required maintenance fees).
- (b) The Company has taken all necessary and desirable action to maintain and protect all of the Owned Intellectual Property. The Company has taken commercially reasonable measures to protect the confidentiality of all trade secrets and any other confidential information of the Company (and any confidential information owned by any Person to whom the Company has a confidentiality obligation). No such trade secrets or other confidential information have been disclosed by the Company to any Person other than pursuant to a written Contract restricting the disclosure and use of such trade secrets or any other confidential information by such Person. No current or former founder, employee, contractor or consultant of the Company has any right, title or interest, directly or indirectly, in whole or in part, in any Owned Intellectual Property. The Company has obtained from all Persons (including all current and former founders, employees and contractors) who have created any Intellectual Property for the Company, valid and enforceable written assignments of any such Intellectual Property to the Company, and the Company has delivered true and complete copies of such assignments to Buyer. No Person is in violation of any such written confidentiality or assignment Contracts.
- (c) The IT Assets are operational, fulfill the purposes for which they were acquired or developed, have security, back-ups and disaster recovery arrangements in place and hardware and Software capacity, support, maintenance and trained personnel which are sufficient in all material respects for the current and anticipated future needs of the business of the Company. The Company has disaster recovery and security plans, procedures and facilities and have taken reasonable steps consistent with or exceeding industry standards to safeguard the availability, security and integrity of the IT Assets and all data and information stored thereon, including from unauthorized access and infection by Malicious Code. The Company has maintained in the Ordinary Course of Business all required licenses and service contracts, including the purchase of a sufficient number of

license seats for all Software, with respect to the IT Assets. The IT Assets have not suffered any security breach or material failure.

- (d) The Company and the former and current products, services and conduct of the business of the Company, including the manufacture, importation, use, offer for sale, sale, licensing, distribution or other commercial exploitation thereof have not infringed, misappropriated or otherwise violated, and do not infringe, misappropriate or otherwise violate, any Intellectual Property rights or rights of publicity of any Person. The Company is not the subject of any pending Proceeding that either alleges a claim of infringement, misappropriation or other violation of any Intellectual Property rights of any Person or challenges the ownership, use, patentability, registration, validity or enforceability of any Owned Intellectual Property, and no such claims have been asserted or threatened against the Company at any time. No Person has notified the Company that any of such Person's Intellectual Property rights are infringed, misappropriated or otherwise violated by the Company or that the Company requires a license to any of such Person's Intellectual Property rights. There is no actual unauthorized use, interference, disclosure, infringement, misappropriation or other violation by any Person of any of the Owned Intellectual Property, and no written or oral claims alleging such infringement, misappropriation or other violation have been made against any Person by the Company.
- (e) The Company is and always has been in compliance with all applicable Privacy and Security Requirements. The Company has not, and no third-party Processing Protected Data on behalf of the Company has, experienced any Security Breaches, and neither the Company nor the Member is aware of any notices or complaints from any Person regarding such a Security Breach. The Company has not received any notices or complaints from any Person (including any Governmental Entity) regarding the unauthorized Processing of Protected Data or non-compliance with applicable Privacy and Security Requirements. The Company does not engage in the sale, as defined by applicable Privacy and Security Requirements, of Personal Information.
- (f) The Company has valid and legal rights to Process all Protected Data that is Processed by or on behalf of the Company in connection with the use and/or operation of its products, services and business, and the execution, delivery, or performance of this Agreement will not affect these rights or violate any applicable Privacy and Security Requirements. The Company has implemented, and has required all third parties that receive Personal Information or Protected Data from or on behalf of the Company to implement, reasonable physical, technical and administrative safeguards consistent with industry standards that are designed to protect Protected Data from unauthorized access by any Person, and to ensure compliance in all material respects with all applicable Privacy and Security Requirements.

Section III.11 <u>Litigation</u>. There are no, and there have not been any, Proceedings pending or threatened against or affecting, the Member or the Company, or any director, manager, officer, executive employee, independent contractor or agent of the Company or any staffing agency used by the Company,

at law or in equity, or before or by any Governmental Entity or arbitrator. The Company is not subject to or bound by any outstanding Orders.

Section III.12 <u>Brokerage</u>. Neither the Company, the Member nor anyone on their behalf has engaged any broker, finder or similar agent in connection with the transactions contemplated by this Agreement. There are no claims for brokerage commissions, finders' fees or similar compensation in connection with the transactions contemplated by this Agreement based on any arrangement or agreement made by or on behalf of the Company.

Section III.13 Employees.

- (a) No officer, executive, key employee or independent contractor and no group of employees and/or independent contractors of the Company has any plans to terminate his, her or their status as an employee or independent contractor of the Company, including upon or in connection with the consummation of the transactions contemplated hereby. No employee or temporary employee is employed under a Contract which cannot be terminated by Buyer with less than two weeks' notice. The Company is not party to or bound by any collective bargaining agreement or other Contract with any labor organization and the Company is not obligated to nor has undertaken to recognize any labor organization as the representative of its employees. Within the past five years the Company has not (i) experienced any strikes, work stoppages or slowdowns, labor grievances, claims of unfair labor practices or other material labor disputes or labor shortages or (ii) engaged in any unfair labor practices. There are no ongoing or threatened union organizing or decertification activities with respect to employees of the Company and no such activities have occurred.
- (b) The Company has provided Buyer with a true, complete and accurate list, as of a date within one (1) week of the date hereof, of each employee of the Company, the date(s) of hire, age, position and title (if any), current rate of compensation and rate of compensation during the 2023 calendar year (in each case, including bonuses, commissions and incentive compensation, if any), whether such person is exempt or non-exempt for overtime pay purposes, the number of such person's accrued but unpaid paid time off, whether such person is absent from active employment and, if so, the date such person became inactive (if known), the reason for such inactive status and, if applicable, the anticipated date of return to active employment. The employment of all employees is "at will" and may be terminated by the Company at any time, for any reason or no reason, in accordance with applicable Law.
- (c) The Company has provided Buyer with a true, complete and accurate list, as of a date within one week of the date hereof, of each individual independent contractor providing services to the Company, the date(s) of engagement, position and title (if any), name of an applicable contact person and contact details, location where services are provided by such independent contractor, and hourly, monthly and annual remuneration of each independent contractor.

- (d) The Company: (i) is and has been in compliance in all material respects with all applicable Laws respecting employment, including provisions thereof relating to employment practices, classification of employment, terms and conditions of employment, wages and hours, pay equity, equal employment, immigration, human rights and accommodation obligations, occupational health and safety, workers compensation and employee privacy, in each case, with respect to current and former employees and independent contractors; (ii) is not liable for, and has not incurred any material unresolved liability with respect to, any arrears of wages, salaries, commissions, bonuses, accrued and unused vacation or other compensation for services performed by any current or former employees or independent contractors, nor any Taxes or any penalty for failure to comply with any of the foregoing; and (iii) is not liable for, and has not incurred any material liability with respect to, any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Entity, with respect to unemployment compensation benefits, social security, insurance or similar benefits or obligations for current and former employees and independent contractors. Each natural person who performs services for or on behalf of the Company has been properly classified by the Company as either an employee, independent contractor, or consultant in accordance with applicable Law. There is no written or verbal commitment of agreement to increase wages or modify the terms and conditions of employment or engagement of any employee, temporary employee or independent contractor of the Company. The Company has delivered to Buyer true and complete copies of all Permits issued under applicable employment Laws. Such Permits are listed on the list of employees described in Section 3.13(c), and the Company is and has been operating in compliance with such Permits.
- (e) Within the past five years, the Company has not implemented any plant closing or layoff of employees that could implicate the Worker Adjustment and Retraining Notification Act of 1988, as amended, or any similar or related Law (the "WARN Act"). Schedule 3.13(e) sets forth a true and complete list of all employees who have been laid off by the Company, by date and location, in the 90 day period preceding the date hereof.
- (f) The Company has provided Buyer with all inspection reports under applicable occupational health and safety Laws relating to the Company. There are no outstanding inspection Orders or any pending or threatened Proceedings made under applicable occupational health and safety Laws relating to the Company, and there have been no fatal or critical accidents within the last five years that would be reasonably likely to lead to Proceedings against the Company or the Member under applicable occupational health and safety Laws. The Company has complied in all respects with any Orders issued under applicable occupational health and safety Laws, and there are no outstanding appeals of any Orders applicable to occupational health and safety Laws relating to the Company.
- (g) All employees of the Company employed at any time in the past five years, including seasonal and temporary employees, have presented proper

documentation (including Form I-9) for employment in the United States with the Company. The Company has not been the subject of any audit of its immigration, employment verification or Form I-9 practices by any Governmental Entity nor has the Company had any penalties assessed against it by any Governmental Entity due to its hire of unauthorized workers or failure to comply with applicable document collection and retention requirements.

(h) There is no complaint or other labor-related or employment-related charge or complaint pending or threatened against the Company with the Equal Employment Opportunity Commission or any equivalent state agency, the National Labor Relations Board, the United States Department of Labor or similar Governmental Entity. There has not been any claim, controversy or investigation relating to, or any act or allegation of or relating to, race or sex-based discrimination, race-based or sexual harassment or sexual misconduct, or breach of any policy of the Company relating to the foregoing, in each case involving the Company or any current or former employee, officer, director, executive, manager, individual independent contractor or other service provider (in relation to his or her work at the Company) of the Company, nor have there been any settlements or similar out-of-court or pre-litigation arrangements relating to any such matters, nor has any such claim, settlement or other arrangement been proposed or threatened.

Section III.14 Employee Benefit Plans.

- (a) Schedule 3.14(a) sets forth a complete and correct list of each "employee benefit plan" (as such term is defined in Section 3(3) of ERISA, whether or not subject to ERISA), each employment, consulting, retirement, option, equity or equity-based, phantom equity, profit sharing, bonus, commission, incentive, severance, separation, change in control, retention, deferred compensation, fringe benefit, vacation, paid time off, medical, dental, life, disability or other welfare and each other benefit or compensation plan, program, policy, agreement, arrangement or Contract (i) that is maintained, sponsored or contributed to (or required to be contributed to) by the Company or any ERISA Affiliate or (ii) under or with respect to which the Company or any ERISA Affiliate has any current or contingent liability or obligation (each, a "Company Employee Benefit Plan"). With respect to each Company Employee Benefit Plan, to the extent applicable, the Company has furnished to Buyer true and complete copies of (A) the plan documents (and all amendments thereto), summary plan descriptions and summaries of material modifications and other material employee communications, (B) the most recent determination or opinion letter received from the Internal Revenue Service (the "IRS"), (C) the Form 5500 Annual Report (including all schedules and other attachments) as filed for the most recent three (3) years, (D) all related trust agreements, insurance Contracts, and other funding arrangements and (E) all material correspondence with any Governmental Entity.
- (b) No Company Employee Benefit Plan provides, and the Company has no obligation to provide or any other liability with respect to, post-employment or post-

termination health or life insurance or other welfare-type benefits for any Person (other than as required under Part 6 of Subtitle B of Title I of ERISA, Section 4980B of the Code or similar state Law ("COBRA") for which the covered Person pays the full cost of coverage). The Company and the ERISA Affiliates have complied and are in compliance with the requirements of COBRA. Neither the Company nor any ERISA Affiliate sponsors, maintains, contributes to (or is obligated to contribute to) or has any liability under or with respect to: (i) any "employee pension benefit plan," as defined in Section 3(2) of ERISA, or other plan that is or was subject to Section 302 or Title IV of ERISA or Section 412 of the Code, (ii) any "multiple employer welfare arrangement" as defined in Section 3(40) of ERISA, or (iii) any multiple employer plan as determined under Section 413 of the Code. The Company does not have any current or contingent liability or obligation by reason of at any time being considered a single employer with any other Person under Section 414 of the Code.

- (c) Each Company Employee Benefit Plan that is intended to be qualified within the meaning of Section 401(a) of the Code is so qualified, has received or is otherwise entitled to rely on a current favorable determination or opinion letter to that effect from the IRS, and no circumstance exists that could result in revocation of any such favorable determination or opinion letter or adversely affect the qualified status of such Company Employee Benefit Plan. Each Company Employee Benefit Plan and any related trust, insurance Contract or fund has been established, maintained, funded, operated, and administered in accordance with its respective terms and in compliance with all applicable laws, including ERISA and the Code. All contributions (including all employer contributions and employee salary reduction contributions), distributions, reimbursements, and premiums or other payments required to be made prior to the Closing have been timely made and all contributions, distributions, reimbursements and premiums or other payments for any period ending on or before the Closing Date that are not yet due have been made or properly accrued. There has been no non-exempt "prohibited transaction" (as defined in Section 4975 of the Code or Section 406 of ERISA) or breach of fiduciary duty (as determined under ERISA) with respect to any Company Employee Benefit Plan. There are no pending or threatened Proceedings with respect to any Such Proceeding.
- (d) No Company Employee Benefit Plan is currently under audit or examination by the IRS or the Department of Labor. There are no pending or threatened, audits, investigations, claims, suits, grievances or other Proceedings, and there are no facts that could reasonably give rise thereto, involving, directly or indirectly, any Company Employee Benefit Plan or any fiduciary or administrator thereof, or any rights or benefits thereby, other than the ordinary and usual claims for benefits by participants, dependents or beneficiaries.
- (e) (i) None of the Company Employee Benefit Plans or any other arrangement obligates the Company to pay any separation, severance, termination or any other benefit or compensation that may be triggered, increased or accelerated or

otherwise results in the acceleration of time of payment, funding, or vesting as a result of the execution and delivery of this Agreement or any transaction contemplated by this Agreement (alone, or in combination with any other event) or as a result of a change in control or ownership within the meaning of Section 280G of the Code and (ii) no unfunded liability exists under any Company Employee Benefit Plan.

- (f) <u>Schedule 3.14(f)</u> lists all Company employees covered by any written employment, consulting, severance, change-in-control or retention Contract and any non-competition, non-solicitation, non-disparagement, confidentiality, proprietary information, intellectual property rights or similar Contract with the Company (each, an "<u>Employment and Services Agreement</u>"). The Company has provided Buyer with true, correct and complete copies of each Employment and Services Agreement.
- (g) Neither the Company nor any ERISA Affiliate maintains or has maintained, has any obligation to contribute to, or has any current or contingent liability or obligation with respect to, any multiemployer plan within the meaning of Section 3(37) of ERISA.

Section III.15 <u>Insurance</u>. <u>Schedule 3.15</u> sets forth a list of all insurance policies the Company has in place, which list sets forth the name of the insurer, policy number, policy limit, deductible, premium, expiration date, scope of coverage and status of any Proceedings pending thereunder for each insurance policy (and includes a description of any self-insurance or co-insurance arrangements, including any reserves). Each such insurance policy is in full force and effect and all premiums are currently paid in accordance with the terms of such insurance policy. No current or historical limits under such insurance policies have been eroded or materially impaired by claims. There has not been a failure by the Company to give notice of any material claim that may be insured under any such insurance policy in a timely fashion or in a manner required by such insurance policy. No reservation of rights letter or other notice of defenses has been received by the Company. There are no notices of, or pending, claims and the Company has not received any notice that any such insurance policy will be cancelled or will not be renewed. The insurance coverage maintained by the Company is customary for businesses of similar size engaged in similar lines of business. The Company has complied and is in compliance with all insurance requirements under any Contract or agreement to which it is a party or bound. Except as set forth on <u>Schedule 3.15</u>, in the past five years, no claim has been made on any of the Company's insurance policies.

Section III.16 Compliance with Laws; Permits.

(a) Except for Federal Cannabis Laws, the Company has complied and is in compliance, in each case, in all material respects, with all applicable Laws and no notices have been received by and no claims have been filed against the Company alleging a violation of any such Laws. The Company has not received any notice of any violation or any alleged violation of any Law. No officer, director, manager, employee, independent contractor, consultant, advisor or agent of the Company has been or is authorized to make or receive, and none of the Company's officers, directors, managers, employees or consultants or advisors or agents have made or received, any bribe, kickback payment or other illegal payment at any time with respect to the business of the

Company. The Leased Real Property has been used, occupied, operated and maintained in accordance with all applicable Laws, including any zoning or building-related Laws.

- (b) The Company (i) holds all Permits required or desirable for the ownership and use of its assets and properties and the conduct of its business (including all Permits necessary to operate a cannabis business in the State of Arizona consistent with Arizona Cannabis Laws (the "Marijuana Permits")) as currently conducted and Schedule 3.16(b) sets forth a list of all of such Permits, and (ii) has been and is in compliance with all terms and conditions of any such Permits. Upon receipt of the Arizona Transaction Approval, all such Permits may be relied upon by Buyer and the Company for lawful operation of the business of the Company on and immediately after the Closing without transfer, reissuance or other Governmental Entity action.
- (c) Neither the Member nor the Company has received any notice of assessment, provisional assessment, reassessment, supplementary assessment, penalty assessment or increased assessment (collectively, "Assessments") or any other communications related thereto from any workers' compensation or workplace safety and insurance board or similar authorities in any jurisdictions where the Company conducts business. There are no Assessments that are unpaid as of the date hereof, and there are no facts or circumstances that would be reasonably likely to result in an increase in liability to the Company after the Closing Date under any applicable workers' compensation or workplace safety and insurance Laws. The Company's accident cost experience relating to the Company's business is such that there are no pending Assessments, and there are no claims or potential claims which may adversely affect the Company's accident cost experience.

Section III.17 Environmental Matters.

- (a) The Company and the Leased Real Property are and have been in compliance with all applicable Environmental Laws. Any real property formerly owned or leased by the Company or otherwise related to the business of the Company was in compliance with all Environmental Laws during the Company's period of ownership or operation. The Company has timely obtained and maintains in full force and effect all Permits required by Environmental Laws to operate the business as conducted as of the Closing Date. The Company has no knowledge of any facts or circumstances concerning any alleged violation or Loss arising under any Environmental Law with respect to the Leased Real Property, the business or any formerly owned or operated real property or any use or condition thereof.
- (b) There exists no Order, notice of violation, notice of potential responsible party liability, nor any Proceeding, pending or threatened, against the Member or the Company pursuant to any Environmental Law relating to (i) the lease, occupation or use of the Leased Real Property or any formerly owned, leased, occupied or used real property by the Company, (ii) any alleged violation of or liability under any Environmental Law by the Company, (iii) the suspected presence, release or threatened release of or the exposure to any Hazardous Materials on, under, in or from the Leased

Real Property, or any formerly owned, leased, occupied or used real property or from any product manufactured or sold by the Company, nor does there exist any valid basis for any such Order, notice of violation, notice of potential responsible party liability or Proceeding (collectively "Environmental Claims").

- (c) Neither the Company nor any of its predecessors or Affiliates has treated, stored, disposed of, arranged for or permitted the disposal of, transported, handled, or released, or exposed any Person to, any Hazardous Material, or owned or operated any real property or facility contaminated by any Hazardous Material, so as to have given or as may give rise to any liabilities (contingent or otherwise), including any investigatory, corrective or remedial obligations, pursuant to Environmental Laws.
- (d) The Company has not assumed, undertaken, become subject to, or provided an indemnity with respect to any liability, including any investigative, corrective or remedial obligation, of any other Person relating to Environmental Laws.
- (e) There are and were no underground storage tanks currently or formerly located on the Leased Real Property used or formerly used by the Company for the purpose of storing any Hazardous Material. There is no asbestos-containing building material on the Leased Real Property or the Leasehold Improvements, and no asbestos abatement or remediation work has been performed on the Leased Real Property. There is no PCB-containing equipment or PCB-containing material located on the Leased Real Property or the Leasehold Improvements.
- (f) The Company has furnished to Buyer true and complete copies of all environmental audits, reports, Order arising under Environmental Laws, documents and pleadings related to any Environmental Claim and other material environmental documents relating to the Company and each of their predecessors and Affiliates, the Leased Real Property and each of their respective past properties, facilities or operations, that are in their possession, custody or control.

Section III.18 <u>Affiliated Transactions</u>. Except as set forth on <u>Schedule 3.18</u>, no Insider is a party to any Contract or other transaction with the Company or has any interest in any property, real or personal or mixed, tangible or intangible, used in or pertaining to the business of the Company.

Section III.19 <u>Indebtedness</u>. Except as set forth on <u>Schedule 3.19</u>, the Company has no Indebtedness.

Section III.20 <u>Product Liability</u>. The Company does not have any liability arising out of any injury to individuals or property as a result of the ownership, possession or use of any products manufactured, sold or delivered by the Company or with respect to any services rendered by the Company. Each product sold or delivered and each service rendered by the Company has been in conformity in all respects with contractual commitments and express and implied warranties and the Company does not have any liability or obligation for replacement thereof. There have been and there are no product recalls or withdrawals or requests for product recalls or withdrawals by any Governmental Entity or by any customer of the Company.

Section III.21 <u>Bank Accounts; Identification Numbers</u>. <u>Schedule 3.21(a)</u> sets forth a true, complete and correct list of all banks or other financial institutions with which the Company has an account, showing the type and account number of each such account, and the names of the Persons authorized as signatories thereon or to act or deal in connection therewith. <u>Schedule 3.21(b)</u> sets forth a true, complete and correct list of all employer identification numbers and state identification numbers of the Company.

Section III.22 <u>Organization</u>; <u>Authorization</u>. The Member has the legal capacity to enter into this Agreement, and all other agreements contemplated hereby to which the Member is a party, and perform the Member's obligations hereunder and thereunder. This Agreement, and all other agreements contemplated hereby to which the Member is a party, have been duly executed and delivered by the Member and constitute the legal, valid and binding obligations of the Member, enforceable in accordance with their respective terms, except as such may be limited by bankruptcy, insolvency, reorganization or other Laws affecting creditors' rights generally and by general equitable principles.

Section III.23 No Other Representations or Warranties. Except for the representations and warranties made by the Company, Cannabist and the Member in this Article III (as qualified by the Schedules), neither the Company nor the Member or other Person makes any other express or implied representation or warranty, either written or oral, with respect to the Company, the Member or the Equity.

Article IV REPRESENTATIONS AND WARRANTIES OF BUYER

As an inducement to the Member, Cannabist and the Company to enter into this Agreement and consummate the transactions contemplated hereby, Buyer hereby represents and warrants that each of the following representations are true and correct as of the date hereof until and including the Closing Date:

Section IV.1 <u>Organization; Authorization</u>. Buyer is a limited liability company duly formed under the Laws of the State of Arizona with full limited liability company power and authority to enter into this Agreement and to perform its obligations hereunder. The execution, delivery and performance of this Agreement and the other agreements contemplated hereby to be executed and delivered by Buyer, and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all requisite action on the part of Buyer and no other Proceedings on the part of Buyer are necessary to authorize the execution, delivery or performance of this Agreement or the other agreements contemplated hereby. This Agreement and the other agreements contemplated hereby to be executed and delivered by Buyer constitute valid and binding obligations of Buyer enforceable against Buyer in accordance with its terms, except as such may be limited by bankruptcy, insolvency, reorganization or other Laws affecting creditors' rights generally and by general equitable principles.

Section IV.2 <u>Non-contravention</u>. Other than the Arizona Transaction Approval and in connection with Parent's outstanding credit facility, the execution, delivery and performance of this Agreement and any related agreements and the consummation of the transactions contemplated hereby and thereby by Buyer do not and will not (a) require the authorization, consent or approval of, an exemption or waiver from, notice or declaration to, or the filing of any

document or with, or the payment of any amounts to, any Person, (b) constitute a default under (whether with or without the giving of notice, the passage of time or both) the governing documents of Buyer or (c) violate any Law or Order (other than Federal Cannabis Laws).

Section IV.3 <u>Sufficiency of Funds</u>. Buyer will have sufficient cash on hand or other sources of immediately available funds to enable it to make payment of the Purchase Price and consummate the transactions contemplated hereby.

Section IV.4 No Other Representations or Warranties. Each of Buyer and Parent has conducted its own independent review and analysis of the Equity and acknowledges that it has been provided with access to the properties, premises and records of the Company for this purpose. In entering into this Agreement, each of Buyer and Parent relied solely upon its own investigation and analysis and the representations and warranties of the Company, Cannabist and the Member set forth in this Agreement, and each of Buyer and Parent acknowledges and agrees that, except for the representations and warranties made by the Company, Cannabist and the Member in Article III (as qualified by the Schedules), neither Cannabist, the Company, nor the Member or other Person makes any other express or implied representation or warranty, either written or oral, with respect to the Company or the Equity, and each of Buyer and Parent has not relied upon and is not relying upon any other express or implied representation or warranty, either written or oral, or any other information or communications in its determination to effect the transactions contemplated by this Agreement.

Article V PRE-CLOSING COVENANTS

Section V.1 <u>Conduct of Business Prior to the Closing</u>. From the date hereof until the Closing, except as otherwise consented to in writing by Buyer, the Company shall conduct its business and the affairs in the Ordinary Course of Business. Without limiting the foregoing, from the date hereof until the Closing Date, the Company shall:

- (a) pay its debts, Taxes, and other obligations when due;
- (b) maintain the assets owned, operated, or used by it in the same condition as they were on the date of this Agreement, subject to reasonable wear and tear and the sale of inventory and other assets in the Ordinary Course of Business;
- (c) (i) perform all of its obligations under all Material Contracts in the Ordinary Course of Business and (ii) not enter into, terminate, materially amend or waive any Material Contract (other than renewals and extensions in the Ordinary Course of Business);
 - (d) maintain its books and records in the Ordinary Course of Business;
- (e) use its commercially reasonable efforts to maintain its existing relations with its Business Relations and employees;

- (f) not take or permit any action that would cause any changes, events, or conditions that could reasonably expect to have, individually or in the aggregate, a Material Adverse Effect;
- (g) not issue, sell, grant, dispose of, pledge or otherwise encumber any Equity, voting securities or equity interests, or any securities or rights convertible into, exchangeable or exercisable for, or evidencing the right to subscribe for any Equity, voting securities or equity interests, or any rights, warrants, options, calls, commitments or any other Contracts of any character to purchase or acquire any Equity, voting securities or equity interests or any securities or rights convertible into, exchangeable or exercisable for, or evidencing the right to subscribe for, any Equity, voting securities or equity interests;
- (h) not (i) redeem, purchase or otherwise acquire any of its outstanding Equity, voting securities or equity interests, or any rights, warrants, options, calls, commitments or any other Contracts or acquire any Equity, voting securities or equity interests or (ii) form any subsidiary;
 - (i) not split, combine, subdivide or reclassify any Equity;
- (j) not incur or assume any Indebtedness or guarantee any indebtedness of another Person or issue or sell any debt securities or options, warrants, calls or other rights to acquire any debt securities of the Company or cancel or compromise any debt or claim or waive or release any material right of the Company regarding such debt;
 - (k) not commit to make any capital expenditure after the Closing Date;
- (l) not directly or indirectly acquire by merging or consolidating with, or by purchasing all of or a substantial equity interest in, or by any other manner, any Person or division, business or equity interest in any Person;
 - (m) not make any loan or advance to or investment in any Person;
- (n) not (i) hire any employees other than in the Ordinary Course of Business, (ii) increase the compensation payable or to become payable by the Company other than in the Ordinary Course of Business, (iii) grant any bonus, benefit or other direct or indirect compensation to any employees other than to new employees or as provided for under any Company Employee Benefit Plan(s) in existence as of the date hereof, (iv) increase the coverage or benefits available under any (or create any new) severance pay, termination pay, vacation pay, salary continuation for disability, sick leave, deferred compensation, bonus or other incentive compensation, insurance, pension or other employee benefit plan or arrangement made to, for or with any employees or otherwise modify or amend or terminate any such plan or arrangement, or (v) enter into any employment, deferred compensation, severance, consulting, non-competition or similar Contract (or amend any such Contract);

- (o) not change or revoke any election concerning Taxes, file any amended Tax Return, enter into any closing agreement or waiver or extension of the statute of limitations period with respect to any Tax Proceeding, settle any Tax Proceeding or obtain any Tax ruling, change of any method of accounting of the Company for Tax purposes, change any annual accounting period of the Company with respect to any Tax or make any election with respect to Taxes that is outside the Ordinary Course of Business;
- (p) not make any changes in accounting methods, principles or practices, except as may be required by a change in GAAP or applicable Law;
 - (q) not amend any Company Governing Documents;
- (r) not adopt a plan or agreement of complete or partial liquidation, dissolution, restructuring, recapitalization, merger, consolidation or other reorganization;
 - (s) not acquire or dispose of any properties or assets outside the Ordinary Course of Business;
 - (t) not allow any properties or assets become subject to a Lien;
 - (u) not settle, compromise or initiate any Proceeding;
- (v) not declare, set aside, establish a record date for, make or pay and dividend or distribution (whether payable in cash, equity, property or a combination thereof) with respect to any of its equity interests, or entered into any Contract with respect thereto; and
- (w) upon Buyer's request, submit to the Arizona Department of Health Services, or such other Governmental Entity as appropriate, any brand, product, or formulation for approval for manufacture and sale in the State of Arizona; provided, however, that the Company may not produce or sell any such brand, product, or formulation prior to the Closing Date.
- (x) maintain its Permits and not initiate or cause to be initiated any Proceeding related to or in connection with the grant of Permits by any Governmental Entity pursuant to, in relation to, or otherwise in connection with the Arizona Cannabis Laws.

Section V.2 Access to Information; Confidentiality.

(a) From the date hereof until the Closing, the Company shall (i) afford Buyer, its Affiliates and their respective representatives reasonable access to and the right to reasonably inspect all of the assets, premises, books and records, Contracts and other documents and data related to the Company or its business; (ii) furnish Buyer, its Affiliates and their respective representatives with such financial, operating, and other data and information related to the Company or its business as Buyer, its Affiliates and their respective representatives may reasonably request; and (iii) instruct the

representatives of the Company to reasonably cooperate with Buyer, its Affiliates and their representatives in their investigation of the Company and its business.

(b) The parties hereto agree that the terms of this Agreement and all information exchanged hereto shall be kept confidential by the Parties and their representatives and not disclosed to any other Person without the prior consent of the other party; provided, that each of Cannabist and Buyer and its Affiliates (i) may issue a press release detailing the general terms of the transactions contemplated hereby, which press release may be publicly filed with Cboe, the SEC or other regulatory bodies and (ii) may disclose such information to the extent required by applicable Law or Cboe policy. Notwithstanding the foregoing, nothing in this Section 5.3(b) will prevent any party hereto from making any other public disclosure required by Law or the rules or policies or any stock exchange.

Section V.3 Notice of Certain Events.

- (a) From the date hereof until the Closing, the Company shall promptly notify Buyer in writing of:
- (i) any fact, circumstance, event, or action, the existence, occurrence, or taking of which (A) has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (B) has resulted in, or could reasonably be expected to result in, any representation or warranty made by the Company or the Member hereunder not being true and correct, (C) has resulted in, or could reasonably be expected to result in a breach of this Article V or (D) has resulted in, or could reasonably be expected to result in, the failure of any of the conditions set forth in Section 7.1 or Section 7.2 to be satisfied;
- (ii) any notice or other communication from any Person alleging that the consent of, or any notice or payment to, such Person is or may be required in connection with the transactions contemplated hereby;
- (iii) any notice or other communication from any Governmental Entity in connection with the transactions contemplated hereby; and
- (iv) Any Proceedings commenced or threatened against, relating to or involving or otherwise affecting the Company that, if pending on the date of this Agreement, would have been required to have been disclosed in the Schedules or that relates to the consummation of the transactions contemplated hereby.
- (b) Within 15 calendar days of the end of each month, the Company shall deliver (or cause to be delivered) to Buyer the applicable financial statements of the Company with respect to each such monthly period and a certificate of an officer of the Company certifying that such financial statements meet the standards set forth in Section 3.4(a).

Section V.4 Governmental Approvals.

- (a) Each Party shall, as promptly as possible following the execution of this Agreement, (i) make, or cause to be made, all filings and submissions required under any Law applicable to such party or any of its Affiliates or any rules or policies of any stock exchange (including those required to obtain the Arizona Transaction Approval); and (ii) use commercially reasonable efforts to obtain, or cause to be obtained, all consents, authorizations, orders, and approvals from all Governmental Entities that may be or become necessary in connection with the execution and delivery of this Agreement and the performance of his, her or its obligations pursuant to this Agreement and any other certificate, agreement, document, or instrument to be executed and delivered by it in connection with the transactions contemplated hereby (including those required to obtain the Arizona Transaction Approval). Each Party shall cooperate fully with the other Parties and their Affiliates in promptly seeking to obtain all such consents, authorizations, orders, and approvals. The Parties shall not willfully take any action that will have the effect of delaying, impairing, or impeding the receipt of any required consents, authorizations, orders, and approvals.
- (b) Without limiting the generality of the undertakings of the Parties pursuant to <u>clause (a)</u> above, each of the Parties shall use all commercially reasonable efforts to:
 - (i) respond to any inquires by any Governmental Entity regarding matters with respect to the transactions contemplated hereby;
 - (ii) avoid the imposition of any Order or the taking of any action that would restrain, alter or enjoin the transactions contemplated hereby; and
 - (iii) In the event any Order adversely affecting the ability of the Parties to consummate the transactions contemplated hereby has been issued, have such Order vacated or lifted.

Section V.5 No Solicitation by the Company. During the period beginning on the date hereof and ending at the Closing or the date this Agreement terminates, the Company and the Member shall not and shall not permit any of their respective representatives to, directly or indirectly, (a) initiate, solicit or knowingly encourage (including by way of furnishing nonpublic information or assistance) any inquiries relating to an Acquisition Proposal or the making of any Acquisition Proposal, (b) enter into discussions or negotiate with any Person in furtherance of such inquiries or with respect to an Acquisition Proposal, or (c) enter into any letter of intent, Contract or any agreement in principle or arrangement relating to an Acquisition Proposal. The Company and the Member each further agrees that it shall promptly (and in no event later than 24 hours after receipt of any Acquisition Proposal) notify Buyer after receipt of any Acquisition Proposal, or any request for non-public information relating to the Company or its business with respect to an Acquisition Proposal, or for access to the properties, books or records of the Company by any Person that has made, or is reasonably expected to make, an Acquisition Proposal. The Company and the Member each agrees immediately to cease and cause to be

terminated any activities, discussions or negotiations conducted prior to the date hereof with any parties other than Buyer with respect to any of the foregoing.

Section V.6 <u>Security Interest.</u>

- (a) As collateral security for the performance in full of all the obligations of the Company and the Member under this Agreement until the earlier of (1) the Closing, (2) in the event of termination of this Agreement under Article VIII herein, the Company's and the Member's repayment of the Deposit owed to Buyer, and (3) termination of this Agreement for failure to pay the Deposit under Section 2.5(c)(i):
 - (i) the Company hereby pledges and assigns to Buyer, and grants to Buyer a Lien on and continuing security interest in, and a right to set off against, any and all of the Company's right, title and interest in and to all of the following tangible and intangible personal property, wherever located, and whether now existing or hereafter arising or acquired from time to time (collectively, the "Company Collateral"): all cash, currency, and cash equivalents, all Accounts, all Inventory, all Contract rights, all Equipment, all Goods, all Instruments (including promissory notes), all Chattel Paper (including Electronic Chattel Paper and Tangible Chattel Paper), all Fixtures, all Commercial Tort Claims (including Proceedings), all Deposit Accounts, all Documents, all General Intangibles, all Permits, all Intellectual Property and software, owned or controlled by the Company as well as all licenses to third party Intellectual Property and software held by the Company, all Investment Property, all Payment Intangibles, all Securities Accounts and Commodities Accounts, all Supporting Obligations, all books and records related to the foregoing, all Accessions, and to the extent not otherwise included above, all Proceeds (including insurance Proceeds), products, accessions, rents and profits of or in respect of any of the foregoing; and
 - (ii) the Member hereby pledges and assigns to Buyer, and grants to Buyer a Lien on and continuing security interest in, and a right to set off against any and all of the Member's right, title and interest in and to all of the following, wherever located, and whether now existing or hereafter arising or acquired from time to time (collectively, the "Pledged Collateral"; together with the Company Collateral, collectively, the "Collateral"): all Equity owned or hereafter acquired by the Member in the Company including, without limitation, the certificates representing such Equity, if certificated, any interest of the Member on the books and records of the Company, and any securities entitlements relating to the Equity, all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any of or all of the Equity and any other warrant, right or option or other agreement to acquire any of the foregoing, all management rights, all voting rights, any interest in any capital account of the Member in the Company on account of the Equity, all rights as and to become a member or stockholder of the Company as a holder of such Equity,

all rights of the Member under any shareholder, equityholder or voting trust agreement or similar agreement relating to the Equity, all of CCAT's right, title and interest relating to the Equity, as a member, unit holder, or manager, to any and all assets or properties of Company, all other rights, powers, privileges, interests, claims and other property in any manner arising out of or relating to any of the foregoing, all Accessions, and to the extent not otherwise included above, all Proceeds, products, accessions, rents and profits of or in respect of any of the foregoing.

- (iii) Capitalized terms used in this <u>Section 5.7</u> that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms in the Uniform Commercial Code as in effect from time to time in the State of New York (the "<u>UCC</u>"), except as such term may be used in connection with the perfection of the Collateral and then the applicable jurisdiction with respect to such affected Collateral shall apply.
- (iv) This Agreement creates a valid Lien and security interest in favor of the Buyer in the (A) Company Collateral of the Company and (b) the Pledged Collateral of the Member and, when properly perfected by filing, shall constitute a valid and perfected, Lien and security interest in such Collateral (including all uncertificated equity consisting of partnership or limited liability company interests that do not constitute Securities).
- (b) Each of the Company and the Member acknowledge and agree that there are no restrictions in its organizational documents or any other agreement which would limit or restrict (i) the grant of a Lien and security interest in the Collateral pursuant to this Agreement, (ii) the perfection of the Lien and security interest in the Collateral or (iii) the exercise of any of Buyer's remedies (including all voting and management rights in respect of the Pledged Collateral), in respect of such Lien and security interest in the Collateral as contemplated by this Agreement.
- (c) The Company and the Member, as applicable shall cause the and Lien security interests granted under this Section 5.7 to be perfected in Buyer as of the date hereof and continuing until the earlier of (1) the Closing, (2) the return of the Deposit in full to the Buyer, and (3) termination of this Agreement for failure to pay the Deposit under Section 2.5(c)(i). As of the date hereof the Member shall deliver to Buyer stock certificates evidencing the Equity, if certificated, duly endorsed in blank or accompanied by stock powers or other instruments of transfer duly executed in blank. The Company hereby irrevocably authorizes Buyer at any time and from time to time to file in any applicable filing office prescribed, any financing statements (including continuation statements) or amendments thereof or supplements thereto or other forms or instruments, or similar filing (i) describing the Company Collateral in the same manner as described herein or contains an indication or description of the Company Collateral that describes such property in any other manner as the Buyer may determine, including without limitation, "all personal property, whether now owned or hereafter acquired", or "all

assets, whether now owned or hereafter acquired" or words of similar effect (or as being of equal or lesser scope or with greater detail) or (ii) that contains any information required by the UCC as in effect from time to time as adopted by any relevant jurisdiction for the sufficiency or filing office acceptance. The Member hereby irrevocably authorizes Buyer at any time and from time to time to file in any applicable filing office prescribed, any financing statements (including continuation statements) or amendments thereof or supplements thereto, or other forms or instruments or similar filing (A) describing the Pledged Collateral in the same manner as described herein or contains an indication or description of the Pledged Collateral that describes such property in any other manner as the Buyer may determine or (B) that contains any information required by the UCC as in effect from time to time as adopted by any relevant jurisdiction for the sufficiency or filing office acceptance.

- (d) Automatically upon the earlier of (1) the Closing, (2) the return of the Deposit in full to the Buyer, and (3) termination of this Agreement for failure to pay the Deposit under Section 2.5(c)(i), all security interests, liens, mortgages, pledges, charges and other encumbrances granted to the Buyer in connection with this Agreement shall be automatically released and terminated without any further action by any Person; provided, however, in the event that the security interests are released pursuant to this Section 5.7(d) in connection with the Closing, this release shall only apply with respect to the security interests granted by the Member. At the expense of the Buyer, the Buyer will promptly upon such termination deliver any such UCC-3 termination statements or other release documents as are reasonably required to release the security interests and liens previously filed by the Buyer or on the Buyer's behalf under this Agreement. Upon such automatic release and termination of the security interests and liens, the Buyer hereby authorizes the Member (or any designee of the Member) to file those certain UCC-3 termination statements and any other lien release or terminations instruments reasonably necessary to release the security interests and liens previously filed by the Buyer or on the Buyer's behalf under this Agreement.
- (e) The Member has caused the Company to amend or to otherwise modify its organizational documents, books, records, and related agreements, documents, and instruments, as applicable, to reflect the rights and interests of the Buyer hereunder, and to the extent required to enable and empower the Buyer to exercise and enforce its rights and remedies hereunder in respect of the Pledged Collateral. The Company, as issuer of the Equity, has by execution of this Agreement, acknowledged, consented and agreed that the Company may, and the Member and the board of directors of the Company, on behalf of Company, has by written consent authorized the Member to, grant a Lien and security interest in the Pledged Collateral pursuant to this Agreement, together with all rights accompanying such Lien and security interest as provided in this Agreement and under applicable Law.
- (f) The Company and the Member further agree upon the request of Buyer, to take any and all other actions as Buyer may determine to be reasonably necessary for the attachment, perfection and first priority of Buyer's security interest in any and all of the

Collateral, including without limitation, (i) executing and delivering and where appropriate filing financing statements and amendments relating thereto under the UCC to the extent, if any, that the Company's or the Member's signature thereon is required therefor and (ii) complying with any provision of any statute, regulation or treaty as to any Collateral if compliance with such provision is a condition to attachment, perfection or priority of, or ability of Buyer to enforce, its Lien and security interest in such Collateral.

- (g) The Company and the Member acknowledge and agree that the Buyer shall have in addition to the rights and remedies provided herein, in any other document related to the transactions described herein, or by applicable Law, (including, but not limited to, levy of attachment, garnishment and the rights and remedies set forth in the UCC of the jurisdiction applicable to the affected Collateral), the rights and remedies of a secured party under the UCC (regardless of whether the UCC applies to the affected Collateral), and further, may, with or without judicial process, notice, demand or the aid and assistance of others, all of which are irrevocably waived by the Company and the Member, take any action with respect to the Collateral to protect its Lien and security interest in such Collateral. In order to permit the Buyer to enforce its Lien and security interest in the Pledged Collateral, the Member hereby grants to Buyer a proxy to exercise all voting rights with respect to the Equity that the Member now owns or hereafter acquires. This proxy is valid and irrevocable. This proxy runs with the Equity and binds all future owners of the Equity. This proxy also runs with the Lien and security interest granted herein, and may be exercised by any assignee of the security interest.
- (h) Notwithstanding the foregoing, this Agreement shall continue to be effective or shall be automatically reinstated, as the case may be, if at all or any of the obligations under this Agreement or the transactions contemplated herein, in whole or in part, are rescinded or must otherwise be restored for any reason, including as a preference, fraudulent conveyance, or otherwise under any debtor relief Law. The Member and Company acknowledge and agree that in the event all or any part of the obligations under this Agreement or the transactions contemplated herein are rescinded or must be restored for any reason, all reasonable costs and expenses (including, without limitation, any reasonable legal fees and disbursements), incurred by the Buyer in defending and enforcing such reinstatement shall be deemed to be included as a part of the obligations secured by the Collateral.

Section V.7 <u>Closing Conditions</u>. From the date hereof until the Closing, each Party shall use commercially reasonable efforts to take such actions as are necessary to expeditiously satisfy the closing conditions set forth in <u>Article VII</u> hereof.

Article VI ADDITIONAL AGREEMENTS

Section VI.1 Survival of Representations and Warranties. All representations, warranties, covenants and agreements set forth in this Agreement or in any writing or certificate delivered in connection with this Agreement shall survive the Closing Date. Notwithstanding the foregoing and except with respect to fraud or intentional misrepresentation, no Party shall be entitled to recover for any Loss pursuant to Section 6.2(a)(i) or Section 6.2(a)(A) unless written notice of a claim thereof is delivered to the Party against whom such indemnity may be sought prior to (a) with respect to the Fundamental Representations, the date that is 60 calendar days after the expiration of the applicable statute of limitations (including any extension, waiver, mitigation, or tolling thereof) and (b) with respect to all other representations and warranties, the date that is 18 months after the Closing Date (the "Survival Period"). Notwithstanding the foregoing, any representation or warranty in respect of which indemnity may be sought under Section 6.2(a)(i) or Section 6.2(a)(A), and the indemnity with respect thereto, shall survive the time at which it would otherwise terminate pursuant to this Section 6.1 if notice of the actual or potential inaccuracy or breach thereof giving rise to such right or alleged right of indemnity shall have been given to the applicable Party prior to such time, and any such representation or warranty, and the right to indemnity with respect thereto, shall survive until the claim for indemnity with respect to such inaccuracy or breach is finally resolved and any applicable obligation to remedy such inaccuracy or breach has been fully satisfied. To the extent the survival periods of the representations and warranties as set forth in this Section 6.1 are greater than or less than the survival period under the applicable statute of limitations, the Parties expressly acknowledge and agree that the survival periods set forth in this <u>Section 6.1</u> are intended to alter such applicable statutes of limitations. The representations and warranties made by the Company and the Member in this Agreement and in any certificate delivered by the Company or the Member shall in no event be affected by (i) any investigation, inquiry or examination made for or on behalf of any of the Buyer Indemnified Parties, (ii) any knowledge of any of the Buyer Indemnified Parties or their respective officers, directors, managers, equityholders, employees or agents or (iii) the acceptance by Buyer of any certificate hereunder.

Section VI.2 General Indemnification.

(a) Cannabist and the Member, on a joint and several basis, shall indemnify the Buyer Indemnified Parties and save and hold each of them harmless from and against, and pay on behalf of or reimburse such Buyer Indemnified Parties for any and all Losses which any such Buyer Indemnified Party may suffer, sustain or become subject to as a result of, arising from, in connection with, by virtue of or related to (i) any breach or inaccuracy of any representation or warranty made by the Cannabist, the Company or the Member in this Agreement, including Article III, or in any certificate furnished by or on behalf of the Company or the Member pursuant to this Agreement, (ii) any breach or non-fulfillment of any covenant, agreement or other provision by Cannabist, the Company or the Member under this Agreement, (iii) any Transaction Expenses to the extent not included in Final Transaction Expenses, (iv) any Transaction Payments to the extent not included in Final Transaction Payments, (v) any Indebtedness to the extent not included

in Final Indebtedness, (vi) any Buyer Tax Losses, (vii) any information, calculation or determination set forth in the Funds Flow or instructions provided by Cannabist or the Company with respect to the payment of the Deposit, Purchase Price or any alleged inaccuracy, discrepancy or impropriety with respect to any of the foregoing, (viii) Cannabist's or its Affiliates Indebtedness, including the Notes, and (ix) the Master Lease Agreement, to the extent not assigned to the Company pursuant to Section 2.5(b)(xx). Notwithstanding anything herein to the contrary, for purposes of determining whether there has been a breach or inaccuracy of any representation or warranty and determining the amount of any Losses that are the subject matter of any indemnification claim hereunder, each representation and warranty in this Agreement shall be read without giving effect to any qualification or limitation as to materiality, Material Adverse Effect or words of similar import contained in any such representation or warranty. Buyer shall indemnify the Member and save and hold the Member harmless from and against, and pay on behalf of or reimburse the Member for any and all Losses which the Member may suffer, sustain or become subject to as a result of, arising from, in connection with, by virtue of or related to (A) any breach or inaccuracy of any representation or warranty made by Buyer in this Agreement, including Article IV, or in any certificate furnished by or on behalf of Buyer pursuant to this Agreement, and (B) any breach or non-fulfillment of any covenant, agreement or other provision by Buyer under this Agreement.

- (b) Cannabist and the Member shall not be liable to the Buyer Indemnified Parties for any Loss (i) pursuant to Section 6.2(a)(i) (other than with respect to the Fundamental Representations) until the aggregate amount of all Losses that Cannabist and the Member would, but for this clause (i), be liable for exceeds \$10,000 in the aggregate (the "Basket Amount"); provided, however, that Cannabist and the Member shall then be liable for the full amount of such Losses back to dollar one; or (ii) to the extent the aggregate amount of all Losses previously indemnified by Cannabist and the Member pursuant to Section 6.2(a)(i) exceeds \$11,879,518.80 (the "Cap"). Buyer shall not be liable to the Member for any Loss (A) pursuant to Section 6.2(a)(A) until the aggregate amount of all Losses that the Buyer would, but for this clause (A), be liable for exceeds the Basket Amount; provided, however, that Buyer shall then be liable for the full amount of such Losses back to dollar one; or (B) to the extent the aggregate amount of all Losses previously indemnified by Buyer pursuant to Section 6.2(a)(A) exceeds the Cap. Notwithstanding anything to the contrary contained herein, the Basket Amount and the Cap shall not apply with respect to any Loss arising from (and such Loss shall not be counted toward the Cap) fraud or intentional misrepresentation.
- (c) Any Losses for which the Buyer Indemnified Parties are entitled to indemnification pursuant to <u>Section 6.2(a)</u> shall be satisfied pursuant to <u>Section 6.2(e)</u>.
 - (d) No Party shall be entitled to a rescission of this Agreement (or any related agreements).
- (e) Any payment to be made by Cannabist or the Member with respect to any indemnification obligations for Losses pursuant to this <u>Article VI</u> shall be satisfied, in

Buyer's sole discretion, (i) by deducting such amount from the amount due to CC VA under the Promissory Note in the order of interest due and owing and then in the order of maturities, (ii) directly against Cannabist and the Member on a joint and several basis, or (iii) by any combination of the foregoing. Any payments to be made by any Party pursuant to Article VI shall be paid by wire transfer of immediately available funds within five calendar days after the determination of such payment obligation.

- (f) The amount of any Loss for which indemnification is provided under this <u>Article VI</u> shall be net of any amounts actually received by the indemnified Party as a result of such Loss under insurance policies or other third party sources of reimbursement or indemnification (with such amount, for the avoidance of doubt, reduced by any fees or expenses (including any payment with respect to attorneys' fees and disbursements and/or any increase in insurance premiums) incurred in obtaining such recovery; <u>provided</u>, <u>however</u>, that in no event shall any indemnified Party be required to seek any recovery under any insurance policy or otherwise as a condition to receiving indemnification under this <u>Article VI</u>.
- (g) No Party shall be entitled to double recovery for any adjustments to consideration provided for hereunder or for any indemnifiable Losses even though such Losses, or any other incident, may have result from the breach of more than one of the representations, warranties and covenants, or any other indemnity, under this Agreement or any related agreement.
- (h) All indemnification payments under this Agreement shall be treated as adjustments to the Purchase Price for all relevant Tax purposes.
 - (i) The procedure for indemnification shall be as set forth in this <u>Section 6.2</u> and <u>Section 6.4</u>.

Section VI.3 Certain Tax Matters.

- (a) The parties agree as follows:
- (i) Without the written consent of Buyer, Cannabist and the Member (and, prior to the Closing, the Company and its Affiliates) shall not, to the extent it may affect, or relate to, the Company, make, change or rescind any Tax election, amend any Tax Return or take any position on any Tax Return, take any action, omit to take any action or enter into any other transaction that would have the effect of increasing the Tax liability of Buyer, Buyer's Affiliates or the Company after the Closing Date.
- (ii) Cannabist, at Cannabist's and the Member's sole cost and expense, shall (A) prepare any IRS Form 1065 including the associated Schedule K-1s thereto (and any comparable state and local Tax Returns) of the Company for any Pre-Closing Tax Period (the "Member Prepared Returns"); and (B) timely pay all Taxes that are shown as payable with respect to any Member Prepared Returns.

All Member Prepared Returns shall be prepared in accordance with existing procedures and practices of the Company, unless otherwise required by Law. Each Member Prepared Return filed after the Closing Date shall be submitted to Buyer for Buyer's review and comment at least 30 days prior to the due date of the Tax Return. The Member shall incorporate any reasonable comments made by Buyer in the final Tax Return prior to filing. No Member Prepared Return may be amended after the Closing without the prior written consent of the Buyer, which consent shall not be unreasonably withheld, conditioned or delayed.

- (iii) Buyer shall cause the Company to prepare and timely file all Tax Returns (other than the Member Prepared Returns) of the Company due after the Closing Date (the "Buyer Prepared Returns"). To the extent that a Member Prepared Return relates solely to a Pre-Closing Tax Period, such Tax Return shall be prepared on a basis consistent with existing procedures and practices of the Company, unless otherwise required by Law. Each Buyer Prepared Return that shows an Indemnified Tax shall be submitted to Cannabist for Cannabist's review and comment at least 30 days prior to the due date of the Tax Return (or, with respect to any Buyer Prepared Return that is not an income Tax Return, within a reasonable time prior to the due date of the Tax Return). Buyer shall incorporate any reasonable comments made by Cannabist in the final Tax Return prior to filing. No failure or delay of Buyer in providing Buyer Prepared Returns for Cannabist to review shall reduce or otherwise affect the obligations or liabilities of the Member pursuant to this Agreement.
- (iv) The Parties agree that the Tax year of the Company shall end for U.S. federal income Tax purposes as of the end of the Closing Date and, to the extent permissible under applicable Laws, the Company shall elect to have each of its other Tax years end as of the end of the Closing Date.
- (b) The Member, Cannabist, Buyer and the Company each shall (i) assist in the preparation and timely filing of any Tax Return of the Company pursuant to this Section 6.3; (ii) assist in any audit or other legal Proceeding with respect to Taxes or Tax Returns of the Company addressed by this Section 6.3; (iii) make available any information, records, or other documents relating to any Taxes or Tax Returns of the Company with respect to any Pre-Closing Tax Period or Straddle Period; and (iv) provide any information in their possession and control necessary or reasonably requested to allow Buyer or the Company to comply with any information reporting or withholding requirements contained in the Code or other applicable Laws with respect to the transactions contemplated by this Agreement or to compute the amount of payroll or other employment Taxes due with respect to any payment made in connection with this Agreement.
- (c) For purposes of determining whether the following Taxes are attributable to a Pre-Closing Tax Period (or the portion of any Straddle Period ending on or prior to the Closing Date) the Parties agree as follows:

- (i) In the case of property Taxes and other similar Taxes imposed on a periodic basis for a Straddle Period, the amounts that are attributable to the portion of the Straddle Period ending on the Closing Date shall be determined by multiplying the Taxes for the entire Straddle Period by a fraction, the numerator of which is the number of calendar days in the portion of the period ending on the Closing Date and the denominator of which is the number of calendar days in the entire Straddle Period.
- (ii) In the case of Taxes in the form of interest or penalties, all such Taxes shall be treated as attributable to a Pre-Closing Tax Period (or the portion of the Straddle Period ending on the Closing Date) to the extent relating to a Tax for a Pre-Closing Tax Period (or portion of a Straddle Period ending on the Closing Date) whether such items are incurred, accrued, assessed or similarly charged on, before or after the Closing Date.
- (iii) In the case of Taxes imposed on the Company or Buyer or any other Buyer Indemnified Party as a result of income of any Flow-Thru Entity owned by the Company realized prior to the Closing Date (such income being computed assuming the Flow-Thru Entity had a year that ends on the Closing Date and closed its books), all such Taxes shall be treated as Taxes of the Company for a Pre-Closing Tax Period.
- (iv) In the case of Taxes imposed on the Company with respect to the payment of any Transaction Expenses (other than Transaction Expenses incurred subsequent to the Closing at the discretion of Buyer), such Taxes shall be treated as Taxes of the Company for a Pre-Closing Tax Period.
- (v) In the case of all other Taxes for a Straddle Period (including income Taxes, employment Taxes, and sales and use Taxes) the amount attributable to the portion of the Straddle Period ending on the Closing Date shall be determined as if the Company filed a separate Tax Return with respect to such Taxes for the portion of the Straddle Period ending as of the end of the day on the Closing Date using a "closing of the books methodology." For purposes of this <u>clause (v)</u>, any item determined on an annual or periodic basis (including amortization and depreciation deductions and the effects of graduated rates) shall be allocated to the portion of the Straddle Period ending on the Closing Date based on the mechanics set forth in <u>clause (i)</u> for periodic Taxes.
- (d) If any Governmental Entity issues to the Company (i) a written notice of its intent to audit or conduct another Proceeding with respect to Taxes for any Pre-Closing Tax Period or Straddle Period or (ii) a written notice of deficiency for Taxes for any Pre-Closing Tax Period or Straddle Period, Buyer shall notify Cannabist of its receipt of such communication from the Governmental Entity within 30 days of receipt. No failure or delay of Buyer in the performance of the foregoing shall reduce or otherwise affect the obligations or liabilities of the Member pursuant to this Agreement. The Company shall control any audit or other Proceeding in respect of any Tax Return or

Taxes of the Company (a "<u>Tax Contest</u>"); <u>provided, however</u>, that (A) Cannabist, at Cannabist's and the Member's sole cost and expense, shall have the right to participate in any such Tax Contest to the extent it relates to a Pre-Closing Tax Period or Straddle Period; (B) Buyer shall not allow the Company to settle or otherwise resolve any Tax Contest if such settlement or other resolution relates solely to Taxes for a Pre-Closing Tax Period without the consent of Cannabist (which shall not be unreasonably withheld, delayed or conditioned).

- (e) Buyer and the Member intend for the purchase of the Equity contemplated by this Agreement to be treated for U.S. federal, state and local income Tax purposes as a transaction governed by Rev. Rul. 99-6, 1999 1 C.B. 434 (Situation 2), with the Member being treated as having sold its Equity, and Buyer being treated as acquiring all of the assets of the Company, in exchange for the Purchase Price (as adjusted pursuant to the terms of this Agreement). The Purchase Price (including adjustments thereto) shall be allocated by Buyer and the Member among the assets of the Company in accordance with Code Section 1060. A statement setting forth such allocation shall be provided by Buyer to the Member within 90 days after the Closing and shall be updated as required by Buyer under Section 1060 of the Code and the Treasury Regulations promulgated thereunder (the "Asset Purchase Price Allocation"). Buyer shall prepare its IRS Form 8594 consistently with the Asset Purchase Price Allocation. The Parties shall report, act and file all Tax Returns in all respects and for all purposes consistent with the Asset Purchase Price Allocation and this Section 6.3, and no party shall take any position (whether in audits, Tax Returns or otherwise) that is inconsistent with Rev. Rul. 99-6, the Asset Purchase Price Allocation Schedule or this Section 6.3 unless required to do so by applicable Law.
- (f) All federal, state, local, non-U.S. transfer, excise, sales, use, ad valorem, value added, registration, stamp, recording, property and similar Taxes or fees applicable to, imposed upon, or arising out of the transfer of the Equity or any other transaction contemplated by this Agreement and all related interest and penalties (collectively, "<u>Transfer Taxes</u>") shall be paid by the Member.
- (g) To the extent there is a conflict between this <u>Section 6.3</u> and <u>Section 6.4</u> with respect to Taxes or any Tax matter, the provisions of this <u>Section 6.3</u> shall control.

Section VI.4 <u>Indemnification Procedures</u>.

(a) Notice of Claims; Assumption of Defense. The indemnified Party shall give notice to the indemnifying Party, in accordance with the terms of Section 9.2, of the assertion of any claim, or the commencement of any Proceeding by any Person, in respect of which indemnity may be sought hereunder, specifying with reasonable particularity the basis therefor and giving the indemnifying Party such information with respect thereto as the indemnifying Party may reasonably request, but the failure to give such notice shall not be a condition precedent to indemnification hereunder except and only to the extent that the indemnifying Party is prejudiced by reason of such failure. The indemnifying Party may, at its own expense, (a) participate in the defense of any Proceeding asserted by a Person that is not a

party to this Agreement (a "Third Party Claim") and (b) upon notice to the indemnified Party and the indemnifying Party's written agreement that the indemnified Party is entitled to indemnification pursuant to this Agreement for all of the indemnified Party's Losses arising out of such Third Party Claim, at any time during the course of any such Third Party Claim, assume the defense thereof; provided, however, that (i) the indemnifying Party's counsel has been approved by the indemnified Party (such approval not to be unreasonably withheld, conditioned or delayed); (ii) the indemnifying Party has confirmed in writing its responsibility for all such Losses to such indemnified Party under this Agreement; (iii) the indemnifying Party shall thereafter consult with the indemnified Party upon the indemnified Party's reasonable request for such consultation from time to time with respect to such Third Party Claim: (iv) such Third Party Claim involves (and continues to involve) solely monetary damages that are not reasonably likely to exceed the then remaining amount due to CC VA under the Promissory Note; and (v) such Third Party Claim does not relate to or arise in connection with any criminal Proceeding. Notwithstanding the foregoing, if the Member is the indemnifying Party, neither the Member nor Cannabist shall be entitled to assume such defense if Buyer reasonably believes that such assumption may adversely affect in any material respect the Company, including any adverse effect upon the Company's commercial relationships or relationships with any Governmental Entity. If the indemnifying Party assumes such defense, the indemnified Party shall have the right (but not the duty) to participate in the defense thereof and to employ counsel, at its own expense, separate from the counsel employed by the indemnifying Party. If, however, in the opinion of the indemnified Party's counsel, the representation by the indemnifying Party's counsel of both the indemnifying Party and the indemnified Party would present such counsel with a conflict of interest, then such indemnified Party may employ separate counsel to represent or defend it in any such Third Party Claim and the indemnifying Party shall pay the fees and disbursements of such separate counsel. Whether or not the indemnifying Party chooses to defend or prosecute any such Third Party Claim, all of the Parties shall cooperate in the defense or prosecution thereof.

(b) Settlement or Compromise. Any settlement or compromise made or caused to be made by the indemnified Party or the indemnifying Party, as the case may be, of any such Third Party Claim shall also be binding upon the indemnifying Party or the indemnified Party, as the case may be, in the same manner as if a final Order had been entered by a court of competent jurisdiction in the amount of such settlement or compromise; provided, however, that the indemnifying Party shall not settle or compromise any such Third Party Claim, or otherwise acknowledge or admit the validity of such claim or any liability in respect thereof if such settlement, compromise, acknowledgement or admission (i) would result in an Order, injunction or other equitable remedy in respect of the indemnified Party or would otherwise have a direct adverse effect upon the indemnified Party's continuing operations, (ii) would give rise to any liability on the part of the indemnified Party for which the indemnifying Party shall have not agreed in writing that such indemnifying Party is solely obligated to satisfy and discharge such Third Party Claim, (iii) would result in liabilities which, taken together with other existing claims under this Article VI, would not be fully indemnified hereunder, (iv) would reasonably be expected to increase the liability of the indemnified Party for Taxes after the Closing Date, (v) does not expressly and unconditionally release the indemnified Party from all liabilities with respect to such Third Party Claim or (vi) includes any statement or an admission of fact as to the

culpability or failure to act by or on behalf of the indemnified Party; in each case, without the prior written consent of the indemnified Party. The indemnified Party will give the indemnifying Party at least 30 days' notice of any proposed settlement or compromise of any Third Party Claim it is defending, during which time the indemnifying Party may assume the defense of, and responsibility for, such Third Party Claim and if it does so the proposed settlement or compromise may not be made. In the event that Cannabist, on behalf of the Member as the indemnifying Party, has affirmatively consented in writing to the settlement of a Third Party Claim, the Member shall have no power or authority to object to the recovery by the Buyer Indemnified Parties of the amount of such settlement pursuant to this <u>Article VI</u>.

- (c) <u>Failure of Indemnifying Party to Act</u>. In the event that the indemnifying Party does not elect to assume the defense of any Third Party Claim, then any failure of the indemnified Party to defend or to participate in the defense of any such Third Party Claim or to cause the same to be done, shall not relieve the indemnifying Party of its obligations hereunder; <u>provided</u>, <u>however</u>, that the indemnified Party shall have given the indemnifying Party at least 30 days' notice of its proposed failure to defend or participate and affords the indemnifying Party the opportunity to assume the defense thereof prior to the end of such period.
- (d) Procedure for Indemnification. Upon becoming aware of a claim for indemnification hereunder (whether as a result of any Third Party Claim or in connection with any Losses incurred by an indemnified Party pursuant to this Article VI or otherwise), the indemnified Party shall give, in accordance with the terms of Section 9.2, notice of such claim (a "Claim Notice") to the indemnifying Party, providing reasonable detail of how the claim has arisen and an estimate of the amount the indemnified Party reasonably anticipates that it will be entitled to on account of indemnification by the indemnifying Party. If the indemnifying Party does not object to such indemnification claim within 30 days of receiving notice thereof, the amount of such Claim Notice shall be deemed final and undisputed and the indemnified Party shall be entitled to recover the amount of such claim. If the indemnifying Party objects to such indemnification claim (by notifying the indemnified Party within 30 days (such notice, an "Objection Notice") of receiving a Claim Notice), the Parties shall attempt to resolve such claim in good faith within 30 days of the date of the Objection Notice. If the Parties are unable to resolve such claim, the indemnified Party shall be free to pursue such remedies as may be available on the terms and subject to the provision of this Agreement.
- Section VI.5 <u>Expenses</u>. Except as otherwise expressly provided in this Agreement, each Party shall be liable for and pay all of its own costs and expenses (including attorneys', accountants' and investment bankers' fees and other out-of-pocket expenses) in connection with the negotiation, documentation and execution of this Agreement and the agreements contemplated hereunder, the performance of such Party's obligations hereunder and the consummation of the transactions contemplated hereby.

Section VI.6 Further Assurance and Post-Closing Actions; Disclosure.

(a) The Member, Cannabist and the Company shall execute and deliver such further instruments of conveyance and transfer and take such additional action as reasonably

requested by Buyer, to consummate, confirm or evidence the transactions contemplated hereby and carry out the purposes of this Agreement.

(b) The Company, Cannabist and the Member consents: (i) to the disclosure of certain information regarding them and the transactions contemplated by this Agreement to Cboe and the SEC, including as may be required by the Securities Laws in any filing with the SEC, Cboe, or other applicable securities regulator; and (B) to the collection, use and disclosure of their information by Cboe, the SEC or the applicable securities commission or as otherwise identified by Cboe, the SEC or applicable securities commissions, from time to time.

Section VI.7 Restrictive Covenants.

(a) <u>Confidentiality</u>.

- Cannabist and the Member each covenants that each shall, and shall cause each of their respective Affiliates and representatives to, not disclose, directly or indirectly, and shall treat and hold as strictly confidential, all Confidential Information and, except as otherwise expressly permitted by this Agreement, refrain from using any Confidential Information (other than for the benefit of the Buyer Group as an employee or consultant thereof after the Closing Date). Upon the request of Buyer at any time after the date hereof, Cannabist and the Member shall each deliver promptly to Buyer or destroy all tangible embodiments (and all copies) of the Confidential Information which are in Cannabist's or the Member's possession or under Cannabist's or the Member's control and provide confirmation thereof in writing. In the event that Cannabist or the Member or any of their respective Affiliates or representatives is requested or required by a Governmental Entity to disclose any Confidential Information, Cannabist or the Member shall notify Buyer promptly of the request or requirement so that Buyer may seek an appropriate protective order or waive compliance with the provisions of this <u>Section 6.7(a)</u>. If, in the absence of a protective order or the receipt of a waiver hereunder, Cannabist or the Member or any of their respective Affiliates or representatives is compelled to disclose any Confidential Information to any Governmental Entity, Cannabist or the Member, as applicable, may disclose the Confidential Information to the Governmental Entity; provided that Cannabist or the Member, as applicable, shall use their best efforts to obtain an order or other assurance that confidential treatment shall be accorded to such portion of the Confidential Information required to be disclosed. Notwithstanding the foregoing, for purposes of this Agreement, Confidential Information shall not include information which is or becomes generally available to the public other than as a result of a disclosure by Cannabist or the Member or any of their respective Affiliates or representatives in violation of this Agreement or any other confidentiality obligation to which any of them is bound.
- (ii) "Confidential Information" means all information of a confidential or proprietary nature (whether or not specifically labeled or identified as "confidential"), in any form or medium, that relates to the Company or the

business, products, services, research and development, relationships, Intellectual Property and goodwill of the Buyer Group or its suppliers, distributors, customers, contractors, licensors, licensees, agents or other business relations related to the Company acquired by the Buyer Group pursuant to this Agreement (each a "Business Relation"), including: (A) non-public internal business information (including historical and projected financial information and budgets and information relating to strategic and staffing plans and practices, business, training, marketing, promotional and sales plans and practices, cost, rate and pricing structures and accounting and business methods); (B) non-public requirements of and specific contractual arrangements with any Business Relation and their confidential information; (C) trade secrets, know-how, source code and methods of operation, techniques, formulae and systems relating to the Buyer Group's products or services and data, data bases, analyses, records, reports, manuals, documentation and models and relating thereto; (D) inventions, innovations, improvements, developments and all similar or related information (whether or not patentable); (E) non-public corporate business structure and business units of the Buyer Group; and (F) non-public acquisition plans, targets and strategies of the Buyer Group.

- (b) Non-Solicitation. Cannabist and the Member each covenants that during the period commencing on the Closing Date and ending on the eighteen-month anniversary of the Closing Date (the "Restricted Period"), Cannabist and the Member shall not, directly or indirectly (e.g., through any other Person, alone or as an equityholder, member, partner, officer, director, manager, investor, agent, independent contractor or employee of any Person), (i) (A) induce or attempt to induce any employee or independent contractor of the Buyer Group who is employed or engaged by the Buyer Group to leave the employ of the Buyer Group, or in any way knowingly interfere with the relationship between the Buyer Group and any employee or independent contractor thereof or (B) hire any employee or independent contractor that is or was, at any time within twelve (12) months of such proposed hiring, employed or engaged by the Buyer Group; (ii) solicit or induce or attempt to solicit or induce any Business Relation to cease or refrain from doing business with, or otherwise modify aversely the business done with, any member of the Buyer Group; or (iii) in any way interfere with the relationship (or prospective relationship) between any Business Relation and the Buyer Group. Notwithstanding the foregoing, this Section 6.7(b) shall not prevent Cannabist or any Member from contact with any Person seeking employment or hire on their own initiative or through a general solicitation for employment or engagement that is available to the general public (through a newspaper, internet or other similar means) and that is not targeted in any way at the Buyer Group's employees or service providers.
- (c) <u>Non-Disparagement</u>. Each Party covenants that it shall not (and shall direct its directors, officers, and senior management personnel not to), directly or indirectly (e.g., through any other Person, alone or as an equityholder, member, partner, officer, director, manager, investor, agent, independent contractor or employee of any Person), make any derogatory or disparaging statement or communication regarding the

other Parties or any of their respect products, services, policies, practices, operations, employees, officers, members, managers, partners, directors or Affiliates.

- (d) Remedies. The Member acknowledges and agrees that money damages would not be an adequate remedy for any breach or threatened breach of the provisions of this Section 6.7 and that, in such event, Buyer, the Company, and their respective successors or assigns shall, in addition to any other rights and remedies existing in their favor, be entitled to specific performance, injunctive or other equitable relief from any court of competent jurisdiction in order to enforce or prevent any violations of the provisions of this Section 6.7 (including the extension of the Restricted Period by a period equal to the length of the court Proceedings necessary to stop such violation). Any injunction shall be available without the posting of any bond or other security and without having to demonstrate irreparable harm. In the event of an alleged breach or violation by Cannabist or the Member of any of the provisions of this Section 6.7, the Restricted Period will be tolled for Cannabist or the Member until such alleged breach or violation is resolved.
- (e) Acknowledgment. Cannabist and the Member each acknowledges and agrees that (i) during the Restricted Period, the Buyer Group would be irreparably damaged if Cannabist or the Member were to engage in any business competing with the businesses of the Buyer Group in the locations operated by the Company in Arizona prior to the Closing and that any such competition by Cannabist or the Member would result in a significant loss of goodwill by Buyer in respect of the Company for which money damages would be an insufficient remedy, (ii) the value of the Company's trade secrets and other Confidential Information arises from the fact that such information is not generally known in the marketplace, (iii) the Company's trade secrets and other Confidential Information will have continuing vitality throughout and beyond the Restricted Period, (iv) Cannabist and the Member each has and will have such sufficient knowledge of the Company's trade secrets and other Confidential Information that, if Cannabist or the Member were to compete with the Company during the Restricted Period, they would cause irreparable harm to the Buyer Group, (v) the covenants and agreements set forth in this Section 6.7 are an additional consideration of the agreements and covenants of Buyer hereunder and were a material inducement to Buyer to enter into this Agreement and to perform their obligations hereunder, and that Buyer and its Affiliates would not obtain the benefit of the bargain set forth in this Agreement as specifically negotiated by the Parties if Cannabist or the Member breached the provisions set forth in this Section 6.7, (vi) the restrictions contained in this Section 6.7 are reasonable in all respects (including, with respect to subject matter, time period and geographical area) and are necessary to protect Buyer's interest in, and the value of, the Equity and the Company (including, the goodwill inherent therein) and (vii) Cannabist and the Member are primarily responsible for the creation of such value.
- (f) <u>Enforcement</u>. If, at the time of enforcement of any of the provisions of this <u>Section 6.7</u>, a court determines that the restrictions stated herein are unreasonable under the circumstances then existing, then the maximum period, scope or geographical

area reasonable under the circumstances shall be substituted for the stated period, scope or area and such court shall be allowed to revise the restrictions contained herein to cover the maximum period, scope or geographical area permitted by Law. For the avoidance of doubt, the Buyer Group shall include the Company for purposes of this <u>Section 6.7</u>.

Section VI.8 Release.

- (a) Effective upon the Closing, Cannabist and the Member (on behalf of their respective heirs, successors, assigns and executors) each hereby irrevocably and unconditionally waives, releases and discharges the Company and the other Buyer Indemnified Parties (and their successors and assigns) from any and all Losses, liabilities and obligations to Cannabist or the Member, as applicable, of any kind or nature whatsoever, whether in such Person's capacity as a Member hereunder, as an equityholder, director, manager, officer or employee of the Company or otherwise (including in respect of rights of contribution or indemnification) as to facts, conditions, transactions, events or circumstances prior to the Closing, in each case, relating to the Company, the Equity or any rights or interests therein. Cannabist and the Member each shall not seek to recover any amounts in connection therewith or thereunder from Buyer, the Company and/or any other Buyer Indemnified Party (and/or any of their successor or assigns); provided, that this Section 6.8 shall not affect the rights of Cannabist or the Member under this Agreement. Cannabist and the Member each represents to Buyer that it has not assigned or transferred, or purported to assign or transfer, to any Person, all or any part of, or any interest in, any Proceeding against the Company and the other Buyer Indemnified Parties, and notwithstanding anything to the contrary in this Agreement, no such assignment or transfer shall be permitted and any purported assignment or transfer shall be legally ineffective.
- (b) Without limiting the foregoing, Cannabist and the Member each shall not (and shall cause their respective Affiliates to not) make any claim for indemnification against the Company, the other Buyer Indemnified Parties or any of their respective Affiliates by reason of the fact that Cannabist or the Member, as applicable, is or was an equityholder, director, manager, officer, employee or agent of the Company or any of its Affiliates or is or was serving at the request of the Company, the other Buyer Indemnified Parties or any of their respective Affiliates as a equityholder, member, partner, director, manager, officer, employee or agent of another entity with respect to any Proceeding brought by any Buyer Indemnified Party against Cannabist or the Member pursuant to or in connection with this Agreement or applicable Law, and Cannabist and the Member each hereby acknowledges and agrees that they shall not have any claim or right to contribution or indemnity from the Company with respect to any amounts paid by them pursuant to or in connection with this Agreement.

Article VII CONDITIONS TO CLOSING

Section VII.1 <u>Conditions to Obligations of All Parties</u>. The obligations of each Party to consummate the transactions contemplated hereby shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions:

- (a) other than with respect to the Federal Cannabis Laws, no Governmental Entity shall have enacted, issued, promulgated, enforced, or entered any Order which is in effect and has the effect of making the transactions contemplated hereby illegal, otherwise restraining or prohibiting consummation of the transactions contemplated hereby, or causing any of the transactions contemplated hereby to be rescinded following completion thereof; and
- (b) no injunction or restraining order shall have been issued by any Governmental Entity, and in effect, which restrains or prohibits the transactions contemplated hereby.

Section VII.2 <u>Conditions to Obligations of Buyer</u>. The obligations of Buyer to consummate the transactions contemplated hereby shall be subject to the fulfillment or Buyer's waiver, at or prior to the Closing, of each of the following conditions:

- (a) the Fundamental Representations shall be true and correct in all respects as of the Closing Date as though such representations and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall be true and correct only as of such date).
- (b) the representations and warranties set forth in <u>Article III</u> (other than the Fundamental Representations) shall be true and correct (disregarding all qualifications or limitations as to "materiality", "in all material respects" or "Material Adverse Effect" set forth therein) in all material respects as of the Closing Date as though such representations and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall be true and correct only as of such date).
- (c) the Company and the Member shall have duly performed and complied in all material respects with all agreements, covenants, obligations and conditions required by this Agreement and the agreements contemplated hereby to be performed or complied with by him, her or it prior to or on the Closing Date.
- (d) the Company shall have delivered (or caused to be delivered) each of the closing deliverables set forth in Section 2.5(b);
 - (e) there shall not have occurred a Material Adverse Effect;

- (f) the Company shall have delivered to Buyer a copy of approval(s) from the Arizona Department of Health Services and any other applicable Governmental Entity, for the transactions contemplated hereby and the transfer of ownership of the Company and in the Marijuana Permits, which approval(s) shall, as determined by Buyer in its reasonable discretion, be free of any uncured regulatory violations (the "Arizona Transaction Approval"); and
- (g) Buyer shall not have sent a notice of termination or otherwise terminated either the Virginia Purchase Agreement or the SWC Arizona Purchase Agreement, and none of Cannabist or the sellers thereunder shall have breached any provisions thereof in any material respect.
- Section VII.3 <u>Conditions to Obligations of the Company, Cannabist and the Member</u>. The obligations of the Company, Cannabist and the Member to consummate the transactions contemplated hereby shall be subject to the fulfillment or Cannabist's waiver, at or prior to the Closing, of each of the following conditions:
 - (a) the representations and warranties set forth in <u>Article IV</u> shall be true and correct in all material respects as of the Closing Date as though such representations and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall be true and correct only as of such date);
 - (b) Buyer shall have duly performed and complied in all material respects with all agreements, covenants, obligations and conditions required by this Agreement and the agreements contemplated hereby to be performed or complied with by them prior to or on the Closing Date; and
 - (c) Buyer (or its Affiliates) shall have delivered each of the closing deliverables set forth in <u>Section 2.5(c)</u>.

Article VIII TERMINATION

Section VIII.1 <u>Termination</u>. This Agreement may be terminated at any time prior to the Closing:

- (a) By the mutual written consent of Cannabist and Buyer;
- (b) By Buyer upon written notice to Cannabist if:
- (i) Buyer is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in, or failure to perform any representation, warranty, covenant, or agreement made by the Company or the Member pursuant to this Agreement that would give rise to the failure of any of the conditions specified in Article VII and such breach, inaccuracy, or failure has

not been cured by the Company or the Member within 15 calendar days of Cannabist's receipt of written notice of such breach from Buyer; or

- (ii) any of the conditions set forth in <u>Section 7.1</u> or <u>Section 7.2</u> shall not have been, or if it becomes apparent that any of such conditions cannot be, fulfilled by September 30, 2024 (the "<u>Outside Date</u>"), unless such failure shall be due to the failure of Buyer to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing; or
- (c) By Cannabist upon written notice to Buyer if the Company, Cannabist and the Member are not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in, or failure to perform any representation, warranty, covenant, or agreement made by Buyer pursuant to this Agreement that would give rise to the failure of any of the conditions specified in <u>Article VII</u> and such breach, inaccuracy, or failure has not been cured by Buyer within 15 calendar days of Buyer's receipt of written notice of such breach from Cannabist; provided, that in the event of a breach of <u>Section 2.5(c)(i)</u>, this Agreement may be terminated by Cannabist immediately upon delivery of written notice of such breach to Buyer.

Section VIII.2 <u>Effect of Termination</u>. In the event of the termination of this Agreement in accordance with this <u>Article VIII</u>, this Agreement shall forthwith become void and there shall be no liability on the part of any Party except:

- (a) as set forth in this Article VIII and Article IX;
- (b) Cannabist, the Company and the Member (on a joint and several basis) shall repay the Deposit to Buyer in immediately available funds within one (1) Business Day of the date of termination; and
- (c) that nothing herein shall relieve any Party from liability for any fraud, intentional misrepresentation, willful misconduct, or willful breach of any provision of this Agreement.

Article IX MISCELLANEOUS

Section IX.1 <u>Amendment and Waiver</u>. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by Buyer and Cannabist, in its individual capacity and as the Member representative. No waiver of any provision or condition of this Agreement shall be valid unless the same shall be in writing and signed by or on behalf of the Party against which such waiver is to be enforced. No waiver by any Party of any default, breach of representation or warranty or breach of covenant hereunder, whether intentional or not, shall be deemed to extend to any other, prior or subsequent default or breach or affect in any way any rights arising by virtue of any other, prior or subsequent such occurrence.

Section IX.2 <u>Notices</u>. All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when personally delivered or sent by email (with hard copy to follow) or the next Business Day when sent by reputable overnight express courier (charges prepaid) to the addresses indicated below (unless another address is specified in writing):

Notices to the Company, Member or Cannabist:

c/o The Cannabist Company Holdings Inc. 321 Billerica Road Chelmsford, MA 01824 Attn: Jonathan Gothorpe

Email: [***]

with a copy (which will not constitute notice) to:

Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210 Attention: [***] Email: [***] Notices to Buyer:

Verano Holdings Corp.
224 W. Hill St., Suite 400
Chicago, Illinois 60610
Attn: George Arches Chaire

Attn: George Archos, Chairman and CEO

Email: [***]

with a copy to (which shall not constitute notice):

Verano Holdings Corp.
224 W. Hill St., Suite 400
Chicago, Illinois 60610
Attn: Darren Weiss, President

Aun. Danen weiss, i

Email: [***]

Section IX.3 <u>Assignment</u>. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned or delegated (including by operation of Law) by the Company, Cannabist or the Member without the prior written consent of Buyer or by Buyer without the prior written consent of Cannabist; <u>provided</u>, that Buyer may, without the consent of any Person, assign in whole or in part its rights and obligations pursuant to this Agreement to (a) one or more of their Affiliates, (b) any purchaser of all or substantially all of Buyer, whether by merger, asset purchase, equity purchase or otherwise and (c) any of their financing sources as collateral security. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of each Party and each Party's successors and permitted assigns.

Section IX.4 <u>Severability</u>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement or the application of any such provision to any Person or circumstance shall be held to be prohibited by or invalid, illegal or unenforceable under applicable Law in any respect by a court of competent jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity, illegality or unenforceability,

without invalidating the remainder of such provision or the remaining provisions of this Agreement. Furthermore, in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible.

Section IX.5 Interpretation. The headings and captions used in this Agreement and the table of contents to this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Any capitalized terms used in any Schedule or Exhibit attached hereto and not otherwise defined therein shall have the meanings set forth in this Agreement. The use of the word "including" herein shall mean "including without limitation". The Parties intend that each representation, warranty and covenant contained herein shall have independent significance. Except where otherwise expressly provided, all amounts in this Agreement are stated and shall be paid in United States currency. The Parties and their respective counsel have reviewed, negotiated and adopted this Agreement as the joint agreement and understanding of the Parties, and the language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent, and no rule of strict construction shall be applied against any Person. This Agreement embodies the justifiable expectations of sophisticated parties derived from arm's-length negotiations and no Person has any special relationship with another Person that would justify any expectation beyond that of an ordinary buyer and an ordinary seller in an arm's-length transaction.

Section IX.6 Entire Agreement. All Schedules attached hereto or referred to herein and the recitals to this Agreement are each hereby incorporated in and made a part of this Agreement. This Agreement and the agreements and documents referred to herein contain the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings, whether written or oral, relating to such subject matter in any way (including the letter of intent with respect to the transactions contemplated hereby), provided, that the covenants contained in Section 6.7 shall not supersede any covenants contained in any other agreement between Cannabist or a Member and any of the Buyer Group, but instead shall coexist with, and be enforceable independent of, any such similar covenants.

Section IX.7 <u>Counterparts; Electronic Delivery.</u> This Agreement and agreements, certificates, instruments and documents entered into in connection herewith may be executed and delivered in one or more counterparts and by email, each of which shall be deemed an original and all of which shall be considered one and the same agreement. No Party shall raise the use of email to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of email as a defense to the formation or enforceability of a Contract and each Party forever waives any such defense.

Section IX.8 <u>Governing law; Waiver of Jury Trial; Arbitration</u>. The Law of the state of Delaware shall govern (a) all claims or matters related to or arising from this Agreement (including any tort or non-contractual claims) and (b) any questions concerning the construction, interpretation, validity and enforceability of this Agreement, and the performance of the obligations imposed by this Agreement, in each case without giving effect to any choice-of-law

or conflict-of-law rules or provisions (whether of the state of Delaware or any other jurisdiction) that would cause the application of the Law of any jurisdiction other than the state of Delaware. EACH PARTY TO THIS AGREEMENT HEREBY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE BETWEEN OR AMONG ANY OF THE PARTIES (WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREBY AND/OR THE RELATIONSHIPS ESTABLISHED AMONG THE PARTIES HEREUNDER. Subject to Section 9.9 below, and except for the dispute resolution provisions set forth in Section 2.4 (Post-Closing Adjustments), the Parties agree to submit all disputes, claims or controversies concerning this Agreement to neutral, binding arbitration at JAMS, pursuant to the JAMS Arbitration Administrative Policies and, unless otherwise agreed in writing by the parties, to the applicable JAMS Arbitration Rules and Procedures, Any such arbitration shall take place in Chicago, Illinois. For cases proceeding under the JAMS Comprehensive Rules, the parties agree that the Expedited Procedures set forth in Rules 16.1 and 16.2 shall be employed. The arbitration shall be conducted by a single arbitrator selected from the JAMS roster of arbitrators. The arbitrator shall be selected through a mutual strike process administered by JAMS if Buyer and Cannabist cannot agree on the selection of a mutually agreeable arbitrator from the JAMS roster. The discovery in any such arbitration shall be reasonably limited by the arbitrator to effectuate the customary goals of arbitration to achieve cost-efficient resolution of disputes. The award of the arbitrator shall be final and binding upon the parties and shall not be appealed from or contested in any court. Any award rendered hereunder may be entered for enforcement, if necessary, in any court of competent jurisdiction. By entering into this Agreement, and subject to Section 9.9 below, the Parties knowingly and voluntarily waive their right to submit any dispute to the federal or state courts of any jurisdiction.

Section IX.9 Specific Performance. Each Party acknowledges and affirms that in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached, money damages would be inadequate (and therefore the non-breaching Party would have no adequate remedy at law) and the non-breaching Party would be irreparably damaged. Accordingly, each Party agrees that each other Party shall be entitled to specific performance, an injunction or other equitable relief (without posting of bond or other security or needing to prove irreparable harm) to prevent breaches of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any Proceeding instituted in any court of the United States or any state thereof having jurisdiction over the Parties and the matter (subject to the provisions set forth in Section 9.8), in addition to any other remedy to which such Person may be entitled, at law or in equity.

Section IX.10 No Third-Party Beneficiaries. This Agreement is for the sole benefit of the Parties and their permitted assigns and nothing herein expressed or implied shall give or be construed to give any Person, other than the Parties and such permitted assigns, any legal or equitable rights hereunder (other than in respect of Buyer Indemnified Parties who are express third-party beneficiaries hereunder and entitled to enforce certain obligations hereunder).

Section IX.11 <u>Schedules</u>. Except as otherwise provided in the Schedules attached hereto (the "<u>Schedules</u>"), all capitalized terms used therein shall have the meanings assigned to them in this Agreement. The inclusion of any information in the Schedules will not be deemed an admission or acknowledgment that such information is required to be listed in the Schedules or that such items are material. The Schedules are arranged in sections corresponding to the sections contained in this Agreement merely for convenience, and the disclosure of an item in one section of the Schedules as an exception to a particular covenant, agreement, representation or warranty will be deemed adequately disclosed as an exception with respect to all other covenants, agreements, representations and warranties to the extent that the relevance of such item to such other covenants, agreements, representations or warranties is reasonably apparent on its face without independent knowledge of the reader by the presence of an appropriate cross-reference thereto or other appropriate means.

Section IX.12 Excluded Claims. While certain states in the United States have adopted Laws that authorize certain activities with relation to cannabis and marijuana, 21 USC §841(A)(I) of the United States Federal Controlled Substances Act 21 USC §811 ("CSA") continues to make the manufacture, distribution, or possession with intent to distribute cannabis illegal under United States Federal Law. The United States Federal Government regulates cannabis possession and use through the CSA, which classifies marijuana as a Schedule I controlled substance. United States Federal Law prohibits physicians from dispensing a Schedule I controlled substance, including marijuana, by prescription. The CSA makes it a crime, amongst other things, to possess and use marijuana even for medical reasons. The United States Supreme Court recognized the authority of the United States Federal Government to prohibit marijuana for all purposes even medical ones, despite valid state Laws authorizing the medical use of marijuana. Therefore, even though these certain states authorize the cultivation, distribution, and sale of medical marijuana, this in no way impairs the ability of the United States Federal Government to seek civil and criminal sanctions against any individual or entity that, in any manner contemplated by the CSA, participates in a state legalized marijuana business. Any asserted claim or demand, arising specifically related to any United States Federal Law relating specifically and only to marijuana in any fashion, whether by cultivation, production, distribution, sale or otherwise, by any Person, whether based on contract, tort, implied or express warranty, strict liability criminal or civil statute, ordinance or regulation, common Law or otherwise, relating to or arising out of any of the foregoing matters or issues, including without limitation any enforcement of United States Federal Laws or statutes (and any related administrative rules or regulations), whether now or hereinafter existing, to the extent not consistent with applicable state Laws, is referred herein as an "Excluded Federal Claim". The foregoing means that each of the Parties could be subject to civil forfeiture of assets or could face criminal penalties. Additionally, the foregoing means that all of the representations and warranties made herein with respect to compliance with any Law are specifically qualified and limited by the fundamental nature of the Parties' business which is not in compliance with Federal Cannabis Laws and, for the avoidance of doubt, no Proceeding may be brought by any Party arising in connection with an Excluded Federal Claim.

* * * * *

Each of the undersigned has caused this Equity Purchase Agreement to be duly executed as of the date first above written.

MEMBER

COLUMBIA CARE-ARIZONA, PRESCOTT, L.L.C.

By: <u>/s/ David Hart</u> Name: <u>David Hart</u> Title: <u>President</u>

CANNABIST

THE CANNABIST COMPANY HOLDINGS INC.

By: <u>/s/ David Hart</u> Name: <u>David Hart</u> Title: <u>CEO</u>

CC VA

CC VA HOLDCO LLC

By: <u>/s/ David Hart</u> Name: <u>David Hart</u> Title: <u>President</u>

COMPANY

ORGANIX L.L.C.

By: <u>/s/ David Hart</u> Name: <u>David Hart</u> Title: <u>President</u>

N BUYER:

VERANO ARIZONA, LLC

By: <u>/s/ George Archos</u>
Name: George Archos
Title: Chief Executive Officer

EXHIBIT A

Form of Landlord Estoppel Certificate

See attached.

131405909.1

EXHIBIT B

Form of Transition Services Agreement

See attached.

2

AMENDMENT TO THE EQUITY PURCHASE AGREEEMENT

THIS AMENDMENT TO THE EQUITY PURCHASE AGREEMENT (this "<u>Amendment</u>") is effective as of October 28, 2024, by and between Verano Arizona, LLC, an Arizona limited liability company ("<u>Buyer</u>"), and The Cannabist Company Holdings Inc., a British Columbia corporation, acting in its individual capacity and as the Member representative ("<u>Cannabist</u>").

RECITALS

WHEREAS, Buyer, 203 Organix, L.L.C., an Arizona limited liability company (the "Company"), Columbia Care-Arizona, Prescott, L.L.C., an Arizona limited liability company, Cannabist and solely for the purposes of Sections 2.4(d) and 6.2(e), CC VA Holdco LLC, a Delaware limited liability company, are party to that certain Equity Purchase Agreement, dated as of July 29, 2024 (the "Purchase Agreement");

WHEREAS, the Purchase Agreement may be amended by the written agreement of Buyer and Cannabist; and

WHEREAS, the parties hereto desire to amend the Purchase Agreement as set forth herein, in accordance with the terms set forth in the Purchase Agreement.

NOW, THEREFORE, in consideration of the premises, the mutual covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

AGREEMENT

- 1. <u>Definitions</u>. Capitalized terms used herein and not defined herein shall have the meaning ascribed to such term as set forth in the Purchase Agreement, and all references to Sections shall mean the Sections of the Purchase Agreement unless reference is made to another document.
 - 2. Amendments to the Purchase Agreement. Section 6.3(e) is hereby deleted in its entirety and replaced with the following:
 - (e) Section 338(h)(10) Election.
 - (i) Buyer and the Member shall join in the making of a timely election under Code Section 338(h)(10) and any corresponding elections under state or local Tax Law (collectively, the "Section 338(h)(10) Election") with respect to the sale of the Equity. As soon as reasonably practicable following the Closing Date, Buyer and the Member shall exchange completed and executed copies of IRS Form 8023 and any other form or schedule required to effect the Section 338(h)(10) Election (and any required schedules thereto) and timely file the same with the IRS and other applicable Governmental Entities. The Member shall pay any Tax on income or gain recognized by the Company as a result of the Section 338(h)(10) Election and shall indemnify Buyer against any Loss arising out of the failure to pay any such Taxes.

131405909.1

- (ii) Reasonably promptly following the determination of the Final Purchase Price, Buyer shall prepare and deliver to the Member for its review a schedule (the "Closing Consideration Allocation"), which shall set forth a calculation and proposed allocation of the "aggregate deemed sales price" (as defined in Treasury Regulations §1.338-4) (the "ADSP") and the "adjusted gross-up basis" (as defined in Treasury Regulations §1.338-5) (the "AGUB") among the assets of the Company deemed sold as a result of the Section 338(h)(10) Election, in each case for U.S. federal and applicable state and local income Tax purposes in a manner consistent with Code Sections 338 and 1060 and the Treasury Regulations promulgated thereunder. If the Member disagrees with Buyer's Closing Consideration Allocation, the Member shall provide the Buyer with comments within 30 days after the Buyer's delivery of the Closing Consideration Allocation to the Member. The Buyer and the Member shall negotiate in good faith to determine the Closing Consideration Allocation in preparing the final allocation schedule (the "Final Allocation"). If the Buyer and the Member are unable to agree upon the Final Allocation after 30 days, the Buyer and the Member shall submit their dispute to the Valuation Firm. The Valuation Firm shall be directed to review such items in accordance with Section 2.4(b) as if it applied to the resolution of the dispute relating to the Final Allocation mutatis mutandis and determine, within 30 days, the changes to Buyer's Closing Consideration Allocation that are required to conform it to the Asset Purchase Price Allocation. The resolution of the disputed items relating to the Final Allocation will be conclusive, final and binding on the Parties and the version, with the determinations of the Valuation Firm, shall be the Final Allocation for purposes of this Agreement. The fees and expenses of the Valuation Firm in resolving the disputes relating to the Final Allocation shall be borne as specified in the procedures set forth in Section 2.4(b) as if they applied to the resolution of the disputes relating to the Final Allocation pursuant to this Section 6.3(e) mutatis mutandis. The Parties shall file all Tax Returns (including Form 8883) in a manner consistent with the Final Allocation, and none of the Parties shall take any Tax position to the contrary to the Final Allocation on any Tax Return or in any proceeding or audit.
- 3. <u>Full Force and Effect</u>. Except as specifically amended, modified, or supplemented by this Amendment, the Purchase Agreement, as amended, shall remain unchanged and in full force and effect.
- 4. <u>Governing Law</u>. The parties hereto expressly agree that this Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware.
- 5. <u>Counterparts</u>. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature) or other commonly recognized transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written.

BUYER:

Verano Arizona, LLC

By <u>/s/ George P. Archos</u> Name: George P. Archos Title: Chief Executive Officer

CANNABIST:

The Cannabist Company Holdings Inc.

By /s/ David Hart
Name: David Hart

Title: Chief Executive Officer

CERTIFICATE OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, George Archos, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Verano Holdings Corp.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(f)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 7, 2024

/s/ George Archos

George Archos (Principal Executive Officer)

CERTIFICATE OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brett Summerer, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Verano Holdings Corp.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(f)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 7, 2024

/s/ Brett Summerer

Brett Summerer (Principal Financial Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verano Holdings Corp. (the "Company") for the three and nine months ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, George Archos, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2024

/s/ George Archos

George Archos (Principal Executive Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verano Holdings Corp. (the "Company") for the three and nine months ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brett Summerer, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2024

/s/ Brett Summerer

Brett Summerer (Principal Financial Officer)